



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 14/47, 14/52, C12N 15/12, 15/19, 15/63, A61K 38/16, 38/19, 48/00	A1	(11) International Publication Number: WO 99/29728 (43) International Publication Date: 17 June 1999 (17.06.99)
(21) International Application Number: PCT/US98/26291 (22) International Filing Date: 11 December 1998 (11.12.98) (30) Priority Data: 60/069,281 11 December 1997 (11.12.97) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 60/069,281 (CON) Filed on 11 December 1997 (11.12.97) (71) Applicant (for all designated States except US): UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE [US/US]; 4321 Hartwick Road, College Park, MD 20740 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): GALLO, Robert, C. [US/US]; 8513 Thornden Terrace, Bethesda, MD 02817 (US). DEVICO, Anthony, L. [US/US]; 4533 Peacock Avenue, Alexandria, VA 22304 (US). GARZINO-DEMO, Alfredo [IT/US]; 601 North Eutaw Street, Baltimore, MD 21201 (US).		(74) Agent: BARRETT, William, A.; Intellectual Property/Technology Law, P.O. Box 14329, Research Triangle Park, NC 27709 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: METHOD AND COMPOSITION TO ENHANCE THE EFFICACY OF A VACCINE USING CHEMOKINES (57) Abstract <p>The present invention relates to a method to enhance the efficacy of a vaccine in a subject treated with the vaccine comprising administering to the subject in combination with the vaccine a one or more chemokines. The present invention also relates to compositions of vaccines containing chemokines.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

METHOD AND COMPOSITION TO ENHANCE THE EFFICACY OF A VACCINE USING CHEMOKINES

1. CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Application Serial No. 60/069,281 filed December 11, 1997.

2. BACKGROUND OF THE INVENTION

The present invention relates to a method to enhance the efficacy of a vaccine by administration of a chemokine, such as macrophage derived chemokine (MDC), in conjunction with the vaccine. The present invention also relates to compositions useful in the method.

2.1. GENERATION OF AN IMMUNE RESPONSE

The introduction of a foreign antigen into an individual elicits an immune response consisting of two major components, the cellular and humoral immune responses, mediated by two functionally distinct populations of lymphocytes known as T and B cells, respectively (see generally Coutinho, 1991, *Immune System, Encyclopedia of Human Biology*, Vol. 4, Ed. Dulbecco, Academic Press, Inc.). A subset of T cells responds to antigen stimulation by producing lymphokines which "help" or activate various other cell types in the immune system.

Another T cell subset is capable of developing into antigen-specific cytotoxic effector cells, which can directly kill antigen-positive target cells. On the other hand, the B cell response is primarily carried out by secretory proteins, antibodies, which directly bind and neutralize antigens.

Helper T cells (TH) can be distinguished from classical cytotoxic T lymphocytes (CTL) and B cells by their cell surface expression of the glycoprotein marker CD4. Although the mechanism by which CD4⁺ TH function has not been fully elucidated, the existence of functionally distinct subsets within the CD4⁺ T cell compartment has been reported (Mosmann and Coffman, 1989, *Ann. Rev. Immunol.*

Z:145-173). In the mouse, type 1 helper T cells (TH1) produce interleukin-2 (IL-2) and τ -interferon (τ -IFN) upon activation, while type 2 helper T cells (TH2) produce IL-4 and IL-5. Based on the profile of lymphokine production, TH1 appear to be involved in promoting the activation and proliferation of other T cell subsets including CTL, whereas TH2 specifically regulate B cell proliferation and differentiation, antibody synthesis, and antibody class switching.

A second T cell subpopulation is the classical CTL which express the CD8 surface marker. Unlike most TH, these cells display cytolytic activity upon direct contact with target cells, rather than through the production of lymphokines. *In vivo*, CTL function is particularly important in situations where an antibody response alone is inadequate. Significant experimental evidence indicates that CTL rather than B cells and their antibody products play a principal role in the defense against viral infections and cancer.

A salient feature of both T and B cell responses is their exquisite specificity for the immunizing antigen; however, the mechanisms for antigen recognition differ between these two cell types. B cells recognize antigens by antibodies, either acting as cell surface receptors or as secreted proteins, which bind directly to antigens on a solid surface or in solution, whereas T cells only recognize antigens that have been processed or degraded into small fragments and presented on a solid phase such as the surface of antigen-presenting cells (APC). Additionally, antigenic fragments must be presented to T cells in association with major histocompatibility complex (MHC)-encoded class I or class II molecules. The MHC refers to a cluster of genes that encode proteins with diverse immunological functions. In man, the MHC is known as HLA. Class I gene products are found on all somatic cells, and they were originally discovered as targets of major transplantation rejection responses. Class II gene products are mostly expressed on cells of various hematopoietic lineages, and they are involved in cell-cell interactions in the immune system. Most importantly, MHC-encoded proteins have been shown to function as receptors for processed antigenic fragments on the surface of APC (Bjorkman et al., 1987, *Nature* 329:506-512).

Another level of complexity in the interaction between a T cell and an antigenic fragment is that it occurs only if the MHC molecules involved are the same on the APC and the responding T cells. In other words, a T cell specific for a particular antigenic epitope expresses a receptor having low affinity for self MHC

proteins, which when such MHC proteins on APC are occupied by the epitope, engage the T cell in a stronger interaction leading to antigen-specific T cell activation. The phenomenon of a T cell reacting with a processed antigen only when presented by cells expressing a matching MHC is known as MHC-restriction.

The specificity of T cell immune responses for antigens is a function of the unique receptors expressed by these cells. The T cell receptor (TCR) is structurally homologous to an antibody; it is a heterodimer composed of disulfide-linked glycoproteins. Four TCR polypeptide chains known as α , β , τ , and δ have been identified, although the vast majority of functional T cells express the $\alpha\beta$ heterodimeric TCR. Transfer of α and β genes alone into recipient cells was shown to be both necessary and sufficient to confer antigen specificity and MHC-restriction (Dembic et al., 1986, *Nature* 320:232-238). Thus, the $\alpha\beta$ TCR appears to be responsible for recognizing a combination of antigenic fragment and MHC determinants.

The apparent basis of MHC restriction is that $CD4^+$ T cells express $\alpha\beta$ TCR which recognize antigenic fragments physically associated with MHC class II proteins, while the TCR on $CD8^+$ CTL recognize MHC class I-associated fragments. Thus, $CD4^+$ T cells can recognize only a restricted class of APC that are class II⁺, whereas $CD8^+$ CTL can interact with virtually any antigen-positive cells, since all cells express class I molecules. $CD4^+$ CTL have been identified, and they are MHC class II restricted, and lyse target cells only if the latter express self-MHC class II determinants associated with specific antigenic fragments. Both CD4 and CD8 molecules also contribute to this interaction by binding to monotypic determinants on the MHC class II and I molecules, respectively.

A second type of TCR composed of $\tau\delta$ heterodimers is expressed by a small percentage of T cells, but the involvement of $\tau\delta$ T cells in antigen-specific recognition is still poorly understood. Some studies have shown that functionally active $\tau\delta$ T cells can be cytolytic in a MHC non-restricted manner.

In summary, the generation of an immune response begins with the sensitization of $CD4^+$ and $CD8^+$ T cell subsets through their interaction with APC that express MHC-class I or class II molecules associated with antigenic fragments. The sensitized or primed $CD4^+$ T cells produce lymphokines that participate in the activation of B cells as well as various T cell subsets. The sensitized $CD8^+$ T cells increase in numbers in response to lymphokines and are capable of destroying any

cells that express the specific antigenic fragments associated with matching MHC-encoded class I molecules. For example, in the course of a viral infection, CTL eradicate virally-infected cells, thereby limiting the progression of virus spread and disease development.

2.2. ANTIGEN PRESENTING CELLS

The presentation of antigens to T cells is carried out by specialized cell populations referred to as antigen presenting cells (APC). Typically, APC include macrophages/monocytes, B cells, and bone marrow derived dendritic cells (DC). APC are capable of internalizing exogenous antigens, cleaving them into smaller fragments in enzyme-rich vesicles, and coupling the fragments to MHC-encoded products for expression on the cell surface (Goldberg and Rock, 1992, *Nature* 357:375-379). Since APC express both MHC-encoded class I and class II glycoproteins, they can present antigenic fragments to both CD4⁺ and CD8⁺ T cells for the initiation of an immune response.

By definition, APC not only can present antigens to T cells with antigen-specific receptors, but can provide all the signals necessary for T cell activation. Such signals are incompletely defined, but probably involve a variety of cell surface molecules as well as cytokines or growth factors. Further, the factors necessary for the activation of naive or unprimed T cells may be different from those required for the re-activation of previously primed memory T cells. The ability of APC to both present antigens and deliver signals for T cell activation is commonly referred to as an accessory cell function. Although monocytes and B cells have been shown to be competent APC, their antigen presenting capacities *in vitro* appear to be limited to the re-activation of previously sensitized T cells. Hence, they are not capable of directly activating functionally naive or unprimed T cell populations.

Although it had been known for a long time that APC process and present antigens to T cells, it was not shown until relatively recently that small antigenic peptides could directly bind to MHC-encoded molecules (Babbitt et al., 1985, *Nature* 317:359; Townsend et al., 1986, *Cell* 44:959). However, it is believed that, normally, complex antigens are proteolytically processed into fragments inside the APC, and become physically associated with the MHC-encoded proteins intracellularly prior to

trafficking to the cell surface as complexes. Two distinct pathways for antigen presentation have been proposed (Braciale et al., 1987, *Immunol. Rev.* 98:95-114). It was thought that exogenous antigens were taken up by APC, processed and presented by the exogenous pathway to class II restricted CD4⁺ T cells, while the endogenous pathway processed intracellularly synthesized proteins, such as products of viral genes in virally-infected cells, for association with MHC class I proteins and presentation to CD8⁺ CTL. However, although the two pathways in antigen processing and presentation may still be correct in some respects, the distinction is blurred in light of recent findings that exogenously added antigens may also be presented to class I-restricted CTL (Moore et al., 1988, *Cell* 54:777).

The term "dendritic cells" (DC) refers to a diverse population of morphologically similar cell types found in a variety of lymphoid and non-lymphoid tissues (Steinman, 1991, *Ann. Rev. Immunol.* 9:271-296). These cells include lymphoid DC of the spleen, Langerhans cells of the epidermis, and veiled cells in the blood circulation. Although they are collectively classified as a group based on their morphology, high levels of surface MHC-class II expression, and absence of certain other surface markers expressed on T cells, B cells, monocytes, and natural killer cells, it is presently not known whether they derive from a common precursor or can all function as APC in the same manner. Further, since the vast majority of published reports have utilized DC isolated from the mouse spleen, results from these studies may not necessarily correlate with the function of DC obtained from other tissue types. (Inaba et al., 1997, *J. Exp. Med.* 166:182-194; Hengel et al., 1987, *J. Immunol.*, 139:4196-4202; Kaut et al., 1988, *J. Immunol.*, 140:3186-3193; Romani et al., 1989, *J. Exp. Med.* 169:1169-1178; Macatonia et al., 1989, *J. Exp. Med.* 169:1255-1264; Inaba et al., 1990, *J. Exp. Med.* 172:631-6640). For example, despite high levels of MHC-class II expression, mouse epidermal Langerhans cells, unlike splenic DC, are not active APC in mixed leucocyte reaction (MLR), unless cultured with granulocyte-macrophage colony stimulating factor (GM-CSF) (Witmer-Pock et al., 1987, *J. Exp. Med.* 166:1484-1498; Heufler et al., 1988, *J. Exp. Med.* 167:700-705). Most human Langerhans cells express the CD1 and CD4 markers, while blood DC do not. Additionally, it has not been established the extent to which the functional characteristics observed with mouse DC are applicable to human DC, especially the DC obtained from non-splenic tissues; in part, due to inherent differences between the

human and murine immune systems.

Recently, a few studies have described the isolation of human DC from the peripheral blood, which involves the use of sheep red blood cells and/or fetal calf serum (Young and Steinman, 1990, *J. Exp. Med.* 171:1315-1332; Freudenthal and Steinman, 1990, *Proc. Natl. Acad. Sci. USA* 87:7698-7702; Macatonia et al., 1989 *Immunol.* 67:285-289; Markowicz and Engleman, 1990, *J. Clin. Invest.* 85:955-961). Engleman et al. described a partial purification procedure of DC from human blood, which does not involve the use of sheep red blood cells and/or fetal calf serum, and showed that the partially purified human DC can, in fact, present exogenous antigens to naive T cells (PCT Publication WO 94/02156 dated February 3, 1994 at page 9, lines 5-32).

Recent studies have indicated that DCs are superior APCs as compared to other APCs such as macrophages and monocytes. First, the potent accessory cell function of DCs provides for an antigen presentation system for virtually any antigenic epitopes which T and B cells are capable of recognizing through their specific receptors. For example, Engleman et al. demonstrate that human DCs can present both complex protein antigens and small peptides to CD4⁺ T cells as well as to CD8⁺ CTL (PCT Publication WO 94/02156 dated February 3, 1994, Example 7, from page 29, line 10 to page 34, line 16). Engleman et al. also show that the *in vitro* priming effect of DCs does not require the addition of exogenous lymphokines, indicating that DCs produce all of the necessary signals in antigen presentation leading to the activation of T cells (PCT Publication WO 94/02156 dated February 3, 1994, from page 32, line 36 to page 33, line 2). More importantly, DCs can induce a primary CD4⁺ T cell-mediated proliferative response when similarly prepared monocytes can not induce such a response (PCT Publication WO 94/02156 dated February 3, 1994 at page 31, lines 23-30). Similarly, when DCs and monocytes were compared for their ability to present antigens for re-activating secondary T cell response, it was observed that DCs were capable of stimulating a stronger response than monocytes (PCT Publication WO 94/02156 dated February 3, 1994 at page 32, lines 12-16).

2.3. CHEMOKINES

Chemokines, or chemoattractant cytokines, are a subgroup of immune factors

that have been shown to mediate chemotactic and other pro-inflammatory phenomena (see, Schall, 1991, *Cytokine* 3:165-183). Chemokines are small molecules of approximately 70-80 residues in length and can generally be divided into two subgroups, α which have two N-terminal cysteines separated by a single amino acid (CxC) and β which have two adjacent cysteines at the N terminus (CC). RANTES, MIP-1 α and MIP-1 β are members of the β subgroup (reviewed by Horuk, R., 1994, *Trends Pharmacol. Sci.* 15:159-165; Murphy, P.M., 1994, *Annu. Rev. Immunol.* 12:593-633; Baggiolini et al. *Annu. Rev. Immunol.* 1997, 15:675-705).

MCP-1 has been shown to attract monocytes but not neutrophils. MCP-1, MCP-2, and MCP-3 share a pyroglutamate proline NH₂-terminal motif and are structurally closely related to each other and to eotaxin (56% to 71% amino acid sequence identity). MCP-1, MCP-2, and MCP-3 attract monocytes, CD4⁺ and CD8⁺ T lymphocytes (Loetscher et al. *FAESB J.* 1994, 8:1055-60), as well as basophil leukocytes. MCP-2, MCP-3, and MCP-4 (but not MCP-1) attracts eosinophil leukocytes. All four MCPs attract activated T lymphocytes, natural killer (NK) cells, and dendritic cells (see Baggiolini et al. *Annu. Rev. Immunol.* 1997, 15:675-705).

Eotaxin acts on eosinophils and is inactive on neutrophils and monocytes, but has weak-to-moderate chemotactic activity toward IL-2-conditioned T lymphocytes (see Baggiolini et al. *Annu. Rev. Immunol.* 1997, 15:675-705). Due to its preferential, powerful action on eosinophils and its occurrence in different species, eotaxin is considered to be an important chemokine in the pathophysiology of allergic conditions and asthma (See Baggiolini et al. *Annu. Rev. Immunol.* 1997, 15:675-705).

IP10 is a CXC chemokine attracts human monocytes, T lymphocytes, and NK cells, and Mig attracts tumor-infiltrating T lymphocytes. It has been suggested that IP10 and Mig may also be involved in the regulation of lymphocyte recruitment and the formation of the lymphoid infiltrates observed in autoimmune inflammatory lesions, delayed-type hypersensitivity, some viral infections, and certain tumors (Baggiolini et al. *Annu. Rev. Immunol.* 1997, 15:675-705).

SDF-1 (stromal cell-derived factor 1), including SDF-1 and SDF-1 β stimulates the proliferation of B cell progenitors, and attracts mature dendritic cells (Finkel et al. *Immunobiology* 1998, 198:490-500). Synthetic human SDF-1 stimulates monocytes, neutrophils, and peripheral blood lymphocytes, as is indicated by [Ca²⁺]_i changes and chemotaxis. SDF-1 is also a powerful HIV-suppressive factor (See Baggiolini et al.

Annu. Rev. Immunol. 1997, 15:675-705).

The amino terminus of the β chemokines RANTES, MCP-1, and MCP-3 has been implicated in the mediation of cell migration and inflammation induced by these chemokines. This involvement is suggested by the observation that the deletion of the amino terminal 8 residues of MCP-1, amino terminal 9 residues of MCP-3, and amino terminal 8 residues of RANTES and the addition of a methionine to the amino terminus of RANTES, antagonize the chemotaxis, calcium mobilization and/or enzyme release stimulated by their native counterparts (Gong et al., 1996, *J. Biol. Chem.* 271:10521-10527; Proudfoot et al., 1996 *J. Biol. Chem.* 271:2599-2603). Additionally, α chemokine-like chemotactic activity has been introduced into MCP-1 via a double mutation of Tyr 28 and Arg 30 to leucine and valine, respectively, indicating that internal regions of this protein also play a role in regulating chemotactic activity (Beall et al., 1992, *J. Biol. Chem.* 267:3455-3459).

The monomeric forms of all chemokines characterized thus far share significant structural homology, although the quaternary structures of α and β groups are distinct. While the monomeric structures of the β and α chemokines are very similar, the dimeric structures of the two groups are completely different. An additional chemokine, lymphotactin, which has only one N terminal cysteine has also been identified and may represent an additional subgroup (γ) of chemokines (Yoshida et al., 1995, *FEBS Lett.* 360:155-159; and Kelner et al., 1994, *Science* 266:1395-1399).

Receptors for chemokines belong to the large family of G-protein coupled, 7 transmembrane domain receptors (GCR's) (See, reviews by Horuk, R., 1994, *Trends Pharmacol. Sci.* 15:159-165; and Murphy, P.M., 1994, *Annu. Rev. Immunol.* 12:593-633). Competition binding and cross-desensitization studies have shown that chemokine receptors exhibit considerable promiscuity in ligand binding. Examples demonstrating the promiscuity among β chemokine receptors include: CCR-1, which binds RANTES and MIP-1 α (Neote et al., 1993, *Cell* 72:415-425), CCR-4, which binds RANTES, MIP-1 α , and MCP-1 (Power et al., 1995, *J. Biol. Chem.* 270:19495-19500), and CCR-5, which binds RANTES, MIP-1 α , and MIP-1 β (Alkhatib et al., 1996, *Science* 272:1955-1958 and Dragic et al., 1996, *Nature* 381:667-674). Erythrocytes possess a receptor (known as the Duffy antigen) which binds both α and β chemokines (Horuk et al., 1994, *J. Biol. Chem.* 269:17730-17733; Neote et al., 1994, *Blood* 84:44-52; and Neote et al., 1993, *J. Biol. Chem.* 268:12247-12249). Thus the sequence and

structural homologies evident among chemokines and their receptors allow some overlap in receptor-ligand interactions.

Godiska et al. identified and described the nucleic acid and amino acid sequences of an additional β chemokine designated macrophage derived chemokine (MDC) (PCT Publication WO 96/40923 dated December 19, 1996, and 1997, *J. Exp. Med.* 185:1595-1604). PCT publication WO 96/40923 further provides materials and methods for the recombinant production of the chemokine, the purified and isolated chemokine protein, and polypeptide analogues thereof. The PCT publication WO 96/40923 does not disclose that the human MDC has chemotactic activity upon DC. While Godiska et al. (1997, *J. Exp. Med.* 185:1595-1604) showed that, in a microchamber migration assay, monocyte-derived DC migrated toward the human MDC, the reference fails to teach that MDC can enhance an immune response to an antigen *in vivo*.

Chang et al. (1997, *J. Biol. Chem.* 272(40):25229-25237), isolated a stimulated T cell chemotactic protein (STCP-1) from an activated macrophage cDNA library. The nucleotide sequence of the STCP-1 is identical to that of the MDC isolated by Godiska et al. (PCT Publication WO 96/40923 dated December 19, 1996, and 1997, *J. Exp. Med.* 185:1595-1604). However, unlike the results observed by Godiska et al. (1997, *J. Exp. Med.* 185:1595-1604), Chang et al. (1997, *J. Biol. Chem.* 272(40):25229-25237) showed that although the STCP-1 acted as a mild chemoattractant for primary activated T lymphocytes and a potent chemoattractant for chronically activated T lymphocytes, the STCP-1 has no chemoattractant activity for monocytes, neutrophils, eosinophils and resting T lymphocytes. Chang et al. further showed that the STCP-1 does not induce Ca^{2+} mobilization in monocytes, dendritic cells, neutrophils, eosinophils, lipopolysaccharide-activated B lymphocytes, and freshly isolated resting T lymphocytes.

2.4. HIV VACCINES

Human immunodeficiency virus (HIV) induces a persistent and progressive infection leading, in the vast majority of cases, to the development of the acquired immunodeficiency syndrome (AIDS) (Barre-Sinoussi et al., 1983, *Science* 220:868-870; Gallo et al., 1984, *Science* 224:500-503). The HIV envelope surface glycoproteins are

synthesized as a single 160 kilodalton precursor protein which is cleaved by a cellular protease during viral budding into two glycoproteins, gp41 and gp120. gp41 is a transmembrane glycoprotein and gp120 is an extracellular glycoprotein which remains non-covalently associated with gp41, possibly in a trimeric or multimeric form (Hammerskjold, M. and Rekosh, D., 1989, *Biochem. Biophys. Acta* 989:269-280). The V3 loop of gp120 is the major determinant of sensitivity to chemokine inhibition of infection or replication (Cocchi et al., 1996, *Nature Medicine* 2:1244-1247; and Oravec et al., 1996, *J. Immunol.* 157:1329-1332).

Although considerable effort is being put into the design of effective therapeutics, currently no curative anti-retroviral drugs against AIDS exist. The HIV-1 envelope proteins (gp160, gp120, gp41) have been shown to be the major antigens for neutralizing anti-HIV antibodies present in AIDS patients (Barin et al., 1985, *Science* 228:1094-1096). Thus far, therefore, these proteins seem to be the most promising candidates to act as antigens for anti-HIV vaccine development. Several groups have begun to use various portions of gp160, gp120, and/or gp41 as immunogenic targets for the host immune system (see, for example, Ivanoff et al., U.S. Pat. No. 5,141,867; Saith et al., PCT publication WO 92/22654; Shafferman, A., PCT publication WO 91/09872; Formoso et al., PCT publication WO 90/07119). Therefore, methods to increase the efficacy of vaccines against HIV, especially vaccines using gp120 as the antigen, are needed.

Additionally a novel vaccine technology, designated genetic vaccination, nucleic acid vaccination or DNA vaccination, has been explored to induce immune responses *in vivo*. Injection of cDNA expression cassettes results in *in vivo* expression of the encoded proteins (Dubensky et al., 1984, *Proc. Natl. Acad. Sci. USA* 81:7529-7533; Raz et al., 1993, *Proc. Natl. Acad. Sci. USA* 90:4523; Wolff et al., 1990, *Science* 247:1465-1468), with the concomitant development of specific cellular and humoral immune responses directed against the encoded antigen(s) (Wang et al., 1995, *Hum. Gene Ther.* 6:407-418; Ulmer et al., 1993, *Science* 259:1745-1749; Tang et al., 1992, *Nature* 356:152-154; Michel et al., 1995, *Proc. Natl. Acad. Sci. USA* 92:5307-5311; and Lowrie et al., 1994, *Vaccine* 12:1537-1540). Humoral and cellular responses have been induced to HIV-1 and SIV antigens through various applications of this technology in macaques (Wang et al., 1995, *Virology* 221:102-112; Wang et al., 1993, *Proc. Natl. Acad. Sci. USA* 90:4156-4160; and Boyer et al., 1996, *J. Med.*

Primatol. 25:242-250) as well as mice (Wang et al., 1995, *Virology* 221:102-112; Lu et al., 1995, *Virology* 209:147-154; Haynes et al., 1994, *AIDS Res. Hum. Retroviruses* 10 (Suppl. 2):S43-S45; Okuda et al., 1995, *AIDS Res. Hum. Retroviruses* 11:933-943).

Recently, Lekutis et al. (1997, *J. Immunol.* 158:4471-4477), assessed the TH cell response elicited by an HIV-1 gp120 DNA vaccine in rhesus monkeys by isolation of gp120-specific, MHC class II-restricted CD4⁺ T cell lines from the vaccinated animals. Lekutis et al. showed that the isolated cell lines proliferated in response to APC in the presence of recombinant gp120, as well as to APC expressing HIV encoded env protein. Lekutis et al. further showed that these cell lines responded to env by secreting IFN- γ and IFN- α without appreciable IL-4 production. These results demonstrate that the animals exhibited a cellular immune response to the DNA vaccine.

Boyer et al. (1997, *Nature Medicine* 3:625-532), inoculated chimpanzees with an HIV-1 DNA vaccine encoding env, rev, and gag/pol, and found that the immunized animals developed specific cellular and humoral immune responses to these proteins. After challenging the immunized animals with a heterologous chimpanzee titrated stock of HIV-1 SF2, Boyer et al. further found, using a Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) assay, that those animals vaccinated with the DNA vaccine were protected against infection whereas the control animals were not so protected.

Kim et al., (1997 *J. Immunol.* 158:816-826), investigated the role of co-delivery of genes for IL-12 and GM-CSF along with DNA vaccine formulation for HIV-1 antigens env and gag/pol in mice. Kim et al. observed a dramatic increase in specific CTL response from the mice immunized with the HIV-1 DNA vaccine and IL-12. Kim et al. also observed that the co-delivery of IL-12 genes resulted in the reduction of specific antibody response, whereas the codelivery of GM-CSF genes resulted in the enhancement of specific antibody response. Kim et al. further observed that co-delivery of IL-12 gene with a HIV DNA vaccine results in splenomegaly (Kim et al. 1997, *J. Immunol.*, 158:816-826), which has been shown in mice to have toxic effects such as weight reduction or even death (Eng et al., 1995, *J. Exp. Med.* 181:1893; Stevensen et al., 1995, *J. Immunol.* 155:2545; and Orange et al., 1995, *J. Exp. Med.* 181:901).

Notwithstanding the recent developments of the HIV DNA vaccine, there still

exists a need for a method to enhance the efficacy of a vaccine, especially an HIV DNA vaccine. For instance, for efficacious vaccine against HIV-1 one preferably induces both cellular and humoral immune responses to control the infection (Boyer et al., 1997, *Nature Medicine* 3:625-532). The induction of both cellular and humoral immune response by the Berjer et al. method is still quite low because only one of the three immunized chimpanzees developed both cellular and humoral responses. Similarly, although co-delivery of an IL-12 encoding gene with a HIV DNA vaccine, as described in Kim et al. (1997, *J. Immun.* 158:816-826), may have enhanced the cellular immune response, this co-delivery also decreased the humoral response.

Citation of a reference hereinabove shall not be construed as an admission that such reference is prior art to the present invention.

3. SUMMARY OF THE INVENTION. SUMMARY OF THE INVENTION. . SUMMARY OF THE INVENTION

The present invention is based upon the ability of chemokines, such as MDC, Rantes, MIP-1d, MIP-1B, and I-309, to enhance the immune response to an antigen, particularly a vaccine. Accordingly, in a first aspect, the present invention provides a method for enhancing the efficacy of a vaccine, which method comprises administration to a subject of one or more purified chemokines, or biologically active fragments, analogues or derivatives thereof, either concurrently with one or more purified antigens against which an immune response is desired or within a time period either before or after administration of the antigens such that the immune response against the antigens is enhanced.

In a second aspect, the present invention provides a method to enhance the efficacy of a vaccine, which method comprises administration to a subject of a first set of one or more purified nucleic acids comprising one or more nucleotide sequences encoding one or more chemokines, or fragments, derivatives, analogues, and/or truncation isoforms thereof, and a second purified nucleic acid comprising a nucleotide sequence encoding one or more antigens against which an immune response is desired, such that, the one or more chemokine(s) and the antigen(s) are expressed in a coordinated manner upon introduction into a suitable cell. Alternatively, the nucleotide sequences encoding one or more chemokines, or

fragments, derivatives, and/or analogues thereof, and the antigens against which an immune response is desired are present on the same nucleic acid.

In a preferred embodiment, the invention provides a method to enhance the efficacy of an HIV vaccine.

In yet another aspect, the present invention provides a composition comprising an immunogenic amount of one or more purified antigens, an amount of one or more purified chemokines, or a fragments, derivatives, analogues and/or truncation isoforms thereof, effective to enhance the immune response to the antigen. In another aspect, the present invention provides a composition comprising a first set of one or more purified nucleic acids comprising one or more nucleotide sequences encoding one or more chemokines, fragments, derivatives analogues and or truncation isoforms thereof, and a second set of purified nucleic acids comprising one or more nucleotide sequences encoding one or more antigens against which an immune response is desired, such that, the chemokine(s) and the antigen are expressed in a coordinated manner upon introduction into a suitable cell. In a preferred embodiment, the antigen is an HIV antigen. In another preferred embodiment, the chemokine is selected from the group consisting of: Macrophage-derived chemokine, Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EBI1-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine 1, HuMIG, H174, Interferon-stimulated T-cell alpha

chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.

4. DESCRIPTION OF FIGURES

Figures 1A and 1B. The nucleotide and amino acid sequences of MDC. 1A depicts the nucleotide sequence of MDC (SEQ ID NO:1), with the coding region indicated by the appearance of the amino acid sequence in the line below; and 1B depicts the amino acid of MDC (SEQ ID NO:2) from GenBank accession no. U83171 (Godiska et al., 1997, *J. Exp. Med.* 185:1595-1604).

5. DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to a method for enhancing the efficacy of a vaccine in a subject comprising administering to the subject one or more purified antigens in conjunction with one or more purified chemokines, or more purified fragments, derivatives or analogues and/or truncation isoforms thereof.

While any chemokine may be employed according to the present invention, the chemokine is preferably selected from the following table:

Chemokine Class	Chemokines	Abbreviations	Accession Number
CC Chemokines	Macrophage-derived chemokine	MDC/STCP-1	u83171; u83239
	Monocyte chemotactic protein 1	MCP-1	x14768
	Monocyte chemotactic protein 2	MCP-2	X99886
	Monocyte chemotactic protein 3	MCP-3	x72308; s57464
	Monocyte chemotactic protein 4	MCP-4	u46767
	activated macrophage specific chemokine 1	AMAC-1	Y13710
	Macrophage inflammatory protein 1 alpha	MIP-1 α	AF043339; X03754; D90144

Chemokine Class	Chemokines	Abbreviations	Accession Number
CC Chemokines (continued)	Macrophage inflammatory protein 1 beta	MIP-1 β	j04130; d90145
	Macrophage inflammatory protein 1 gamma	MIP-1 γ	
	Macrophage inflammatory protein 1 delta	MIP-1 δ	AF031587
	Macrophage inflammatory protein 2 alpha	MIP-2 α	AF043340
	Macrophage inflammatory protein 3 alpha	MIP-3 α	u77035
	Macrophage inflammatory protein 3 beta	MIP-3 β	u77180
	Regulated upon activation, normal T cell expressed and secreted (and its variants)	RANTES	M21211
	I-309		M57502
	EBI1-ligand chemokine	ELC	AB000887
	Pulmonary and activation regulated chemokine	PARC/DC-CK-1/MIP4	AB000221
	Liver and activation-regulated chemokine	LARC	D86955
	Thymus and activation regulated chemokine	TARC	D43767
	Eotaxin (and variants)		D49372; Z69291; Z75669; Z75668
	Human chemokine 1	HCC1; NCC2	Z49270; z49269
	Human chemokine 2	HCC2; NCC3, MIP-5, MIP-1 δ	Z70292
	Human chemokine 3	HCC3	Z70293
	IL-10-inducible chemokine	HCC4	U91746
	liver-expressed chemokine.	LEC; HCC4;NCC4	AB007454
	6Ckine		AF001979
	Exodus 1		u64197
	Exodus 2		U88320
	Exodus 3		U88321
	thymus-expressed chemokine	TECK	U86358
	Secondary Lymphoid tissue chemokine	SLC	AB002409

Chemokine Class	Chemokines	Abbreviations	Accession Number
CC Chemokines (continued)	Lymphocyte and Monocyte chemoattractant; Monotactin	LMC	AF055467
	Activation-induced, chemokine-related molecule	ATAC	x86474
	Myeloid progenitor inhibitory factor-1	MPIF-1; MIP-3 or ckbeta8	u85767
	Myeloid progenitor inhibitory factor-2	MPIF-2	u85768
	Stromal cell-derived factor 1 alpha	SDF-1 α ; PBSF	L36034
CXC chemokines	Stromal cell-derived factor 1 beta	SDF-1 β ; PBSF	L36033
	B-cell-attracting chemokine 1	BLC	AJ002211
	HuMIG		x72755 s60728
	H174		AF002985
	Interferon-stimulated T-cell alpha chemoattractant	I-TAC	AF030514
	Interleukin-8	IL-8	m17017; y00787
	IP-10		X02530
	platelet factor 4	PF4	M20901
	growth-regulated gene-alpha	GRO- α	J03561
	growth-regulated gene-beta	GRO- β	M36820
	growth-regulated gene-gamma	GRO- γ	M36821
	Neutrophil-activating protein 2	NAP-2; CTAP-3	M54995; M38441
	ENA-78		L37036
	granulocyte chemotactic protein 2	GCP-2	Y08770
C-CHEMOKINES	LYMPHOTACTIN	SCM-1	D63789 D63790
CX₃C-CHEMOKINES	Fractalkine/neurotactin		U91835 U84487

The present invention also relates to the use of fragments, analogues and derivatives of the foregoing chemokines, as well as truncation isoforms of such chemokines which are known in the art.

The present invention also relates to therapeutic compositions comprising one or more chemokines, nucleic acids encoding one or more chemokines, derivatives, analogues, and/or truncation isoforms thereof, and nucleic acids encoding the same, that are effective to enhance the immune response of a subject to a vaccine.

In another preferred embodiment of the invention, nucleic acids comprising

nucleotide sequences encoding one or more chemokines or fragments or derivatives, including truncation isoforms, thereof, and encoding one or more antigens against which an immune response is desired, which coding sequences are operatively linked to gene regulatory sequences capable of directing the expression of the one or more chemokines and the one or more antigens upon introduction into a suitable cell, for example, but not limited to, the cell (of a subject), are administered to a subject such that the one or more chemokines, or fragments or derivatives, including truncation isoforms, thereof, and one or more antigens, are expressed in the subject.

For clarity of disclosure, and not by way of limitation, the detailed description of the invention is divided into the subsections which follow.

5.1. METHODS AND COMPOSITIONS TO ENHANCE THE EFFICACY OF A VACCINE

The present invention provides methods for enhancing the efficacy of a vaccine in a subject, which methods comprise administering to a subject an immunogenic amount of one or more purified antigens against which an immune response is desired in the subject in conjunction with an amount of one or more purified chemokines, or fragments, derivatives, analogues and/or truncation isoforms thereof, effective to enhance the immune response against the antigen. In one aspect, the purified chemokine(s), or fragment(s), derivative(s), analogue(s) and/or truncation isoforms thereof, are administered to the subject concurrently with (e.g., in the same composition with) the purified antigen or antigens against which an immune response is desired. In another, aspect, the purified chemokine(s), or fragment(s), derivative(s), analogue(s) and/or truncation isoforms thereof, are administered either before or after the administration of one or more purified antigens against which immunity is desired in the subject, but is administered within such time that the chemokine(s) enhance the immune response to the one or more antigens. For example, but not by way of limitation, the purified chemokine(s) are administered during the time that the subject mounts an immune response against the administered one or more antigens, or, the purified MDC is administered within, for example, but not limited to, 30 minutes, 1 hour, 5 hours, 10 hours, 1 day, 2 days of (preferably, after) administration of the one or more purified antigens against which immunity is desired.

In a preferred embodiment, the present invention provides compositions comprising an immunogenic amount of one or more purified antigens and an amount of purified MDC, or one or more fragments, derivatives or analogues thereof, effective to enhance the immune response to said antigen and, preferably, the composition further comprises a pharmaceutically acceptable carrier.

A preferred chemokine for use in the methods and compositions of the present invention is any MDC protein, fragment or derivative thereof, that is capable of enhancing the efficacy of a vaccine (for example, but not limited to, as determined by the assays described in Section 5.4, *infra*). In one specific embodiment, the MDC is purified full length MDC, preferably full length MDC having the amino acid sequence of SEQ ID NO: 2 (Figure 1B). In another embodiment, the MDC is a purified protein, the amino acid sequence of which consists of amino acid numbers 2-69 of SEQ ID NO: 2 (Figure 1B). In another specific embodiment, the MDC is a purified protein, the amino acid sequence of which consists of amino acid numbers 3-69 of SEQ ID NO: 2 (Figure 1B). In still another specific embodiment, the MDC is a purified protein, the N-terminal amino acid sequence of which consists of the amino acid sequence Tyr-Gly-Ala-Asn-Met-Glu-Asp-Ser-Val-Cys-Cys-Arg-Asp-Tyr-Val-Arg-Tyr-Arg-Leu (portion of SEQ ID NO: 2). In yet another specific embodiment, the MDC is a purified protein, the N-terminal amino acid sequence of which consists of the amino acid sequence Pro-Tyr-Gly-Ala-Asn-Met-Glu-Asp-Ser-Val-Cys-Cys-Arg (portion of SEQ ID NO: 2). In yet another specific embodiment, the MDC is a purified derivative of a protein, the N-terminal amino acid sequence of which protein consists of the amino acid sequence Tyr-Gly-Ala-Asn-Met-Glu-Asp-Ser-Val-Cys-Cys-Arg-Asp-Tyr-Val-Arg-Tyr-Arg-Leu (SEQ ID NO:2), which derivative has activity to enhance the efficacy of the vaccine. In yet another specific embodiment, the MDC is a purified derivative of a protein, the N-terminal amino acid sequence of which protein consists of the amino acid sequence Pro-Tyr-Gly-Ala-Asn-Met-Glu-Asp-Ser-Val-Cys-Cys-Arg (SEQ ID NO:2), which derivative has activity to enhance the efficacy of the vaccine.

In yet another specific embodiment, the chemokine is a purified derivative of the protein, which derivative has one or more insertions of or substitutions with one or more non-classical amino acids relative to a corresponding wildtype chemokine, which derivative will enhance the efficacy of the vaccine. In yet another specific

embodiment, the chemokine is a purified derivative of the protein that has only one or more conservative substitutions in sequence relative a corresponding wildtype chemokine, which derivative will enhance the efficacy of the vaccine. The chemokines useful in the present invention may be derived from any suitable source and obtained by any method known in the art, for example but not limited to the methods described in Section 5.2 *infra*.

Preferably, the chemokine(s) are of the same species as the subject to which the vaccine is administered. In a preferred embodiment, one or more human chemokines are administered to a human subject, e.g., human MDC is administered to a human subject, alone or in combination with another chemokine.

The present invention also provides a method to enhance the efficacy of a vaccine in a subject, which method comprises administering to a subject a purified first nucleic acid comprising a nucleotide sequence encoding an antigen against which an immune response is desired in a subject and a purified second nucleic acid comprising a nucleotide sequence encoding one or more chemokines, or fragment(s), derivative(s) or analogue(s) thereof, where the expression of the encoded antigen(s) and chemokine(s), or fragment(s), derivative(s) or analogue(s) thereof, are under control of one or more appropriate gene regulatory elements (which regulatory elements can be any regulatory element known in the art, for example, but not limited to, those regulatory elements described in Section 5.2 *supra*), such that, upon introduction of said first and second nucleic acids into a suitable cell (e.g., a cell of the subject), the antigen and chemokine(s), or fragment(s), derivative(s) or analogue(s) thereof, are coordinately expressed, *i.e.*, are expressed either at the same time or within an appropriate time period (*i.e.*, sufficient for the chemokine(s) to enhance the immune response against the antigen relative to a corresponding immune response in the absence of the chemokine) and the antigen(s) are expressed in an immunogenic amount and the chemokine(s), or fragment(s), derivative(s) or analogue(s) thereof, are expressed in an amount sufficient to enhance the immune response against the antigen(s). In a specific embodiment, the nucleotide sequences encoding the chemokine(s) and the antigen are present on separate nucleic acids. In another embodiment, the nucleotide sequences encoding the chemokine(s) and the antigen(s) are present on the same nucleic acid.

The present invention also provides compositions to enhance the

efficacy of a vaccine in a subject, which compositions comprise a purified first nucleic acid comprising a nucleotide sequence encoding one or more antigen(s) and a purified second nucleic acid comprising a nucleotide sequence encoding one or more chemokines, or fragments or derivatives, including truncation isoforms, thereof, wherein the nucleotide sequences encoding the antigens and the chemokine(s) are operably linked to one or more gene regulatory elements such that, upon introduction of said first and second nucleic acids into a suitable cell (e.g., a cell of the subject), the antigen(s) and chemokine(s) are expressed in a coordinated manner and the antigen(s) are expressed in an immunogenic amount and the chemokine(s) are expressed in an amount effective to enhance the immune response against the antigen, relative to a corresponding immune response in the absence of such chemokine(s).

The present invention also provides compositions to enhance the efficacy of a vaccine in a subject, which compositions comprise a purified first set of one or more purified nucleic acids comprising one or more nucleotide sequences encoding one or more antigens and a purified second set of one or more purified nucleic acids comprising a nucleotide sequence encoding one or more chemokines, or fragments, analogues, derivatives, (including truncation isoforms) thereof, wherein the nucleotide sequence(s) encoding the antigen(s) and the chemokine(s) are operably linked to one or more gene regulatory elements such that, upon introduction of said first and second sets of nucleic acids into a suitable cell (e.g., a cell of the subject), the antigen(s) and chemokine(s) are expressed in a coordinated manner and the antigen(s) are expressed in an immunogenic amount and the chemokine(s) are expressed in an amount effective to enhance the immune response against the antigen, relative to a corresponding immune response in the absence of such chemokine(s).

The present invention also provides compositions to enhance the efficacy of a vaccine in a subject, which compositions comprise a purified nucleic acid comprising a first set of one or more nucleotide sequences encoding one or more antigens and a second set of one or more nucleotide sequence encoding one or more chemokines, or fragments, derivatives, or analogues thereof (including truncation isoforms), wherein the first and second sets of nucleotide sequences are operably linked to one or more gene regulatory elements such that, upon introduction into a suitable cell, the antigen(s) and the chemokine(s) are expressed in a coordinated manner and the antigen(s) are expressed in an immunogenic amount and the chemokine(s) are

expressed in an amount effective to enhance the immune response against the antigen(s).

Any nucleic acid comprising a nucleotide sequence encoding one or more chemokine proteins, or fragments or derivatives, thereof (including truncation isoforms), that are capable of enhancing the immune response to the antigen (for example, but not limited to, as determined by any of the assays described in Section 5.2., *infra*) can be used in the methods and compositions of the present invention.

In a preferred embodiment, the nucleotide sequence encodes MDC. In another embodiment, the MDC-encoding nucleotide consists of the nucleotide sequence of SEQ ID NO:1 (Figure 1A). In another specific embodiment, the method or composition of the invention uses a nucleic acid encoding an MDC derivative having deletional, insertional or substitutional mutations and combination thereof, which derivative has activity to enhance the immune response against an antigen in a subject.

Such compositions of nucleic acids encoding an antigen are often referred to as DNA vaccines.

Such DNA vaccines are produced by any method known in the art for constructing an expression plasmid vector containing the nucleotide sequences of the antigen(s) and/or chemokine(s) to be expressed which vector is suitable for expression of the encoded proteins in the subject or in cells recombinant for the expression vector, which cells are to be provided to the subject. Such expression vectors may contain various promoters, terminators and polyadenylation coding regions to control the expression of the encoded protein.

The DNA vaccine can be administered by any method known in the art for administration of DNA. The DNA vaccine may be delivered either directly, in which case the subject is directly exposed to the DNA vaccine such that the DNA enters and is expressed in cells of the subject, or indirectly, in which case, the DNA vaccine is first introduced into suitable cells by any method known in the art *in vitro*, then the cells containing the DNA vaccine are transplanted into the subject.

In a specific embodiment, the DNA vaccine is directly administered *in vivo*, where it is expressed to produce the encoded antigens and chemokine(s). This can be accomplished by any of numerous methods known in the art, e.g., by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, e.g., by infection using a defective or attenuated retroviral or

other viral vector (see U.S. Patent No. 4,980,286), or by direct injection of naked DNA, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, encapsulation in liposomes, microparticles, or microcapsules, or by administering it in linkage to a peptide which is known to enter the nucleus, by administering it in linkage to a ligand subject to receptor-mediated endocytosis (see e.g., Wu and Wu, *J. Biol. Chem.* 262:4429-4432 (1987)) (which can be used to target cell types specifically expressing the receptors), etc. In another embodiment, a nucleic acid-ligand complex can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation. In a preferred embodiment, the nucleic acid of a DNA vaccine is injected into the muscle of the subject to be immunized.

Another approach is to introduce the nucleic acid of the DNA vaccine into a cell prior to administration *in vivo* of the resulting recombinant cell. Such introduction can be carried out by any method known in the art, including but not limited to transfection, electroporation, microinjection, infection with a viral or bacteriophage vector containing the nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, microcell-mediated gene transfer, spheroplast fusion, etc. Numerous techniques are known in the art for the introduction of foreign nucleic acid into cells (see e.g., Loeffler and Behr, *Meth. Enzymol.* 217:599-618 (1993); Cohen et al., *Meth. Enzymol.* 217:618-644 (1993); Cline, *Pharmac. Ther.* 29:69-92 (1985)) and may be used in accordance with the present invention. Usually, the method of transfer includes the transfer of a selectable marker to the cells. The cells are then placed under selection to isolate those cells that have taken up and are expressing the transferred gene.

Cells into which a DNA vaccine can be introduced for purposes of immunization encompass any desired, available cell type, and include but are not limited to epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes; blood cells such as T lymphocytes, B lymphocytes, monocytes, macrophages, neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor cells, in particular hematopoietic stem or progenitor cells, e.g., as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, etc.

The resulting recombinant cells can be delivered to a subject by various

methods known in the art. In a preferred embodiment, the recombinant cells are injected, e.g., subcutaneously. In another embodiment, recombinant skin cells may be applied as a skin graft onto the patient. Recombinant blood cells (e.g., hematopoietic stem or progenitor cells) are preferably administered intravenously. The cells can also be encapsulated in a suitable vehicle and then implanted in the subject (see, e.g., Dionne et al. PCT Publication WO 92/19195, dated November 12, 1992). The amount of cells envisioned for use depends on the desired effect, subject state, etc., and can be determined by one skilled in the art.

By way of example, and not by way of limitation a DNA vaccine may be generated as described by Lekutis et al. for an HIV DNA vaccine (1997, *J. Immunol.* 158:4471-4477). Briefly, an expression vector is constructed with the promoter, enhancer and intron A of human cytomegalovirus (CMV) and the termination and polyadenylation sequences of bovine growth hormone in a plasmid backbone. Additionally, the nucleotide sequence for signal sequence of tissue plasminogen activator is either substituted for the signal sequence of the antigen, if the antigen has a signal sequence or is added onto the amino-terminus of the antigen, thereby eliminating the dependence on viral proteins for expression (e.g., in the case of gp120 expression, rev and env proteins are required unless the HIV-1 signal sequence is so substituted). The resulting formulation is then injected intra-muscularly.

Further examples of DNA vaccines are set forth in Boyer et al. (1996, *J. Med. Primatol.*, 25:242-250), which describes the construction of a plasmid encoding the HIV-1 gp160 envelope glycoprotein as well as the rev-tax region cloned into pMAMneoBlue vector (Clontech, Inc., Palo Alto, CA), and a vector encoding the envelope glycoprotein and rev from HIV-1 strain MN under the control of the CMV promoter. Another vector which can be used in the present invention is as described in Boyer et al. (1997, *Nature Medicine* 3:526-532) and contains expression cassettes encoding the envelope and Rev proteins of HIV-1 strain MN, and encoding the Gag/Pol proteins of HIV-1 strain IIIB.

For the practice of the present invention, the nucleotide sequence for the one or more chemokines, or fragments, derivatives, or analogues thereof, can either be incorporated into the same expression vector containing the nucleotide sequence encoding the antigen in such a manner that the chemokine(s) are expressed. Alternatively, the nucleotide sequence encoding the chemokine(s), or fragment(s),

derivative(s) or analogue(s) thereof, can be cloned into a separate expression vector (e.g., as described above for the expression vector containing the sequences coding for antigen) and the expression vector that expresses the antigen(s) mixed with the expression vector that expresses the chemokine(s). The mixture of the two expression vectors can then be administered to the subject.

The methods and compositions of the present invention may be used as a vaccine in a subject in which immunity for the antigen(s) is desired. Such antigens can be any antigen known in the art to be useful in a vaccine formulation. The methods and compositions of the present invention can be used to enhance the efficacy of any vaccine known in the art. The vaccine of the present invention may be used to enhance an immune response to infectious agents and diseased or abnormal cells, such as but not limited to bacteria, parasites, fungi, viruses, tumors and cancers. The compositions of the invention may be used to either treat or prevent a disease or disorder amenable to treatment or prevention by generating an immune response to the antigen provided in the composition. In one preferred embodiment, the antigen(s) are proteins, fragments or derivatives, including truncation isoforms, thereof, encoded by any genes of the HIV genome including the *env*, *gag*, *pol*, *nef*, *vif*, *rev*, and *tat* genes. In a more preferred embodiment, the antigen is an HIV-associated gp120 protein.

The methods and compositions of the present invention may be used to elicit a humoral and/or a cell-mediated response against the antigen(s) of the vaccine in a subject. In one specific embodiment, the methods and compositions elicit a humoral response against the administered antigen in a subject. In another specific embodiment, the methods and compositions elicit a cell-mediated response against the administered antigen in a subject. In a preferred embodiment, the methods and compositions elicit both a humoral and a cell-mediated response.

The subjects to which the present invention is applicable may be any mammalian or vertebrate species, which include, but are not limited to, cows, horses, sheep, pigs, fowl (e.g., chickens), goats, cats, dogs, hamsters, mice and rats, monkeys, rabbits, chimpanzees, and humans. In a preferred embodiment, the subject is a human. The compositions and methods of the invention can be used to either prevent a disease or disorder, or to treat a particular disease or disorder, where an immune response against a particular antigen or antigens is effective to treat or prevent the

disease or disorder. Such diseases and disorders include, but are not limited to, viral infections, such as HIV, CMV, hepatitis, herpes virus, measles, etc, bacterial infections, fungal and parasitic infections, cancers, and any other disease or disorder amenable to treatment or prevention by eliciting an immune response against a particular antigen or antigens. In another preferred embodiment, the subject is infected or at risk of being infected with HIV virus.

In another preferred embodiment the invention provides methods and compositions to enhance the efficacy of an HIV vaccine, such a vaccine can be administered to either prevent or treat HIV.

5.2. CHEMOKINE GENES AND PROTEINS

Chemokine proteins and nucleic acids can be obtained by any method known in the art. Chemokine nucleotide and amino acid sequences are available in public databases such as Genbank and are also published in various references known to those of skill in the art. The gene bank accession numbers for the preferred chemokines of the present invention are provided in Table I, in Section 5 above. The ensuing discussion uses MDC by way of example, but applies equally to other chemokines as well.

The MDC nucleotide and amino acid sequences for, *inter alia*, human, are available in the public databases (e.g. Genbank accession No. U83171) also published in Godiska et al., 1997, *J. Exp. Med.* 185:1595-1604. The nucleotide sequence and the amino acid sequence for the human MDC are provided in Figures 1A and B (SEQ ID NOS:1 and 2, respectively).

Chemokines used herein include, but are not limited to, chemokines from mice, hamsters, dogs, cats, monkeys, rabbits, chimpanzees, and human. In one preferred embodiment, the chemokine is of human origin.

Any vertebrate cell potentially can serve as the nucleic acid source for the isolation of chemokine nucleic acids. The nucleic acid sequences encoding the chemokine(s) can be isolated from vertebrate, mammalian, human, porcine, bovine, feline, avian, equine, canine, as well as additional primate sources, etc. The DNA may be obtained by standard procedures known in the art from cloned DNA (e.g., a

DNA "library"), by chemical synthesis, by cDNA cloning, or by the cloning of genomic DNA, or fragments thereof, purified from the desired cell (see, for example, Sambrook et al., 1989, *Molecular Cloning, A Laboratory Manual*, 2d Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York; Glover, D.M. (ed.), 1985, *DNA Cloning: A Practical Approach*, MRL Press, Ltd., Oxford, U.K. Vol. I, II.) Clones derived from genomic DNA may contain regulatory and intron DNA regions in addition to coding regions; clones derived from cDNA will contain only exon sequences. Whatever the source, the gene should be molecularly cloned into a suitable vector for propagation of the gene.

In the molecular cloning of the gene from cDNA, cDNA is generated from totally cellular RNA or mRNA by methods that are well known in the art. The gene may also be obtained from genomic DNA, where DNA fragments are generated (e.g. using restriction enzymes or by mechanical shearing), some of which will encode the desired gene. The linear DNA fragments can then be separated according to size by standard techniques, including but not limited to, agarose and polyacrylamide gel electrophoresis and column chromatography.

Once the DNA fragments are generated, identification of the specific DNA fragment containing all or a portion of the chemokine gene may be accomplished in a number of ways.

A preferred method for isolating a chemokine gene is by the polymerase chain reaction (PCR), which can be used to amplify the desired chemokine sequence in a genomic or cDNA library or from genomic DNA or cDNA that has not been incorporated into a library. Oligonucleotide primers which would hybridize to chemokine sequences can be used as primers in PCR.

Additionally, a portion of the chemokine (of any species) gene or its specific RNA, or a fragment thereof, can be purified (or an oligonucleotide synthesized) and labeled, the generated DNA fragments may be screened by nucleic acid hybridization to the labeled probe (Benton, W. and Davis, R., 1977, *Science* 196:180; Grunstein, M. And Hogness, D., 1975, *Proc. Natl. Acad. Sci. U.S.A.* 72:3961). Those DNA fragments with substantial homology to the probe will hybridize. Chemokine nucleic acids can be also identified and isolated by expression cloning using, for example, anti-chemokine antibodies for selection.

Alternatives to obtaining the chemokine DNA by cloning or amplification

include, but are not limited to, chemically synthesizing the gene sequence itself from the known chemokine sequence or making cDNA to the mRNA which encodes the chemokine protein. Other methods are possible and within the scope of the invention. Once a clone has been obtained, its identity can be confirmed by nucleic acid sequencing (by any method well known in the art) and comparison to known chemokine sequences. DNA sequence analysis can be performed by any techniques known in the art, including but not limited to the method of Maxam and Gilbert (1980, Meth. Enzymol. 65:499-560), the Sanger dideoxy method (Sanger, F., et al., 1977, Proc. Natl. Acad. Sci. U.S.A. 74:5463), the use of T7 DNA polymerase (Tabor and Richardson, U.S. Patent No. 4,795,699), use of an automated DNA sequencer (e.g., Applied Biosystems, Foster City, CA) or the method described in PCT Publication WO 97/15690.

Nucleic acids which are hybridizable to a chemokine nucleic acid, or to a nucleic acid encoding a chemokine derivative can be isolated, by nucleic acid hybridization under conditions of low, high, or moderate stringency (see also Shilo and Weinberg, 1981, Proc. Natl. Acad. Sci. USA 78:6789-6792). For example, the nucleic acid of SEQ ID No: 1 is hybridizable to an MDC nucleic acid.

Chemokine proteins and derivatives, analogs and fragments of chemokine proteins can be obtained by any method known in the art, including but not limited to recombinant expression methods, purification from natural sources, and chemical synthesis.

For example, chemokines can be obtained by recombinant protein expression techniques. For recombinant expression, the chemokine gene or portion thereof is inserted into an appropriate cloning vector for expression in a particular host cell. A large number of vector-host systems known in the art may be used. Possible vectors include, but are not limited to, plasmids or modified viruses, but the vector system must be compatible with the host cell used. Such vectors include, but are not limited to, bacteriophages such as lambda derivatives, or plasmids such as pBR322 or pUC plasmid derivatives or the Bluescript vector (Stratagene). The insertion into a cloning vector can, for example, be accomplished by ligating the DNA fragment into a cloning vector which has complementary cohesive termini. However, if the complementary restriction sites used to fragment the DNA are not present in the cloning vector, the ends of the DNA molecules may be enzymatically modified. Alternatively, any site

desired may be produced by ligating nucleotide sequences (linkers) onto the DNA termini; these ligated linkers may comprise specific chemically synthesized oligonucleotides encoding restriction endonuclease recognition sequences. In an alternative method, the cleaved vector and chemokine gene may be modified by homopolymeric tailing. Recombinant molecules can be introduced into host cells via transformation, transfection, infection, electroporation, etc., so that many copies of the gene sequence are generated.

In an alternative method, the desired gene may be identified and isolated after insertion into a suitable cloning vector in a "shot gun" approach. Enrichment for the desired gene, for example, by size fractionation, can be done before insertion into the cloning vector.

In specific embodiments, transformation of host cells with recombinant DNA molecules that incorporate the isolated chemokine gene, cDNA, or synthesized DNA sequence enables generation of multiple copies of the gene. Thus, the gene may be obtained in large quantities by growing transformants, isolating the recombinant DNA molecules from the transformants and, when necessary, retrieving the inserted gene from the isolated recombinant DNA.

The nucleotide sequence coding for a chemokine protein or a functionally active analog or fragment or other derivative thereof, can be inserted into an appropriate expression vector, *i.e.*, a vector which contains the necessary elements for the transcription and translation of the inserted protein-coding sequence. The necessary transcriptional and translational signals can also be supplied by the native chemokine gene and/or its flanking regions. A variety of host-vector systems may be utilized to express the protein-coding sequence. These include but are not limited to mammalian cell systems infected with virus (e.g., vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (e.g., baculovirus); microorganisms such as yeast containing yeast vectors, or bacteria transformed with bacteriophage, DNA, plasmid DNA, or cosmid DNA. The expression elements of vectors vary in their strengths and specificities. Depending on the host-vector system utilized, any one of a number of suitable transcription and translation elements may be used.

Any of the methods previously described for the insertion of DNA fragments into a vector may be used to construct expression vectors containing a chimeric gene consisting of appropriate transcriptional/translational control signals and the protein

coding sequences. These methods may include *in vitro* recombinant DNA and synthetic techniques and *in vivo* recombinants (genetic recombination). Expression of nucleic acid sequence encoding a chemokine protein or peptide fragment may be regulated by a second nucleic acid sequence so that the chemokine protein or peptide is expressed in a host transformed with the recombinant DNA molecule. For example, expression of a chemokine protein may be controlled by any promoter/enhancer element known in the art. Promoters which may be used to control chemokine expression include, but are not limited to, the SV40 early promoter region (Bernoist and Chambon, 1981, *Nature* 290:304-310), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto, et al., 1980, *Cell* 22:787-797), the herpes thymidine kinase promoter (Wagner et al., 1981, *Proc. Natl. Acad. Sci. U.S.A.* 78:1441-1445), the regulatory sequences of the metallothionein gene (Brinster et al., 1982, *Nature* 296:39-42); prokaryotic expression vectors such as the β -lactamase promoter (Villa-Kamaroff, et al., 1978, *Proc. Natl. Acad. Sci. U.S.A.* 75:3727-3731), or the *tac* promoter (DeBoer, et al., 1983, *Proc. Natl. Acad. Sci. U.S.A.* 80:21-25); see also "Useful proteins from recombinant bacteria" in *Scientific American*, 1980, 242:74-94; promoter elements from yeast or other fungi such as the Gal 4 promoter, the ADC (alcohol dehydrogenase) promoter, PGK (phosphoglycerol kinase) promoter, alkaline phosphatase promoter, and the following animal transcriptional control regions, which exhibit tissue specificity and have been utilized in transgenic animals: elastase I gene control region which is active in pancreatic acinar cells (Swift et al., 1984, *Cell* 38:639-646; Ornitz et al., 1986, *Cold Spring Harbor Symp. Quant. Biol.* 50:399-409; MacDonald, 1987, *Hepatology* 7:425-515); insulin gene control region which is active in pancreatic beta cells (Hanahan, 1985, *Nature* 315:115-122), immunoglobulin gene control region which is active in lymphoid cells (Grosschedl et al., 1984, *Cell* 38:647-658; Adames et al., 1985, *Nature* 318:533-538; Alexander et al., 1987, *Mol. Cell. Biol.* 7:1436-1444), mouse mammary tumor virus control region which is active in testicular, breast, lymphoid and mast cells (Leder et al., 1986, *Cell* 45:485-495), albumin gene control region which is active in liver (Pinkert et al., 1987, *Genes and Devel.* 1:268-276), alpha-fetoprotein gene control region which is active in liver (Krumlauf et al., 1985, *Mol. Cell. Biol.* 5:1639-1648; Hammer et al., 1987, *Science* 235:53-58; alpha 1-antitrypsin gene control region which is active in the liver (Kelsey et al., 1987, *Genes and Devel.* 1:161-171), beta-globin gene control region

which is active in myeloid cells (Mogham et al., 1985, Nature 315:338-340; Kollias et al., 1986, Cell 46:89-94), myelin basic protein gene control region which is active in oligodendrocyte cells in the brain (Readhead et al., 1987, Cell 48:703-712), myosin light chain-2 gene control region which is active in skeletal muscle (Sani, 1985, Nature 314:283-286), and gonadotropic releasing hormone gene control region which is active in the hypothalamus (Mason et al., 1986, Science 234:1372-1378).

For example, a vector can be used that comprises a promoter operably linked to an chemokine-encoding nucleic acid, one or more origins of replication, and, optionally, one or more selectable markers (e.g., an antibiotic resistance gene).

In a specific embodiment, an expression construct is made by subcloning a chemokine coding sequence into the *EcoRI* restriction site of each of the three pGEX vectors (Glutathione S-Transferase expression vectors; Smith and Johnson, 1988, Gene 7:31-40). This allows for the expression of the chemokine protein product from the subclone in the correct reading frame.

Expression vectors containing chemokine gene inserts can be identified by three general approaches: (a) nucleic acid hybridization, (b) presence or absence of "marker" gene functions, and (c) expression of inserted sequences. In the first approach, the presence of a chemokine gene inserted in an expression vector can be detected by nucleic acid hybridization using probes comprising sequences that are homologous to an inserted chemokine gene. In the second approach, the recombinant vector/host system can be identified and selected based upon the presence or absence of certain "marker" gene functions (e.g., thymidine kinase activity, resistance to antibiotics, transformation phenotype, occlusion body formation in baculovirus, etc.) caused by the insertion of a chemokine gene in the vector. For example, if the chemokine gene is inserted within the marker gene sequence of the vector, recombinants containing the chemokine insert can be identified by the absence of the marker gene function. In the third approach, recombinant expression vectors can be identified by assaying the product expressed by the recombinant. Such assays can be based, for example, on the physical or functional properties of the chemokine protein in *in vitro* assay systems, e.g., binding with anti-chemokine antibody or the chemokine's receptor.

Once a particular recombinant DNA molecule is identified and isolated, several methods known in the art may be used to propagate it. Once a suitable host

system and growth conditions are established, recombinant expression vectors can be propagated and prepared in quantity. As previously explained, the expression vectors which can be used include, but are not limited to, the following vectors or their derivatives: human or animal viruses such as vaccinia virus or adenovirus; insect viruses such as baculovirus; yeast vectors; bacteriophage vectors (e.g., lambda), and plasmid and cosmid DNA vectors, to name but a few.

In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Expression from certain promoters can be elevated in the presence of certain inducers; thus, expression of the genetically engineered protein may be controlled. Furthermore, different host cells have characteristic and specific mechanisms for the translational and post-translational processing and modification (e.g., glycosylation, phosphorylation of proteins. Appropriate cell lines or host systems can be chosen to ensure the desired modification and processing of the foreign protein expressed. For example, expression in a bacterial system can be used to produce an unglycosylated core protein product. Expression in yeast will produce a glycosylated product. Expression in mammalian cells can be used to ensure "native" glycosylation of a heterologous protein. Furthermore, different vector/host expression systems may effect processing reactions to different extents.

In other specific embodiments, the chemokine protein(s), fragment(s), analogue(s), or derivative(s) may be expressed as a fusion, or chimeric protein product (comprising the protein, fragment, analog, or derivative joined via a peptide bond to a heterologous protein sequence (of a different protein)). Such a chimeric product can be made by ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other by methods known in the art, in the proper coding frame, and expressing the chimeric product by methods commonly known in the art. Alternatively, such a chimeric product may be made by protein synthetic techniques, e.g., by use of a peptide synthesizer. In a specific embodiment, a chimeric protein containing all or a portion of the chemokine is joined via a peptide bond to all or a portion of an antigen against which immunity is desired.

Both cDNA and genomic sequences can be cloned and expressed.

The chemokine protein(s) may also be isolated and purified by standard methods including chromatography (e.g., ion exchange, affinity, and sizing column

chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins. The functional properties may be evaluated using any suitable assay (see Section 5.5). Alternatively, the protein can be synthesized by standard chemical methods known in the art (e.g., see Hunkapiller, M., et al., 1984, *Nature* 310:105-111). The chemokine-encoding nucleic acid sequence(s) can be mutated *in vitro* or *in vivo*, to create and/or destroy translation, initiation, and/or termination sequences, or to create variations in coding regions. Any technique for mutagenesis known in the art can be used, including, but not limited to, *in vitro* site-directed mutagenesis (Hutchinson et al., 1978, *J. Biol. Chem.* 253:6551), use of TAB linkers (Pharmacia), mutation-containing PCR primers, etc.

The experimentation involved in mutagenesis consists primarily of site-directed mutagenesis followed by phenotypic testing of the altered gene product. Some of the more commonly employed site-directed mutagenesis protocols take advantage of vectors that can provide single stranded as well as double stranded DNA, as needed. Generally, the mutagenesis protocol with such vectors is as follows. A mutagenic primer, i.e., a primer complementary to the sequence to be changed, but consisting of one or a small number of altered, added, or deleted bases, is synthesized. The primer is extended *in vitro* by a DNA polymerase and, after some additional manipulations, the now double-stranded DNA is transfected into bacterial cells. Next, by a variety of methods, the desired mutated DNA is identified, and the desired protein is purified from clones containing the mutated sequence. For longer sequences, additional cloning steps are often required because long inserts (longer than 2 kilobases) are unstable in those vectors. Protocols are known to those skilled in the art and kits for site-directed mutagenesis are widely available from biotechnology supply companies, for example from Amersham Life Science, Inc. (Arlington Heights, IL) and Stratagene Cloning Systems (La Jolla, CA).

In other specific embodiments, the chemokine derivative(s) or analogue(s) may be expressed as a fusion, or chimeric protein product (comprising the protein, fragment, analogue, or derivative joined via a peptide bond to a heterologous protein sequence (of a different protein)). Such a chimeric product can be made by ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other by methods known in the art, in the proper coding frame, and expressing the chimeric product by methods commonly known in the art.

In addition, chemokine proteins, derivatives (including fragments and chimeric proteins), and analogues can be chemically synthesized. See, e.g., Clark-Lewis et al., 1991, *Biochem.* 30:3128-3135 and Merrifield, 1963, *J. Amer. Chem. Soc.* 85:2149-2156. For example, chemokines, derivatives and analogues can be synthesized by solid phase techniques, cleaved from the resin, and purified by preparative high performance liquid chromatography (e.g., see Creighton, 1983, *Proteins, Structures and Molecular Principles*, W.H. Freeman and Co., N.Y., pp. 50-60). Chemokines, derivatives and analogues that are proteins can also be synthesized by use of a peptide synthesizer. The composition of the synthetic peptides may be confirmed by amino acid analysis or sequencing (e.g., the Edman degradation procedure; see Creighton, 1983, *Proteins, Structures and Molecular Principles*, W.H. Freeman and Co., N.Y., pp. 34-49).

The chemokine proteins, derivatives, or analogues of the invention may be synthesized in their entirety by the sequential addition of amino acid residues or alternatively as fragment subcomponents which may be combined using techniques well known in the art, such as, for example, fragment condensation (Shin et al., 1992, *Biosci. Biotech. Biochem.* 56:404-408; Nyfeler et al., 1992, *Peptides*, Proc. 12th Amer. Pep. Soc., Smith and Rivier (eds), Leiden, pp 661-663); and Nokihara et al., 1990, *Protein Research Foundation*, Yanaihara (ed), Osaka, pp 315-320).

In a less preferred embodiment, chemokine derivatives can be obtained by proteolysis of the protein followed by purification using standard methods such as those described above (e.g., immunoaffinity purification).

In another alternate embodiment, native chemokine proteins can be purified from natural sources, by standard methods such as those described above (e.g., immunoaffinity purification).

5.3. COMPOSITION FORMULATIONS AND METHODS OF ADMINISTRATION

The composition formulations of the invention comprise an effective immunizing amount of an immunologically active ingredient, i.e., one or more antigens, and an amount of one or more chemokine(s), or fragment(s) or derivative thereof, effective to enhance the immune response against the antigen in a subject, and a pharmaceutically acceptable carrier or excipient. In a specific embodiment, the

chemokines are selected from the group consisting of Macrophage-derived chemokine, Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EBI1-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine 1, HuMIG, H174, Interferon-stimulated T-cell alpha chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.

Pharmaceutically acceptable carriers or excipients are well known in the art and include but are not limited to saline, buffered saline, dextrose, water, glycerol, ethanol, sterile isotonic aqueous buffer, and combinations thereof. One example of such an acceptable carrier is a physiologically balanced culture medium containing one or more stabilizing agents such as stabilized, hydrolyzed proteins, lactose, etc. The carrier is preferably sterile. The formulation should suit the mode of administration.

In addition, if desired, the vaccine or composition preparation may also include minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and/or adjuvants which enhance the effectiveness of the vaccine or composition. Suitable adjuvants may include, but are not limited to: mineral gels,

e.g., aluminum hydroxide; surface active substances such as lysolecithin, pluronic polyols; polyanions; peptides; oil emulsions; alum; MDP, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine, and N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine. The effectiveness of an adjuvant may be determined by comparing the induction of antibodies directed against a MDC-containing composition in the presence and in the absence of various adjuvants.

In instances where the recombinant antigen is a hapten, *i.e.*, a molecule that is antigenic in that it can react selectively with cognate antibodies, but not immunogenic in that it cannot elicit an immune response, the hapten may be covalently bound to a carrier or immunogenic molecule; for instance, a large protein such as serum albumin will confer immunogenicity to the hapten coupled to it. The hapten-carrier may be formulated for use as a vaccine.

The composition can be a liquid solution, suspension, emulsion, tablet, pill, capsule, sustained release formulation, or powder. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc.

The chemokine(s), or fragment(s) or derivative(s) thereof, and/or the antigen(s) may be formulated into the composition as neutral or salt forms. Pharmaceutically acceptable salts include the acid addition salts (formed with free amino groups of the peptide) and which are formed with inorganic acids, such as, for example, hydrochloric or phosphoric acids, or organic acids such as acetic, oxalic, tartaric, maleic, and the like. Salts formed with free carboxyl groups may also be derived from inorganic bases, such as, for example, sodium potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine and the like.

The vaccines of the invention may be multivalent or univalent. Multivalent vaccines are made from recombinant viruses that direct the expression of more than one antigen.

An effective dose (immunizing amount) is that amount sufficient to produce an immune response to the antigen(s) in the host to which the vaccine preparation is administered. The precise dose of the composition to be employed in the formulation will depend on the route of administration, and the nature of the subject to be

immunized, and should be decided by the practitioner according to standard clinical techniques. Effective doses of the vaccines or compositions of the present invention may also be extrapolated from dose-response curves derived from animal model test systems.

The invention also provides a pharmaceutical pack or kit comprising one or more containers comprising one or more of the ingredients of the composition formulations of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is administered by injection, an ampoule of sterile diluent can be provided so that the ingredients may be mixed prior to administration.

In a specific embodiment, a lyophilized immunologically active ingredient and one or more chemokine polypeptide(s) of the invention are provided in a first container; a second container comprises diluent consisting of an aqueous solution of 50% glycerin, 0.25% phenol, and an antiseptic (e.g., 0.005% brilliant green).

Many methods may be used to introduce the composition formulations of the invention; these include but are not limited to oral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal routes, and via scarification (scratching through the top layers of skin, e.g., using a bifurcated needle).

The DNA vaccines of the invention can be administered by any method known in the art for delivery of DNA to subject (for example, as described in Section 5.3 supra)

5.4. DETERMINATION OF COMPOSITION EFFICACY

The activity of one or more chemokines, or a fragment, derivative or analogue thereof, to enhance immune response to an antigen can be determined by monitoring the immune response in test animals following immunization with a composition containing the chemokine(s) and an antigen and comparing the response to that following immunization with the antigen in the absence of the chemokine(s). Generation of a humoral (antibody) response and/or cell-mediated immunity, may be taken as an indication of an immune response. Test animals may include mice, hamsters, dogs, cats, monkeys, rabbits, chimpanzees, etc., and eventually human subjects. Assays for humoral and cell-mediated immunity are well known in the art.

Methods of introducing the composition may include oral, intracerebral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal or any other standard routes of immunization. The immune response of the test subjects can be analyzed by various approaches well known in the art, such as but not limited to: testing the reactivity of the resultant immune serum to the antigen of the chemokine-containing vaccine, as assayed by known techniques, e.g., immunosorbant assay (ELISA), immunoblots, radioimmunoprecipitations, etc.

As one example of suitable animal testing, a composition of the present invention may be tested in mice for the ability to enhance an antibody response to an antigen (using for example, but not limited to, the method as described in Section 6, *infra*) and the delayed-type hypersensitivity (DTH) response (also described in Section 6 *infra*), measured by an increase in footpad swelling after inoculation in the footpad of the test animal, as compared to the measurements in animals administered the antigen in a composition not containing chemokine. For example, as test animals BALB/c mice may be used. The test group each receives an inoculation with fixed amount of antigen and varying amount of one or more chemokines. The control group receives an inoculation of comparable amount of antigen alone.

Serum samples may be drawn from the mice after the final inoculation (for example every one or two weeks after inoculation), and serum is analyzed for antibodies against the antigen using known methods in the art, e.g., using an ELISA. DTH responses to the antigen may be measured after the final inoculation (e.g. within 1-7 days). An increase in the serum titer of antibodies recognizing the antigen and/or

an increase in footpad swelling in the animals receiving the antigen-compositions containing the chemokine(s) as compared to the serum titer of antibodies against the antigen and/or the footpad swelling in the animals receiving the antigen composition not containing the chemokine(s), indicates that the chemokine(s) enhance the immune response to antigen. An increase in the serum titer of antibodies recognizing the antigen and/or an increase in footpad swelling in the animals receiving the antigen-compositions containing the chemokines as compared to the serum titer of antibodies against the antigen and/or the footpad swelling in the animals receiving the antigen composition not containing chemokine(s), indicates that the chemokine(s) enhances the immune response to antigen. An increase in the serum titer of antibodies recognizing the antigen and/or an increase in footpad swelling in the animals receiving the antigen-compositions containing MDC as compared to the serum titer of antibodies against the antigen and/or the footpad swelling in the animals receiving the antigen composition not containing MDC, indicates that the MDC enhances the immune response to antigen. An increase in the serum titer of antibodies recognizing the antigen and/or an increase in footpad swelling in the animals receiving the antigen-compositions containing MDC as compared to the serum titer of antibodies against the antigen and/or the footpad swelling in the animals receiving the antigen composition not containing MDC, indicates that the MDC enhances the immune response to antigen.

6. EXAMPLE: IMMUNIZATION WITH MDC-CONTAINING COMPOSITION

The following experiment illustrates the evaluation of whether MDC will act as an adjuvant for a protein antigen and enhance the efficacy of a vaccine. However, it will be appreciated that the description applies equally to other chemokines and combinations of chemokines.

6.1. MATERIALS AND METHODS

6.1.1. ANIMALS AND REAGENTS

BALB/c mice are purchased from Harlan-Sprague-Dawley (Indianapolis, IN).

Human MDC (hMDC) was obtained from CD8⁺ T cell clones immortalized *in vitro* prepared as previously described (Markham et al., 1983 *Int. J. Cancer* 31:413; Markham et al. 1984, *Int. J. Cancer* 33:13). One such immortalized CD8⁺ T cell clone, F3b Clone 19, was adapted to growth in serum-free medium by the following procedure and used for further studies. F3b Clone 19 cells were grown in complete medium containing rIL-2 (16 ng/ml) at 37°C in a CO₂ incubator. After expanding the culture to 200 ml, the cells were pelleted and resuspended in RPMI medium containing HB101 (Irvine Scientific) supplemented with 16 ng/ml of rIL-2, 1% glutamine and 1% penicillin/streptomycin. The cells were grown to full confluence and the medium harvested by centrifugation at 670 x g for 10 minutes.

Human MDC (hMDC) was purified from F3b Clone 19 as described in Pal et al., 1997, *Science* 278:695-698. Briefly, the cell free culture supernatant from F3b Clone 19 was clarified by high speed centrifugation and fractionated by heparin affinity chromatography, taking advantage of the heparin binding characteristics of chemokines (Witt and Lander, 1994, *Current Biology* 4:394; Proost et al., 1996, *Method: A Companion to Methods in Enzymology* 10:82). Culture supernatant (1200 ml) from F3b Clone 19, grown to high cell density in serum-free medium supplemented with rIL-2 was clarified by high speed centrifugation (100,000 x g for 60 minutes at 4°C) and applied to a 5 ml HiTrap heparin affinity FPLC column (Pharmacia) equilibrated in 10 mM Tris-HCl, pH 7.6 containing 0.1 M NaCl (column buffer). The column was then washed extensively with column buffer and the bound proteins eluted from the column with 10 mM Tris-HCl, pH 7.6 containing 2.0 M NaCl at a flow rate of 0.5 to 1 ml/minute. Virtually all of the HIV suppressive activity effective against primary NSI and SI isolates and HIV-1₁₁₁₈ was recovered in the column eluate (data not shown). The heparin affinity column eluate was brought to pH 2.0 by addition of trifluoroacetic acid (TFA) and subjected to reversed phase HPLC on a PEEK C-18 column (Waters Instruments) equilibrated in H₂O containing 0.1 % TFA. Proteins bound to the column were eluted with a 5 minute linear gradient of aqueous acetonitrile (0 to 35 %) containing 0.1% TFA. After 10 minutes at 35% acetonitrile, the column was further developed with a 60 minute linear gradient of 35-70% aqueous acetonitrile in TFA. The flow rate was maintained at 0.5 to 1 ml/minute. The fractions obtained were then tested for suppressor activity in the acute infectivity assay using HIV-1₁₁₁₈. Active fractions were pooled, diluted twofold in H₂O with 0.1 % TFA

and reapplied to the column. The column was then developed with a 30 minute linear aqueous acetonitrile gradient (0-60%) containing 0.1% TFA at a flow rate of 0.5 to 1 ml/minute. The fractions obtained were assayed as above. Active fractions were pooled, diluted with H₂O/0.1 % TFA and fractionated under the same conditions to obtain a single protein peak. The fraction corresponding to the peak and flanking fractions were tested in the infectivity assay to verify that suppressor activity was cofractionated with the protein.

Suppressive activity against HIV-1_{IIIb} in the absence of cytotoxic effects consistently copurified with a single protein peak that appeared as a homogeneous 8 kDa band when analyzed by SDS-polyacrylamide gel electrophoresis. This protein was not reactive in ELISAs for RANTES, MIP-1 α or MIP-1 β (R&D Systems).

Recombinant gp120 protein derived from HIV-1 IIIB isolate is purchased from Intracel (Foster City, CA).

6.1.2 IMMUNIZATION OF MICE

The hMDC and the gp120 is resuspended in a total volume of 50 μ l of phosphate-buffered saline (PBS). Mice are divided into 5 groups with 3-4 mice in each group. Groups 1-4 are inoculated with 10 μ g gp120 and 0.3 μ g, 0.1 μ g, 0.03 μ g, and 0.01 μ g of hMDC, respectively. As a control, group 5 is inoculated with 10 μ g of gp120 in the absence of hMDC. For primary inoculation, each group of mice is inoculated with 10 μ l of the hMDC and gp120 solution via footpad. Two to three weeks after the primary inoculation, each mouse is given the same does of hMDC/gp120 that is used in primary inoculation.

6.1.3 ELISA ASSAY

Serum samples are collected one week after the second inoculation via tail vein bleed. gp120 serum responses are measured using standard gp120 antibody ELISA assays.

6.1.4 DTH ASSAY

The delayed-type hypersensitivity (DTH) response is measured from 1-7 days after the second inoculation. A caliper is to be used to measure footpad swelling.

6.2. RESULTS

Mice inoculated with hMDC/gp120 are expected to have greater serum antibody and DTH responses than mice inoculated with gp120 alone. The improved responses will be reflected in either increased titers of serum antibody responses or increased footpad swelling. A dose response effect is expected - increasing the dose of hMDC used is expected to cause a corresponding improvement in the serum and DHT gp120-specific responses.

7. EXAMPLE: OTHER CHEMOKINES AND COMBINATIONS OF CHEMOKINES

The foregoing experiments can be repeated using other chemokines and combinations of chemokines. For example, the experiments are preferably repeated using one or more chemokines selected from the group consisting of: Macrophage-derived chemokine, Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EB11-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine., 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine 1, HuMIG, H174, Interferon-stimulated T-cell alpha chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.

The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims.

Various references are cited herein, the disclosures of which are incorporated by reference in their entireties.

THE CLAIMS:

1. A method to enhance the efficacy of a vaccine in a subject comprising administering to the subject an immunogenic amount of one or more purified antigens against which an immune response is desired in the subject and an amount of one or more chemokines, or purified fragments or derivatives thereof, effective to enhance the efficacy of said vaccine.
2. The method of claim 1, wherein the one or more chemokines are selected from a chemokine class selected from the group consisting of: CC, CXC, C-C and CX3C.
3. The method of claim 1, wherein the one or more chemokines are selected from the group consisting of: Macrophage-derived chemokine, Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EBI1-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine 1, HuMIG, H174, Interferon-stimulated T-cell alpha chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-

regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.

4. The method of claim 1, wherein the one or more chemokines are selected from the group consisting of: MDC, SDF-1, BLC, and MCP-1.
5. The method of claim 1 wherein the fragment(s) or derivative(s) are truncation isoforms.
6. The method of claim 1, wherein the one or more chemokines include MDC comprising the amino acid sequence of SEQ ID NO: 2.
7. The method of claim 1, wherein the one or more chemokine fragment includes an MDC fragment selected from the group consisting of amino acid numbers 2-69, 3-69, 5-69, 7-69 and 9-69 of SEQ ID NO: 2.
8. The method of claim 1, wherein the one or more chemokine fragment includes an MDC fragment selected from the group consisting of amino acid numbers 2-69, 3-69, 5-69, 7-69 and 9-69 of SEQ ID NO: 2., which derivative has activity to enhance the efficacy of the vaccine.
9. The method of claim 1, wherein the one or more chemokine derivatives has one or more insertions or substitutions with one or more non-classical amino acids relative to a corresponding wildtype chemokine, which derivative has activity to enhance the efficacy of the vaccine.
10. The method of claim 1, including a chemokine derivative having one or more conservative substitutions in sequence relative a wildtype MDC, which derivative has activity to enhance the efficacy of the vaccine.
11. The method of claim 1, wherein the one or more chemokines include a human chemokine.

12. The method of claim 1, wherein the purified chemokine(s) or purified fragment(s) or derivative(s) thereof is/are administered concurrently with the purified antigen(s).
13. The method of claim 1 wherein the purified chemokine(s) or purified fragment(s) or derivative(s) thereof, are administered within a time period before or after administration of the purified antigen, which time period permits the purified MDC or purified fragment or derivative thereof MDC to enhance the efficacy of the vaccine.
14. The method of claim 1, wherein the antigen is an HIV antigen.
15. The method of claim 14, wherein the HIV antigen is HIV-associated gp120 protein.
16. The method of claim 1, wherein the subject is a human.
17. The method of claim 1, wherein the subject is infected or at risk of being infected with HIV virus.
18. The method of claim 1, wherein the vaccine elicits a humoral response against the antigen in the subject.
19. The method of claim 1, wherein the vaccine elicits a cell-mediated response against the antigen in the subject.
20. The method of claim 1, wherein the vaccine elicits both a humoral and a cell-mediated response against the antigen in the subject.
21. The method of claim 1, wherein the vaccine further comprises pharmaceutically acceptable excipient, auxiliary substance, adjuvant, wetting or emulsifying agent, or pH buffering agent.

22. A method to enhance the efficacy of a vaccine in a subject comprising administering to the subject a first amount of a first set of one or more purified nucleotide sequences encoding one or more antigens against which an immune response is desired in the subject and a second second set of one or more purified nucleic acids, each comprising a nucleotide sequence encoding one or more chemokines, or fragments or derivatives thereof, wherein the antigen(s) and the chemokine(s) are expressed in a coordinated manner upon introduction into a suitable cell, said first amount is immunogenic and said second amount is effective in enhancing the efficacy of the vaccine.
23. The method of claim 22, wherein the one or more chemokines are selected from a chemokine class selected from the group consisting of: CC, CXC, C-C and CX3C.
24. The method of claim 22, wherein the one or more chemokines are selected from the group consisting of: Macrophage-derived chemokine, Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EBI1-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine

- 1, HuMIG, H174, Interferon-stimulated T-cell alpha chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.
25. The method of claim 22, wherein the one or more chemokines are selected from the group consisting of: MDC, SDF-1, BLC, and MCP-1.
26. The method of claim 22 wherein the fragment(s) or derivative(s) are truncation isoforms.
27. The method of claim 22, wherein the nucleotide sequence encoding one or more chemokines comprises the nucleotide sequence of SEQ ID NO:1.
28. The method of claim 22, wherein one or more of the chemokine derivative(s) have deletional, insertional or substitutional mutations and combination thereof, which derivative has activity to enhance the efficacy of the vaccine.
29. The method of claim 22, wherein the vaccine elicits a humoral response against the antigen in the subject.
30. The method of claim 22, wherein the vaccine elicits a cell-mediated response against the antigen in the subject.
31. The method of claim 22, wherein the vaccine elicits both a humoral and a cell-mediated response against the antigen in the subject.
32. The method of claim 22, wherein the vaccine further comprises pharmaceutically acceptable excipient, auxiliary substance, adjuvant, wetting or emulsifying agent, or pH buffering agent.
33. A composition comprising: an immunogenic amount of one or more purified antigens and an amount of one or more purified chemokines, or purified

fragments or derivatives thereof, effective to enhance the immune response to said antigen(s); and a pharmaceutically acceptable carrier.

34. The composition of claim 33, wherein the one or more chemokines are selected from the group consisting of: MDC, SDF-1, BLC, and MCP-1.
35. The composition of claim 33, wherein the one or more chemokines are selected from a chemokine class selected from the group consisting of: CC, CXC, C-C and CX3C.
36. The composition of claim 33, wherein the one or more chemokines are selected from the group consisting of: Macrophage-derived chemokine, Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EBI1-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine 1, HuMIG, H174, Interferon-stimulated T-cell alpha chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating

protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.

37. The composition of claim 33, wherein the fragment(s) or derivative(s) are truncation isoforms.
38. The composition of claim 33, wherein the one or more chemokine fragment includes an MDC fragment selected from the group consisting of amino acid numbers 2-69, 3-69, 5-69, 7-69 and 9-69 of SEQ ID NO: 2.
39. The composition of claim 33, wherein the one or more chemokine fragment includes an MDC fragment selected from the group consisting of amino acid numbers 2-69, 3-69, 5-69, 7-69 and 9-69 of SEQ ID NO: 2, which derivative has activity to enhance the efficacy of the vaccine.
40. The composition of claim 33, wherein the one or more chemokine derivatives has one or more insertions of or substitutions with one or more non-classical amino acids relative to a corresponding wildtype chemokine, which derivative has activity to enhance the efficacy of the vaccine.
41. The composition of claim 33, wherein the one or more chemokine derivatives has one or more conservative substitutions in sequence relative a corresponding wildtype chemokine, which derivative has activity to enhance the efficacy of the vaccine.
42. The composition of claim 33, wherein the chemokine is a human chemokine.
43. The composition of claim 33, wherein the antigen is an HIV antigen.
44. The composition of claim 43, wherein the antigen is HIV associated gp120 protein.
45. A composition comprising an amount of a first set of purified nucleic acids comprising one or more nucleotide sequences encoding one or more antigens

and a second set of purified nucleic acids comprising one or more nucleotide sequences encoding one or more chemokines, or fragments or derivatives thereof, wherein the antigen(s) and the chemokine(s), or fragment(s) or derivative(s) thereof, are expressed from said first set of nucleic acid(s) and second set of nucleic acid(s) in a coordinated manner such that upon introduction into a suitable cell, the amount of said first set of nucleic acid(s) is sufficient to express an immunogenic amount of the antigen and the amount of the said second set of nucleic acid(s) is effective in enhancing the efficacy of the vaccine; and a pharmaceutically acceptable carrier.

46. The composition of claim 45, wherein the chemokine is MDC and the nucleic acid encoding the MDC comprises the nucleotide sequence of SEQ ID NO: 1.
47. The composition of claim 45, wherein the chemokine derivative(s) have deletional, insertional or substitutional mutations and/or combinations thereof, and the derivative(s) have activity to enhance the efficacy of the vaccine.
48. The composition of claim 45, further comprising pharmaceutically acceptable excipient, auxiliary substance, adjuvant, wetting or emulsifying agent, or pH buffering agent.
49. A composition comprising a first set of purified nucleotide sequences encoding one or more antigens and a second set of purified nucleotide sequences encoding one or more chemokines, or fragments or derivatives thereof, wherein the antigen(s) and the chemokine(s) are expressed in a coordinated manner such that upon introduction into a suitable cell, the sets produce an amount of said antigen(s) that is immunogenic and an amount of chemokine(s), or fragment(s) or derivative(s) thereof, that is effective in enhancing the efficacy of the vaccine relative to a corresponding vaccine composition without such chemokine(s), fragment(s) or derivative(s) thereof.
50. The composition of claim 49, wherein the one or more chemokines are selected from the group consisting of: Macrophage-derived chemokine,

Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EBI1-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine 1, HuMIG, H174, Interferon-stimulated T-cell alpha chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.

51. The method of claim 49, wherein the one or more chemokines are selected from a chemokine class selected from the group consisting of: CC, CXC, C-C and CX3C.
52. The method of claim 49, wherein the one or more chemokines are selected from the group consisting of: MDC, SDF-1, BLC, and MCP-1.
53. The composition of claim 49, wherein the fragment(s) or derivative(s) are truncation isoforms.

54. The composition of claim 49, wherein the nucleic acid is administered directly to the subject.
55. The composition of claim 49, wherein the nucleic acid is introduced into a suitable host cell and said suitable host cell is introduced into the subject.

GAGACATACA	GGACAGAGC	ATG	GCT	CGC	CTA	CAG	ACT	GCA	CTC	CTG	GTT	GTC	52			
Met Ala Arg Leu Gln Thr Ala Leu Val Val													-15			
-24													-20			
CTC	GTC	CTC	CTT	GCT	GTG	GCG	CTT	CAA	GCA	ACT	GAG	GCA	GGC	CCC	TAC	100
Leu	Val	Leu	Leu	Ala	Val	Ala	Leu	Gln	Ala	Thr	Glu	Ala	Gly	Pro	Tyr	
-10													-5	1		
GGC	GCC	AAC	ATG	GAA	GAC	AGC	GTC	TGC	TGC	CGT	GAT	TAC	GTC	CGT	TAC	148
Gly	Ala	Asn	Met	Glu	Asp	Ser	Val	Cys	Cys	Arg	Asp	Tyr	Val	Arg	Tyr	
5													10	15		
CGT	CTG	CCC	CTG	CGC	GTG	GTG	AAA	CAC	TTC	TAC	TGG	ACC	TCA	GAC	TCC	196
Arg	Leu	Pro	Leu	Arg	Val	Val	Lys	His	Phe	Tyr	Trp	Thr	Ser	Asp	Ser	
20													25	30	35	
TGC	CCG	AGG	CCT	GGC	GTG	GTG	TTG	CTA	ACC	TTC	AGG	GAT	AAG	GAG	ATC	244
Cys	Pro	Arg	Pro	Gly	Val	Val	Leu	Leu	Thr	Phe	Arg	Asp	Lys	Glu	Ile	
40													45	50		
TGT	GCC	GAT	CCC	AGA	GTG	CCC	TGG	GTG	AAG	ATG	ATT	CTC	AAT	AAG	CTG	292
Cys	Ala	Asp	Pro	Arg	Val	Pro	Trp	Val	Lys	Met	Ile	Leu	Asn	Lys	Leu	
55													60	65		

1/6

FIG. 1A-1

AGC CAA TGAAGAGCCT ACTCTGATGA CCGTGGCCTT GGCTCCTCCA GGAAGGCTCA	348
Ser Gln	
GGAGCCCTAC CTCCTTGCCA TTATAGCTGC TCCCCGCCAG AAGCCTGTGC CAACTCTCTG	408
CATTCCCTGA TCTCCATCCC TGTGGCTGTC ACCCTTGGTC ACCTCCGTGC TGTCAC TGCC	468
ATCTCCCCC TGACCCCTCT AACCCATCCT CTGCCTCCCT CCCTGCAGTC AGAGGGTCCT	528
GTTCCCATCA GCGATTCCCC TGCTTAAACC CTTC CATGAC TCCCCACTGC CCTAAGCTGA	588
GGTCAGTCTC CCAAGCCTGG CATGTGGCCC TCTGGATCTG GGTTC CATCT CTGTCTCCAG	648
CCTGCCCACT TCCCTTCATG AATGTTGGT TCTAGCTCCC TGTTCCTCAA ACCATACTA	708
CACATCCCAC TTCTGGGTCT TTGCCTGGGA TGTGTGTGAC ACTCAGAAAG TCCACCAACC	768
TGCACATGTG TAGCCCCACC AGCCCTCCAA GGCATTGCTC GCCCAAGCAG CTGGTAATTC	828
CATTTCATGT ATTAGATGTC CCCTGGCCCT CTGTCCCCCTC TTAATAACCC TAGTCACAGT	888
CTCCGCAGAT TCTTGGGATT TGGGGGTTTT CTCCCCCACC TCTCCACTAG TTGACCAAG	948

FIG. 1A-2

<u>GTTTCTAGCT</u>	<u>AAGTTACTCT</u>	<u>AGTCTCCAAG</u>	<u>CCTCTAGCAT</u>	<u>AGAGCACTGC</u>	<u>AGACAGGCC</u>	1008
TGGCTCAGAA	TCAGAGCCCA	GAAAGTGGCT	GCAGACAAA	TCAATAAAC	TAATGTCCCT	1068
CCCCTCTCCC	TGCCAAAGG	CAGTTACATA	TCAATACAGA	GACTCAAGGT	CACTAGAAAT	1128
GGGCCAGCTG	GGTCAATGTG	AAGCCCCAAA	TTTGCCCGA	TTCACCTTTC	TTCCCCCACT	1188
CCCTTTTTTT	TTTTTTTTTT	TTTGAGATGG	AGTTTCGCTC	TTGTCACCCA	CGCTGGAGTG	1248
CAATGGTGTG	GTCTTGGCTT	ATTGAAGCCT	CTGCCTCCTG	GGTTCAAGTG	ATTCTCTTGC	1308
CTCAGCCCTC	TGAGTAGCTG	GGATTACAGG	TTCTTGCTAC	CACGCCCCAGC	TAATTTTTGT	1368
ATTTTtagTA	GAGACGAGGC	TTCACCATGT	TGGCCAGGCT	GGTCTCGAAC	TCCTGTCCCTC	1428
AGGTAATCCG	CCCACCTCAG	CCTCCCCAAG	TGCTGGGATT	ACAGGCGTGA	GCCACAGTGC	1488
CTGGCCTCTT	CCCTCTCCCC	ACTGCCCCCC	CCAACTTTTT	TTTTTTTTTT	ATGGCAGGTT	1548
CTCACTCTGT	CGCCAGGCT	GGAGTGCAGT	GGCGTGATCT	CGGCTCACTA	CAACCTCGAC	1608
CTCCTGGGTT	CAAGTGATTC	TCCCACCCCA	GCCTCCCAAG	TAGCTGGGAT	TACAGGTGTG	1668

3/6

FIG. 1A-3

<u>TGCCACTACG</u>	<u>GCTGGCTAAT</u>	<u>TTTTGTATTT</u>	<u>TTAGTAGAGA</u>	<u>CAGGTTTCAC</u>	<u>CATATGGCC</u>	1728
AGGCTGGTCT	TGAACTCCTG	ACCTCAAGTG	ATCCACCTTC	CTTGCTCTCC	CAAAGTGCTG	1788
AGATTACAGG	CGTGAGCTAT	CACACCCAGC	CTCCCCCTTT	TTTTCCCTAAT	AGGAGACTCC	1848
TGTACCTTC	TTCGTTTAC	CTATGTGTCG	TGTCTGCTTA	CATTTCCTTC	TCCCCTCAGG	1908
CTTTTTTTGG	GTGGTCCTCC	AACCTCCAAT	ACCCAGGCCT	GGCCTCTTCA	GAGTACCCCC	1968
CATTCCACTT	TCCCTGCCTC	CTTCCTTAAA	TAGCTGACAA	TCAAATTCAT	GCTATGGTGT	2028
GAAAGACTAC	CTTTGACTTG	GTATTATAAG	CTGGAGTTAT	ATATGTATTT	GAAAACAGAG	2088
TAAATACTTA	AGAGGCCAAA	TAGATGAATG	GAAGAATTTT	AGGAACTGTG	AGAGGGGGAC	2148
AAGGTGAAGC	TTTCCTGGCC	CTGGGAGGAA	GCTGGCTGTG	GTAGCGTAGC	GCTCTCTCTC	2208
TCTGTCTGTG	GCAGGAGCCA	AAGAGTAGGG	TGTAATTGAG	TGAAGGAATC	CTGGGTAGAG	2268
ACCATTCTCA	GGTGGTTGGG	CCAGGCTAAA	GACTGGGAGT	TGGGTCTATC	TATGCCTTTC	2328
<u>TGGCTGATTT</u>	<u>TTGTAGAGAC</u>	<u>GGGTTTTCG</u>	<u>CATGTTACCC</u>	<u>AGGCTGGTCT</u>	<u>CAAACCTCCTG</u>	2388

FIG. 1A-4

GGCTCAAGCG	ATCCTCCTGG	CTCAGCCTCC	CAAAGTGCTG	GGATTACAGG	CGTGAATCAC	2448
TGCGCCTGGC	TTCCCTCTTCC	TCTTGAGAAA	TATTCTTTTC	ATACAGCAAG	TATGGGACAG	2508
CAGTGTCCCA	GGTAAAGGAC	ATAAATGTTA	CAAGTGCTG	GTCCTTTCTG	AGGAGGCTG	2568
GTGCCGCTCT	GCAGGGTATT	TGAACCTGTG	GAATTGGAGG	AGGCCATTTC	ACTCCCTGAA	2628
CCCAGCCTGA	CAAATCACAG	TGAGAATGTT	CACCTTATAG	GCTTGCTGTG	GGGCTCAGGT	2688
TGAAAGTGTG	GGGAGTGACA	CTGCCCTAGC	ATCCAGCTCA	GTGTCATCCA	GGGCCTGTGT	2748
CCCTCCCGAA	CCCAGGGTCA	ACCTGCCCTGC	CACAGGCACT	AGAAGGACGA	ATCTGCCTAC	2808
TGCCCATGAA	CGGGGCCCTC	AAGCGTCCTG	GGATCTCCTT	CTCCCTCCTG	TCCTGTCCTT	2868
GCCCCTCAGG	ACTGCTGGAA	AATAAATCCT	TTAAATAAGT	AAAAAATAAA	AAAAA	2923

5/6

FIG. 1A-1
FIG. 1A-2
FIG. 1A-3
FIG. 1A-4
FIG. 1A-5

FIG. 1A

FIG. 1A-5

[illegible]

FIG. 1B

SEQUENCE LISTING

(1) GENERAL INFORMATION

(i) APPLICANT: Gallo, Robert C.
DeVico, Anthony L.
Garzino, Alfredo

(ii) TITLE OF THE INVENTION: METHOD AND COMPOSITION TO ENHANCE
THE EFFICACY OF A VACCINE USING MACROPHAGE DERIVED CHEMOKINE

(iii) NUMBER OF SEQUENCES: 2

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Pennie & Edmonds LLP
(B) STREET: 1155 Avenue of the Americas
(C) CITY: New York
(D) STATE: New York
(E) COUNTRY: USA
(F) ZIP: 10036/2711

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Diskette
(B) COMPUTER: IBM Compatible
(C) OPERATING SYSTEM: DOS
(D) SOFTWARE: FastSEQ Version 2.0

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: To be assigned
(B) FILING DATE: Herewith
(C) CLASSIFICATION:

(vii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Misrock, S. Leslie
(B) REGISTRATION NUMBER: 18,872
(C) REFERENCE/DOCKET NUMBER: 8769-029

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 212-790-9090
(B) TELEFAX: 212-869-8864
(C) TELEX: 66141 PENNIE

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2923 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:

(A) NAME/KEY: mat_peptide
(B) LOCATION: 92..298

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GAGACATACA	GGACAGAGC	ATG GCT CGC CTA CAG ACT GCA CTC CTG GTT GTC	52
	Met Ala Arg Leu Gln Thr Ala Leu Val		
	-24 -20 -15		
CTC GTC CTC CTT GCT GTG GCG CTT CAA GCA ACT GAG GCA GGC CCC TAC		100	
Leu Val Leu Ala Val Ala Leu Gln Ala Thr Glu Ala Gly Pro Tyr			
	-10 -5 1		
GGC GCC AAC ATG GAA GAC AGC GTC TGC CGT GAT TAC GTC CGT TAC		148	
Gly Ala Asn Met Glu Asp Ser Val Cys Arg Asp Tyr Val Arg Tyr			
	5 10 15		
CGT CTG CCC CTG CGC GTG AAA CAC TTC TAC TGG ACC TCA GAC TCC		196	
Arg Leu Pro Leu Arg Val Lys His Phe Tyr Trp Thr Ser Asp Ser			
20 25 30 35			
TGC CCG AGG CCT GGC GTG TTG CTA ACC TTC AGG GAT AAG GAG ATC		244	
Cys Pro Arg Pro Gly Val Leu Thr Phe Arg Asp Lys Glu Ile			
	40 45 50		
TGT GCC GAT CCC AGA GTG CCC TGG GTG AAG ATG ATT CTC AAT AAG CTG		292	
Cys Ala Asp Pro Arg Val Pro Trp Val Lys Met Ile Leu Asn Lys Leu			
	55 60 65		
AGC CAA TGAAGAGCCT ACTCTGATGA CCGTGGCCTT GGCTCCTCCA GGAAGGCTCA		348	
Ser Gln			

```

GGAGCCCTAC CTCCCTGCCA TTATAGCTGC TCCCCGCCAG AAGCCTGTGC CAACTCTCTG 408
CATTCCCTGA TCTCCATCCC TGTGGCTGTC ACCCTTGGTC ACCTCCGTGC TGTCAC TGCC 468
ATCTCCCCC TGACCCCTCT AACCCTATCCT CTGCCTCCCT CCCTGCAGTC AGAGGGTCTT 528
GTTCCCATCA GCGATTCCCC TGCTTAAACC CTTCATGAC TCCCCACTGC CCTAAGCTGA 588
GGTCAGTCTC CCAAGCCTGG CATGTGGCCC TCTGGATCTG GGTTCATCT CTGTCTCCAG 648
CCTGCCCACT TCCCTTCATG AATGTTGGGT TCTAGCTCCC TGTTCTCCAA ACCCATACTA 708
CACATCCAC TTCTGGGTCT TTGCCTGGGA TGTGCTGAC ACTCAGAAAG TCCCACCACC 768
TGCACATGTG TAGCCCCACC AGCCCTCCAA GGCATTGCTC GCCCAAGCAG CTGGTAATTC 828
CATTTATGT ATTAGATGTC CCCTGGCCCT CTGTCCCTC TTAATAACCC TAGTCACAGT 888
CTCCGAGAT TCTTGGGATT TGGGGGTTTT CTCCCCACC TCTCCACTAG TTGGACCAAG 948
GTTTCTAGCT AAGTTACTCT AGTCTCCAAG CCTCTAGCAT AGAGCACTGC AGACAGGCCC 1008
TGGCTCAGAA TCAGAGCCCA GAAAGTGGCT GCAGACAAA TCAATAAAC TAATGTCCCT 1068
CCCCTCTCCC TGCCAAAAG CAGTTACATA TCAATACAGA GACTCAAGGT CACTAGAAAT 1128
GGCCAGCTG GTCAATGTG AAGCCCCAA TTTGCCAGA TTCACCTTC TTCCCCCACT 1188
CCCTTTTTT TTTTTTTTT TTTGAGATGG AGTTTCGCTC TTGTACCCA CGCTGGAGTG 1248
CAATGTGTG GTCTGGCTT ATTGAAGCCT CTGCCTCCTG GGTTCAGTG ATTCTCTGTC 1308
CTCAGCTCC TGAGTAGCTG GGATTACAGG TTCTGTGAC CACGCCAGC TAATTTTGT 1368
ATTTTACTA GAGACGAGG TCCACATGT TGGCAGGCT GGTCTCGAAC TCCTGTCTCTC 1428
AGGTAATCCG CCCACCTCAG CCTCCCAAAG TGCTGGGATT ACAGGCGTGA GCCACAGTGC 1488
CTGGCTCTT CCTCTCCCC ACTGCCCCC CCAACTTTT TTTTTTTTT ATGGCAGGGT 1548
CTCACTCTGT CGCCAGGCT GGAGTGCAGT GGCCTGATCT CGGCTCACTA CAACCTCGAC 1608
CTCTGGGTT CAAGTGATT TCCCACCCA GCCTCCAAAG TAGCTGGGAT TACAGGTGTG 1668
TGCCACTACG GCTGGCTAAT TTTGTATTT TTAGTAGAGA CAGGTTTCAC CATATTGGCC 1728
AGGCTGGTCT TGAATCCTG ACCTCAAGTG ATCCACCTTC CTTGTGCTCC CAAAGTGCTG 1788
AGATTACAGG CGTGAGCTAT CACACCCAGC CTCCCCCTT TTTTCTAAT AGGAGACTCC 1848
TGTACCTTTC TTCGTTTAC CTATGTGTCG TGTCTGCTTA CATTTCCTTC TCCCCTCAGG 1908
CTTTTTTGG GTGGTCTCC AACCTCCAAT ACCCAGGCT GGCCTCTTCA GAGTACCCCC 1968
CATTCCACTT TCCTGCCTC CTTCCTTAA TAGCTGACAA TCAAATTCAT GCTATGGTGT 2028
GAAAGACTAC CTTTGA CTGATTATAAG CTGGAGTAT ATATGTATTT GAAAACAGAG 2088
TAAATACTTA AGAGGCCAAA TAGATGAATG GAAGAAATTT AGGAACTGTG AGAGGGGGAC 2148
AAGGTGAAGC TTTCTGGCC CTGGGAGGAA GCTGGCTGTG GTAGCGTAGC GCTCTCTCTC 2208
TCTGTCTGTG GCAGGAGCCA AAGAGTAGGG TGTAATTGAG TGAAGGAATC CTGGGTAGAG 2268
ACCATTCTCA GGTGGTTGGG CCAGGCTAAA GACTGGGAGT TGGGTCTATC TATGCCCTTC 2328
TGGCTGATTT TGTAGAGAC GGGGTTTTG CATGTTACCC AGGCTGGTCT CAACTCCTG 2388
GGCTCAAGCG ATCCTCCTGG CTCAGCTCC CAAAGTGCTG GGATTACAGG CGTGAATCAC 2448
TGCGCCTGGC TTCCTCTCC TCTTGAGAAA TATTCTTTC ATACAGCAAG TATGGGACAG 2508
CAGTGTCCTA GGTAAAGGAC ATAAATGTTA CAAGTGTCTG GTCCTTCTG AGGGAGGCTG 2568
GTCCCGCTCT GCAGGGTATT TGAACCTGTG GAATTGGAGG AGGCCATTT ACTCCCTGAA 2628
CCCAGCTGA CAAATCACAG TGAGAATGTT CACCTTATAG GCTGTGCTGT GGGCTCAGGT 2688
TGAAAGTGTG GGGAGTGACA CTGCCTAGGC ATCCAGCTCA GTGTCATCCA GGGCCTGTGT 2748
CCCTCCCGAA CCCAGGGTCA ACCTGCCTGC CACAGGCACT AGAAGGACGA ATCTGCCTAC 2808
TGCCCATGAA CGGGGCCCTC AAGCGTCTG GATCTCCTT CTCCCTCTG TCCTGTCCTT 2868
GCCCTCAGG ACTGCTGGAA AATAATCCT TTAATAAGT AAAAAAAAAA AAAAA 2923

```

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 93 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```

Met Ala Arg Leu Gln Thr Ala Leu Val Leu Val Leu Ala
-24          -20          -15          -10
Val Ala Leu Gln Ala Thr Glu Ala Gly Pro Tyr Gly Ala Asn Met Glu
          -5          1          5
Asp Ser Val Cys Arg Asp Tyr Val Arg Tyr Arg Leu Pro Leu Arg
10          15          20
Val Lys His Phe Tyr Trp Thr Ser Asp Ser Cys Pro Arg Pro Gly
25          30          35          40
Val Leu Thr Phe Arg Asp Lys Glu Ile Cys Ala Asp Pro Arg
          45          50          55
Val Pro Trp Val Lys Met Ile Leu Asn Lys Leu Ser Gln
60          65

```

C-CHEMOKINES

LYMPHOTACTIN

(SCM-1)

D63789 D63790

CX3C-chemokines

Fractalkine/neurotactin

U91835 U84487

LOCUS HSU83171 2923 bp mRNA PRI 31-MAY-1997
 DEFINITION Human macrophage-derived chemokine precursor (MDC) mRNA,
 complete
 cds.
 ACCESSION U83171
 NID g1931580
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
 Hominidae;
 Homo.
 REFERENCE 1 (bases 1 to 2923)
 AUTHORS Godiska,R., Chantry,D., Raport,C.J., Sozzani,S., Allavena,P.,
 Leviten,D., Mantovani,A. and Gray,P.W.
 TITLE Human macrophage-derived chemokine (MDC), a novel
 chemoattractant
 for monocytes, monocyte-derived dendritic cells, and natural
 killer
 cells
 JOURNAL J. Exp. Med. 185 (9), 1595-1604 (1997)
 MEDLINE 97296313
 REFERENCE 2 (bases 1 to 2923)
 AUTHORS Godiska,R. and Gray,P.W.
 TITLE Direct Submission
 JOURNAL Submitted (23-DEC-1996) ICOS Corporation, 22021 20th Avenue SE,
 Bothell, WA 98021, USA
 FEATURES Location/Qualifiers
 source 1..2923
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /chromosome="16"
 gene 20..301
 /gene="MDC"
 sig_peptide 20..91
 /gene="MDC"
 CDS 20..301
 /gene="MDC"
 /function="chemotactic for dendritic cells and natural
 killer cells"
 /codon_start=1
 /product="macrophage-derived chemokine precursor"
 /db_xref="PID:g1931581"
 /translation="MARLQTALLVVLVLLAVALQATEAGPYGANMEDSVCCRDYVRYR
 LPLRVVKHFYWTSDSCPRPGVLLTFRDKEICADPRVPWVKMILNKLSSQ"
 mat_peptide 92..298
 /gene="MDC"
 /product="macrophage-derived chemokine"
 repeat_region complement(1194..1805)
 /rpt_family="ALU"
 repeat_region complement(2335..2443)
 /rpt_family="ALU"
 BASE COUNT 605 a 861 c 669 g 788 t
 ORIGIN
 1 gagacatata ggacagagca tggctcgcc acagactgca ctcttggttg tctctgtcct
 61 ccttgctgtg gcgcttcaag caactgagge aggcccttac ggcgccaaca tggaagacag
 121 cgtctgtgtc cgtgattacg tccgttaccg tctgccccctg cgcgtggtga aacacttcta
 181 ctggacctca gactcctgcc cgaggcctgg cgtggtgttg ctaaccttca gggataagga
 241 gatctgtgcc gatcccagag tgccctgggt gaagatgatt ctcaataagc tgagccaatg
 301 aagagcctac tctgatgacc gtggccttgg ctctccagg aaggctcagg agccctacct
 361 ccctgccatt atagctgtc cccgccagaa gcctgtgcca actctctgca ttccctgatc
 421 tccatccctg tggctgtcac ccttgggtcac ctccgtgctg tcaactgcat ctccccctg
 481 accctcttaa cccatcctct gcctccctcc ctgcagtcag agggctcctg tcccatcagc
 541 gattccccctg cttaaacctc tccatgactc cccactgccc taagctgagg tcagtctccc
 601 aagcctggca tgtggccctc tggatctggg ttccatctct gtctccagcc tgcccacttc
 661 ccttcacgaa tgttgggttc tagctccctg ttctccaaac ccatactaca catcccactt
 721 ctgggtcttt gcctgggatg ttgctgacac tcagaaagtc ccaccacctg cacatgtgta
 781 gccccaccag cctccaagg cattgctcgc ccaagcagct ggtaattcca ttctatgtat
 841 tagatgtccc ctggccctct gtccctcttt aataacccta gtcacagtct ccgcagattc

```

901 ttgggatttg ggggttttct cccccacctc tccactagtt ggaccaaggt ttctagctaa
961 gttactctag tctccaagcc tctagcatag agcactgcag acaggccctg gctcagaatc
1021 agagcccaga aagtggctgc agacaaaatc aataaaacta atgtccctcc cctctccctg
1081 ccaaaaggca gttacatatc aatacagaga ctcaaggta ctagaaatgg gccagctggg
1141 tcaatgtgaa gccccaaatt tgcccagatt cacctttctt cccccactcc cttttttttt
1201 tttttttttt tgagatggag ttctgctctt gtcaccacag ctggagtgc atggtgtggt
1261 cttggcttat tgaagcctct gcctcctggg ttcaagtgat tctcttgct cagcctcctg
1321 agtagctggg attacagggt cctgctacca cgcccagcta atttttgtat ttttagtaga
1381 gacgaggctt caccatgttg gccaggctgg tctcgaactc ctgtcctcag gtaatccgcc
1441 cactcagccc tcccaaagtg ctgggattac aggcgtgagc cacagtgcct ggcctcttcc
1501 ctctccccac tgcccccccc aacttttttt ttttttttat ggcagggtct cactctgtcg
1561 cccaggctgg agtgcagtgg cgtgatctcg gctcactaca acctcgacct cctgggttca
1621 agtgattctc ccaccccagc ctcccaagta gctgggatta cagggtgtg ccactacggc
1681 tggctaattt ttgtattttt agtagagaca ggtttcacca tattggccag gctgggtctt
1741 aactcctgac ctcaagtgat ccaccttctt tgtgctccca aagtgtgag attacaggcg
1801 tgagctatca caccagcctt cccctttttt ttctaatag gagactcctg tacctttctt
1861 cgttttaact atgtgtcgtg tctgettaca ttctcttctc ccctcagggt tttttgggt
1921 ggtcctccaa cctccaatac ccaggcctgg cctcttcaga gtacccccc ttccactttc
1981 cctgcctcct tccttaaata gctgacaatc aaattcatgc tatggtgtga aagactacct
2041 ttgacttggg attataagct ggagttatat atgtatttga aaacagagta aatacttaag
2101 agggccaaata gatgaatgga agaattttag gaactgtgag agggggacaa ggtgaagctt
2161 tcttgccctt gggaggaagc tggctgtggt agcgtagcgc tctctctctc tgtctgtggc
2221 agggagccaaa gagtaggggt taattgagtg aaggaaatcct gggtagagac cattctcagg
2281 tggttggggc aggctaaaga ctgggagttg ggtctatcta tgctttctg gctgattttt
2341 gttagagacgg ggttttgcca tgttaccaga gctgggtctc aactcctggg ctcaagcgat
2401 cctcctggct cagcctccca aagtgtctgg attacaggcg tgaatcactg cgctggcctt
2461 cctcttctct ttgagaaata ttcttttcat acagcaagta tgggacagca gtgtcccagg
2521 taaaggacat aaatgttaca agtgtctggg cctttctgag ggaggctggg gccgctctgc
2581 aggggtattt aacctgtgga attggaggag gccatttcac tccctgaacc cagcctgaca
2641 aatcacagtg agaattgtca ccttataggc ttgctgtggg gctcagggtt aaagtgtggg
2701 gagtgacact gcctaggcat ccagctcagt gtcattccagg gctgtgttcc ctcccgaacc
2761 cagggtcaac ctgcctgcc caggcactag aaggacgaat ctgcctactg cccatgaacg
2821 gggccctcaa gcgtcctggg atctccttct cctcctgtc ctgtccttgc ccctcaggac
2881 tgctggaaaa taaatccttt aaaatagtaa aaaaaaaaaa aaa

```

```

//
LOCUS      HSU83239          932 bp    mRNA          PRI          02-MAY-1997
DEFINITION Human CC chemokine STCP-1 mRNA, complete cds.
ACCESSION  U83239
NID        G2062424
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 932)
AUTHORS    Chang,M.S., McNinch,J., Elias III,C., Manthey,C.L.,
            Grosshans,D.,
            Meng,T., Boone,T. and Andrew,D.P.
TITLE      Molecular cloning and functional characterization of a novel CC
            chemokine STCP-1 which specifically acts on activated T
            lymphocytes
JOURNAL    Unpublished
REFERENCE  2 (bases 1 to 932)
AUTHORS    Chang,M.S., McNinch,J., Elias III,C., Manthey,C.L.,
            Grosshans,D.,
            Meng,T., Boone,T. and Andrew,D.P.
TITLE      Direct Submission
JOURNAL    Submitted (26-DEC-1996) Research Computing, Amgen Institute,
620        University Ave, Suite 706, Toronto, ON M5G 2C1, Canada
FEATURES   Location/Qualifiers
            source          1..932
                        /organism="Homo sapiens"
                        /note="Amgen EST program"
                        /db_xref="taxon:9606"
            CDS              15..296
                        /codon_start=1
                        /product="CC chemokine STCP-1"
                        /db_xref="PID:g2062425"

/translation="MARLQTALLVVLVLLAVALQATEAGPYGANMEDSVCCRDYVRYR

```


LPLRVVKHFYWTSDSCPRPGVLLTFRDKEICADPRVPWVKMILNKLSQ*

BASE COUNT	166 a	330 c	201 g	235 t
------------	-------	-------	-------	-------

ORIGIN

```

1  atacaggaca gagcatggct cgcctacaga ctgcactcct ggttgctctc gtcctccttg
61  ctgtggcgct tcaagcaact gaggcaggcc cctacggcgc caacatggaa gacagcgtct
121 gtgcecgta ttacgtccgt taccgtctgc cctgcgcgt ggtgaaacac ttctactgga
181 ctcagactc ctgcccagg cctggcgtgg tgttgctaac cttcagggat aaggagatct
241 gtgccgatac cagagtggcc tgggtgaaga tgattctcaa taagctgagc caatgaagag
301 cctactctga tgaccgtggc cttggctcct ccagggaaggc tcaggagccc tacctcctg
361 ccattatagc tgctccccgc cagaagcctg tgccaactct ctgcattccc tgatctccat
421 cctgtgggct gtcacccttg gtcaccctcg tgctgtcact gccatctccc cctgacccc
481 tctaaccat cctctgcctc cctccctgca gtcagagggt cctgttccca tcagcgattc
541 cctgtcttaa acccttccat gactcccaac tgccctaagc tgaggctcag ctcccaagcc
601 tggcatgttg cctctctggat ctgggttcca tctctgtctc cagcctgccc acttcccttc
661 atgaatgttg ggctctagct cctgttctc caaacccata ctacacatcc cacttctggg
721 tctttgcctg ggatgttgct gacactcaga aagtcaccac acctgcacat gtgtagcccc
781 accagccctc caaggcattg ctgcaccaag cagctggtaa ttccatttca tgtattagat
841 gtccccctgg cctctgtccc cctttaataa ccttagtcac agtctccgca gattcttggg
901 atttgggggt tttctccccc acctctccac ta

```

//

LOCUS	HSMCP1	725 bp	RNA	PRI	03-APR-1995
-------	--------	--------	-----	-----	-------------

DEFINITION H.sapiens mRNA for monocyte chemoattractant protein 1 (MCP-1).

ACCESSION X14768

NID g34513

KEYWORDS monocyte chemoattractant protein 1.

SOURCE human.

ORGANISM Homo sapiens

Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata; Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 725)

AUTHORS Yoshimura, T., Yuhki, N., Moore, S.K., Appella, E., Lerman, M.I. and Leonard, E.J.

TITLE Human monocyte chemoattractant protein-1 (MCP-1). Full-length

cDNA

cloning, expression in mitogen-stimulated blood mononuclear leukocytes, and sequence similarity to mouse competence gene JE

JOURNAL FEBS Lett. 244 (2), 487-493 (1989)

MEDLINE 89153605

COMMENT ZAPII.

FEATURES

source	Location/Qualifiers
	1..725
	/organism="Homo sapiens"
	/db_xref="taxon:9606"
	/cell_type="glioma cells"
	/cell_line="U105MG"
	/clone_lib="lambda"
sig_peptide	54..122
	/note="signal peptide (AA -23 to -1)"
CDS	54..353
	/codon_start=1
	/product="monocyte chemoattractant preprotein"
	/db_xref="PID:g34514"
	/db_xref="SWISS-PROT:P13500"

/translation="MKVSAALLCLLLIAATFIPQGLAQPDAINAPVTCCYNFTNRKIS

VQRLASYRRITSSKCPKEAVIFKTIIVAKEICADPKQKWVQDSMDHLQKQTQTPKT"

mat_peptide	123..350
	/note="MCP-1 (AA 1 - 76)"
misc_feature	162..170
	/note="pot. N-linked glycosylation site"
misc_feature	707..712
	/note="pot. polyA signal"
polyA_site	725
	/note="polyA site"

BASE COUNT	208 a	171 c	126 g	220 t
------------	-------	-------	-------	-------

ORIGIN

```

1  ctaaccagca aacatccaat tctcaaactg aagctcgcac tctcgccctc agcatgaaa
61  tctctgccgc cctctgtgct ctgctgtcta tagcagccac cttcattccc caagggtctg
121 ctcagccaga tgcaatcaat gccccagtc cctgctgtta taacttcacc aataggaaga
181 tctcagtgcg gaggtctcgc agctatagaa gaatcaccag cagcaagtgt cccaaagaag

```

```

241 ctgtgatctt caagaccatt gtggccaagg agatctgtgc tgacccaag cagaagtggg
301 ttcaggattc catggaccac ctggacaagc aaacccaaac tccgaagact tgaacactca
361 ctccacaacc caagaatctg cagctaactt attttcccct agctttcccc agacaccctg
421 ttttatttta ttataatgaa ttttgtttgt tgatgtgaaa cattatgect taagtaatgt
481 taattcttat ttaagttatt gatgttttaa gtttatcttt catggtacta gtgtttttta
541 gatacagaga cttggggaaa ttgcttttcc tcttgaacca cagttctacc cctgggatgt
601 tttgagggtc tttgcaagaa tcattaatac aaagaatttt ttttaacatt ccaatgcatt
661 gctaaaatat tattgtggaa atgaatattt tgtaactatt acaccaaata aatatatttt
721 tgtac

```

//

```

LOCUS      HSMCP2      2991 bp      DNA      PRI      20-MAR-1997
DEFINITION H.sapiens MCP-2 gene.
ACCESSION  X99886
NID        g1905800
KEYWORDS   MCP-2 gene; monocyte chemotactic protein 2; SCYA10 gene.
SOURCE     human.
  ORGANISM Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 2991)
  AUTHORS  Van Coillie,E., Fiten,P., Nomiyama,H., Sakaki,Y., Miura,R.,
            Yoshie,O., Van Damme,J. and Opdenakker,G.
  TITLE    The human MCP-2 gene (SCYA8): cloning, sequence analysis,
tissue     expression, and assignment to the CC chemokine gene contig on
            chromosome 17q11.2
  JOURNAL  Genomics 40 (2), 323-331 (1997)
  MEDLINE  97237052
  REFERENCE 2 (bases 1 to 2991)
  AUTHORS  Opdenakker,G.M.M.
  TITLE    Direct Submission
  JOURNAL  Submitted (07-AUG-1996) G.M.M. Opdenakker, Rega Institute for
            Medical Research, Minderbroedersstraat 10, B 3000 Leuven,

```

BELGIUM

```

FEATURES             Location/Qualifiers
    source             1..2991
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /chromosome="17"
                        /map="q11.2"
    repeat_region      209..219
                        /note="DR-A"
                        /rpt_type=DIRECT
    repeat_region      240..248
                        /note="DR-B"
                        /rpt_type=DIRECT
    CAAT_signal        296..300
    repeat_region      310..318
                        /note="IR-A"
                        /rpt_type=INVERTED
    repeat_region      406..415
                        /note="DR-B"
                        /rpt_type=DIRECT
    repeat_region      407..416
                        /note="IR-B"
                        /rpt_type=INVERTED
    repeat_region      425..435
                        /note="DR-A"
                        /rpt_type=DIRECT
    repeat_region      429..437
                        /note="IR-B"
                        /rpt_type=INVERTED
    repeat_region      455..465
                        /note="IR-C"
                        /rpt_type=INVERTED
    TATA_signal        467..472
    repeat_region      492..502
                        /note="IR-C"
                        /rpt_type=INVERTED
    repeat_region      492..500
                        /note="IR-A"

```

```

        /rpt_type=INVERTED
exon      534..639
          /gene="MCP-2 (SCYA10)"
          /number=1
gene      534..1969
          /gene="MCP-2 (SCYA10)"
CDS       join(534..639,1331..1448,1864..1969)
          /gene="MCP-2 (SCYA10)"
          /codon_start=1
          /product="monocyte chemotactic protein-2"
          /db_xref="PID:e279930"
          /db_xref="PID:g1905801"

/translation="MLKLTPPSKMKVSAALLCLLLMAATFSPQGLAQPDVSVIPITC
CFNVINRKIPIQRLESYTRITNIQCPKEAVIFKTQRGKEVCADPKERWVRDSMKHLDQ
IFQNLKP"
intron    640..1330
          /gene="MCP-2 (SCYA10)"
          /number=1
exon      1331..1448
          /gene="MCP-2 (SCYA10)"
          /number=2
intron    1449..1863
          /gene="MCP-2 (SCYA10)"
          /number=2
exon      1864..1969
          /gene="MCP-2 (SCYA10)"
          /number=3
BASE COUNT      799 a      709 c      632 g      851 t
ORIGIN
1   agattctggg gcattaagac ttagttccag gattctgtca ttctgccaac gttctgtggc
61  tgggggttcta aaggagcttg cctggccttag aactgcaagt gactctagtg tgatggagag
121 caccagcaaaa gccttagggc ccatccctgg cctcctgtta cccacagagg ggtaagcctt
181 ggctctcttc cactatgacg tcagcttcca ttcttccttt cttatagaca attttccatt
241 tcaaggaaat cagagccctt aatagttcag tgaggctact ttgctgagca caatcccata
301 cccttcagcc tctgtctccac agagcctaag caaaagatag aaactcacaa cttccttggt
361 ttgttatctg gaaattatcc caggatctgg tgcttactca gcatattcaa ggaaggctctt
421 acttcattct tccttgattg tgaccatgcc caggctctct gctccctata aaaggcaggc
481 agagccaccg aggagcagag aggttgagaa caaccagaa accttcacct ccatgctga
541 agctcacacc cttgccctcc aagatgaagg tttctgcagc gcttctgtgc ctgctgtcga
601 tggcagccac tttcagccct cagggacttg ctcagccagg taagacctct ccctttttaa
661 ggggagacca aaagaggaaat taagaagagc cattatgtca cagctcataa ggaacaaaac
721 cagaactaaa ggctcaggtc actgaggctg gttcccttga tcttctctga ccccgatttt
781 gggaggagac agtggagccg ctacagcaac aaccctccca ttgtttgggg aaataatcca
841 gaacgaagaa ctgtttctca ctgtgggtgt aaaggacatt tcaggccgta gtggagaggg
901 agaaactatt gcctgaagct tcaaattttg gttatggttc agtgtaacct ccagaacagt
961 ggctgtgtaa agaggatgag gaccagagg aatctcagcg tatggcatag gctaactcta
1021 aagcccatga ggatgaaaga ctgggaagca aggtattgga acttatgttc ccagtgtcag
1081 aagtttttggg ttagtagaca aggactagct tgttactcaa aatgtttcca aaccagtcga
1141 acaatgacgg gccgcagagt tcaatagagg aaagagactc acaggcaaca ttttatctct
1201 gggatctgga ctaagacact gaactggga tggtgacttc ttggtcttct ccttcttctt
1261 cttcttttcc ttacaaatgc acacttacgg tgggtcctaa atgtctcatt ctttgcaaaa
1321 tttctttcag attcagtttc cattccaatc acctgctgct ttaacgtgat caataggaaa
1381 attcctatcc agaggctgga gagctacaca agaatcacca acatccaatg tcccaaggaa
1441 gctgtgatgt gagtggacag tgcctggcac ccccatccta aagttctgat ggacaacata
1501 gagaagtcaa gattcatgtc catatgagtc ggatgcatat aacttctatc caaagggggc
1561 ctctacccca tagagaaact cagtcctgta gaaggagtec ataactgtct taggattccc
1621 ttctaggggc ttggtgaaac taaccaata tctgtagcca ggacctgga ggggttcacc
1681 tggacagcaa gagcagagct tccttctgga gcttcttct cccactcttc ccttcccttc
1741 tctcccgggt cgggtccttc cacctaagga ccaagggctg atcagtccta gggaccaatg
1801 gccacagtc ctgtgcagga tcttcaaagt ctccatcta attgtgccct ctctcccca
1861 cagcttcaag acccaacggg gcaaggagggt ctgtgctgac cccaaggaga gatgggtcag
1921 ggattccatg aagcatctgg accaaatatt tcaaaatctg aagccatgag ccttcataca
1981 tggactgaga gtcagagctt gaagaaaagc ttatttattt tccccaacct cccccagggtg
2041 cagtgtgaca ttattttatt ataacatcca caaagagatt atttttaaat aatttaaagc
2101 ataattttc ttaaaaagta ttaattata ttaagttgt tgatgtttta actctatctg
2161 tcatacatcc tagtgaatgt aaaatgcaaa atcctgggtg tggtgttttt gtttttgttt
2221 tccgtgagc tcaactaagt tcacggcaaa atgtcattgt tctccctcct acctgtctgt
2281 agtgttgtgg ggtcctccca tggatcatca aggtgaaaca ctttggattt ctttggcaat
2341 cagtgtcctt gtaagtcaaa tgtgtgcttt gtactgctgt tgttgaaatt gatgttactg

```

```

2401 tatataacta tggaattttg aaaaaaaatt tcaaaaagaa aaaaatatat ataatttaac
2461 actacttagt cttattcttc ttggggtaac atttagctgg gagtgagttt tgggcatcat
2521 ggggtgacagt ttgggcatgg acggggccatt tttcaagaat gtcttctggc tacgttggac
2581 tcaaccaagg ttctcagaga acttggtggg accaggccag gatgttccag ctctctgact
2641 ctagtcccta acttcagcag ccttgattcg ctageccttc ttgtttctct tgtttatata
2701 ttatccagcc taaggatttt tgttatagct gccccaaaag actaagataa tctccatcac
2761 tctaccccca accccaatcc caagaacttg caagcatcca tttaaaggcg tggaaacctct
2821 tctttttgac agccttttaa ggtcaagatt cccctgtact tagtgagctt agctgaatct
2881 tcttacaac atgtgaccgc ccatattgag ccatacatac cgagcttatt atttttccag
2941 cttattggga aaacacgtct aaggcaaca aatttattgt actgttgaac c
//LOCUS      HSY16645      1368 bp      mRNA      PRI      25-SEP-1998
DEFINITION   Homo sapiens mRNA for monocyte chemotactic protein-2.
ACCESSION    Y16645
NID          g2916795
KEYWORDS     MCP-2 gene; monocyte chemotactic protein 2.
SOURCE       human.
ORGANISM     Homo sapiens
              Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
              Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1 (bases 1 to 1368)
AUTHORS      Van Coillie,E.
TITLE        Functional comparison of two human monocyte chemotactic
protein-2
              isoforms, role of the amino-terminal pyroglutamic acid and
              processing by CD26/dipeptidyl peptidase IV
JOURNAL      Biochemistry 37, 12672-12680 (1998)
REFERENCE    2 (bases 1 to 1368)
AUTHORS      Van Coillie,E.
TITLE        Direct Submission
JOURNAL      Submitted (23-FEB-1998) E. Van Coillie, Rega Institute for
Medical
              Research, Minderbroedersstraat 10, 3000 Leuven, BELGIUM
COMMENT      Related sequences: X99886, Y10802.
FEATURES
  source      Location/Qualifiers
              1..1368
              /organism="Homo sapiens"
              /db_xref="taxon:9606"
              /chromosome="17"
              /tissue_type="testis"
              /clone_lib="Clontech"
              /clone="HL1142q"
              /map="ql1.2"
  gene        473..772
              /gene="MCP-2"
  sig_peptide 473..541
              /gene="MCP-2"
  CDS         473..772
              /gene="MCP-2"
              /codon_start=1
              /product="monocyte chemotactic protein-2"
              /db_xref="PID:e1253690"
              /db_xref="PID:g2916796"

/translation="MKVSAALLCLLLMAATFSPQGLAQPDVSIPITCCFNVINRKIP
IQRLESYTRITNIQCPKEAVIFKTKRGKEVCADPKERWVRDSMKHLDQIFQNLKP"
  mat_peptide 542..769
              /gene="MCP-2"
  variation    677
              /gene="MCP-2"
              /note="polymorphism, Lys -> Gln"
              /replace="c"
BASE COUNT   457 a    292 c    243 g    376 t
ORIGIN
      1 atccattgtg ctctaaagtg atggagagca ccagcaaagc cttagggccc atccctggcc
     61 tcctgttacc cacagagggg taggcccttg gctctcttc actatgacgt cagcttccat
    121 tcttcctttc ttatagacaa ttttccattt caaggaaatc agagccctta atagtccagt
    181 gaggtcactt tgctgagcac aatcccatac ccttcagcct ctgctccaca gaggcctaagc
    241 aaaagataga aactcacaac ttccttgttt tgttatctgg aaattatccc aggatctggg
    301 gcttactcag catattcaag gaaggtctta cttcattctt ccttgattgt gaccatgcc
    361 aggctctctg ctccctataa aaggcaggca gagccaccga ggagcagaga ggttgagaac

```

```

421 aaccagaaa ccttcacctc tcatgctgaa gctcacaccc ttgccctcca agatgaaggt
481 ttctgcagcg cttctgtgcc tgetgctcat ggcagccact ttcagccctc agggacttgc
541 tcagccagat tcagtttcca ttccaatcac ctgctgcttt aacgtgatca ataggaaaat
601 tcctatccag aggctggaga gctacacaag aatcaccaac atccaatgtc ccaagggaagc
661 tgtgatcttc aagaccaaac ggggcaagga ggtctgtgct gaccccaagg agagatgggt
721 cagggattcc atgaagcatc tggaccaaat atttcaaaat ctgaagccat gagccttcat
781 acatggactg agagtcagag cttgaagaaa agcttattta ttttcccaa cctccccag
841 gtgcagtgtg acattatttt attataacat ccacaaagag attattttta aataatttaa
901 agcataatat ttcttaaaaa gtatttaatt atatttaagt tgttgatgtt ttaactctat
961 ctgtcataca tcctagttaa tgtaaaatgc aaaatcctgg tgatgtgttt tttgttttg
1021 ttttcctgtg agctcaacta agttcacggc aaaatgtcat tgttctccct cctacctgc
1081 tgtagtgttg tgggtgcctc ccatggatca tcaagggtgaa acactttgtt attccttggc
1141 aatcagtgtc cctgtaagtc aaatgtgtgc tttgtactgc tgttggtgaa attgatgtta
1201 ctgtatataa ctatggaatt ttgaaaaaaa atttcaaaaa gaaaaaaaata tatataattt
1261 aaaactaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa
1321 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa
//LOCUS      HSMCP3A      1085 bp      DNA      PRI      25-JUL-1994
DEFINITION   H.sapiens MCP-3 mRNA for monocyte chemotactic protein-3.
ACCESSION    X72308 S57464
NID          g313707
KEYWORDS     monocyte chemotactic protein 3.
SOURCE       human.
ORGANISM     Homo sapiens
              Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
              Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1 (bases 1 to 1085)
AUTHORS      Opdenakker,G., Froyen,G., Fiten,P., Proost,P. and Van Damme,J.
TITLE        Human monocyte chemotactic protein-3 (MCP-3): molecular cloning
of
              the cDNA and comparison with other chemokines
              Biochem. Biophys. Res. Commun. 191 (2), 535-542 (1993)
JOURNAL      93213290
MEDLINE
REFERENCE    2 (bases 1 to 1085)
AUTHORS      Opdenakker,G.M.
TITLE        Direct Submission
JOURNAL      Submitted (27-MAY-1993) G.M. Opdenakker, Rega Institute,
University   of Leuven, Minderbroedersstraat 10, B-3000 Leuven, BELGIUM
REFERENCE    3 (bases 1 to 1085)
AUTHORS      Opdenakker,G., Fiten,P., Nys,G., Froyen,G., Van Roy,N.,
              Speleman,F., Laureys,G. and Van Damme,J.
TITLE        The human MCP-3 gene (SCYA7): cloning, sequence analysis, and
              assignment to the C-C chemokine gene cluster on chromosome
              17q11.2-q12
JOURNAL      Genomics 21 (2), 403-408 (1994)
MEDLINE      94375065
FEATURES
  source      Location/Qualifiers
              1..1085
              /organism="Homo sapiens"
              /db_xref="taxon:9606"
  gene        299..810
              /gene="MCP-3"
  CDS         299..628
              /gene="MCP-3"
              /codon_start=1
              /product="monocyte chemotactic protein-3"
              /db_xref="PID:g313708"
              /db_xref="SWISS-PROT:P80098"

/translation="MWKPMPSPSNMKASAALLCLLLTAAAFSPQGLAQPVGINTSTTC
CYRFINKKIPKQRLSYRRTTSSHCPREAIVIFKTKLDKEICADPTQKWVQDFMKHLDK
              KTQTPKL"
  sig_peptide 299..397
              /gene="MCP-3"
  mat_peptide 398..625
              /gene="MCP-3"
              /product="monocyte chemotactic protein-3"
  polyA_signal 806..810
              /gene="MCP-3"
BASE COUNT   314 a      214 c      229 g      328 t

```

ORIGIN

```

1  ggtttctatt gacttgggtt aatcgtgtga ccgcggtggc tggcacgaaa ttgaccaacc
61  ctgggggttag tatagcttag ttaaactttc gtttattgct aaagggtaat cactgctgtt
121 tcccgtgggg gtgtggcttag gctaagcgtt ttgagctgca ttgctgctgt cttgatgctt
181 gtcccttttg atcgtgggtga tttagagggt gaactcactg gaatggggat gcttgcatgt
241 gtaatcttac taagagctaa tagaaaggct aggaccaaac cagaaacctc caattctcat
301 gtggaagccc atgccctcac cctccaacat gaaagcctct gcagcacttc tgtgtctgct
361 gctcacagca gctgctttca gccccagggt gcttgctcag ccagttggga ttaactcttc
421 aactacctgc tgctacagat ttatcaataa gaaaatccct aagcagaggc tggagagcta
481 cagaaggacc accagtagcc actgtccccg ggaagctgta atcttcaaga ccaaactgga
541 caaggagatc tgtgctgacc ccacacagaa gtgggtccag gactttatga agcacctgga
601 caagaaaacc caaactccaa agctttgaac attcatgact gaactgaaaa caagccatga
661 cttgagaaac aaataatttg tataccctgt cctttctcag agtgggtctg agattatatt
721 aatctaattc taaggaatat gagctttatg taataatgtg aatcatgggt tttcttagta
781 gattttaaaa gttattaata ttttaattta atcttccatg gattttgggt ggttttgaac
841 ataaagcctt ggatgtatat tgcattctag tgctgtaaaa actgtgggag gctcctcctt
901 tctctacctc atgggggtat tgtataagtc cttgcaagaa tcagtgcata gatttgcttt
961 aattgttaag atatgatgtc cctatggaag catattgtta ttatataatt acatatattgc
1021 atatgtatga ctcccaaatt ttcacataaa atagattttt gtataacaaa aaaaaaaaaa
1081 aaaaa

```

//

```

LOCUS      HSMCP3A      1085 bp      DNA      PRI      25-JUL-1994
DEFINITION H.sapiens MCP-3 mRNA for monocyte chemotactic protein-3.
ACCESSION  X72308 S57464
NID        g313707
KEYWORDS   monocyte chemotactic protein 3.
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 1085)
AUTHORS    Opdenakker,G., Froyen,G., Fiten,P., Proost,P. and Van Damme,J.
TITLE      Human monocyte chemotactic protein-3 (MCP-3): molecular cloning
of         the cDNA and comparison with other chemokines
JOURNAL    Biochem. Biophys. Res. Commun. 191 (2), 535-542 (1993)
MEDLINE    93213290
REFERENCE  2 (bases 1 to 1085)
AUTHORS    Opdenakker,G.M.
TITLE      Direct Submission
JOURNAL    Submitted (27-MAY-1993) G.M. Opdenakker, Rega Institute,
University of Leuven, Minderbroedersstraat 10, B-3000 Leuven, BELGIUM
REFERENCE  3 (bases 1 to 1085)
AUTHORS    Opdenakker,G., Fiten,P., Nys,G., Froyen,G., Van Roy,N.,
            Speleman,F., Laureys,G. and Van Damme,J.
TITLE      The human MCP-3 gene (SCYA7): cloning, sequence analysis, and
            assignment to the C-C chemokine gene cluster on chromosome
            17q11.2-q12
JOURNAL    Genomics 21 (2), 403-408 (1994)
MEDLINE    94375065
FEATURES   Location/Qualifiers
            source      1..1085
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
            gene        299..810
                        /gene="MCP-3"
            CDS          299..628
                        /gene="MCP-3"
                        /codon_start=1
                        /product="monocyte chemotactic protein-3"
                        /db_xref="PID:g313708"
                        /db_xref="SWISS-PROT:P80098"

/translation="MWKPMSPSPNMKASAAALLCLLLTAAAFSPQGLAQPVGINTSTTC
CYRFINKKIPKQRLSYRRTTSSHCPCREAVIFKTKLDKEICADPTQKWVQDFMKHLDK
            KTQTPKL"
            sig_peptide 299..397
                        /gene="MCP-3"
            mat_peptide 398..625

```

```

                                /g ne="MCP-3"
                                /product="monocyte chemotactic protein-3"
polyA_signal 806..810
                                /gene="MCP-3"
BASE COUNT 314 a 214 c 229 g 328 t
ORIGIN
1 ggtttctatt gacttgggtt aatcgtgtga ccgcggtggc tggcacgaaa ttgaccaacc
61 ctgggggttag tatagcttag ttaaactttc gtttattgct aaaggttaat cactgctgtt
121 tcccgtgggg gtgtggctag gctaagcgtt ttgagctgca ttgctgcgtg cttgatgctt
181 gtcccttttg atcgtgggtga tttagagggt gaactcactg gaatggggat gcttgcatgt
241 gtaatcttac taagagctaa tagaaaggct aggaccaaac cagaaacctc caattctcat
301 gtggaagccc atgccctcac cctccaacat gaaagcctct gcagcacttc tgtgtctgct
361 gctcacagca gctgctttca gcccccaggg gcttgctcag ccagttggga ttaatacttc
421 aactacctgc tgctacagat ttatcaataa gaaaatccct aagcagagcta tggagagcta
481 cagaaggacc accagtagcc actgtccccg ggaagctgta atcttcaaga ccaaactgga
541 caaggagatc tgtgctgacc ccacacagaa gtgggtccag gactttatga agcacctgga
601 caagaaaacc caaactccaa agctttgaac attcatgact gaactgaaaa agattatctt
661 cttgagaaac aaataatttg tataccctgt cctttctcag agtggttctg agattatctt
721 aatctaattc taagggaatat gagctttatg taataatgtg aatcatggtt tttcttagta
781 gattttaaaa gttattaata ttttaattta atcttccatg gattttggtg ggttttgaac
841 ataaagcctt ggatgtatat gtcattcagc tgctgtaaaa actgtgggat gctcctccct
901 tctctacctc atgggggtat gtataagtc cttgcaagaa tcagtgcgaa gatttgcttt
961 aattgttaag atatgatgtc cctatggaag catattgtta ttatataatt acatatttgc
1021 atatgtatga ctcccaaatt ttcacataaa atagattttt gtataacaaa aaaaaaaaaa
1081 aaaaa

//LOCUS HSU46767 825 bp mRNA PRI 16-DEC-1996
DEFINITION Human monocyte chemoattractant protein-4 precursor (MCP-4)
mRNA,
complete cds.
ACCESSION U46767
NID g1732122
KEYWORDS
SOURCE human.
ORGANISM Homo sapiens
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 825)
AUTHORS Garcia-Zepeda, E.A., Combadiere, C.C., Rothenberg, M.E.,
Sarafi, M.N., Lavigne, F., Hamid, Q., Murphy, P. and Luster, A.D.
TITLE Human monocyte chemoattractant Protein (MCP)-4: A novel CC
chemokine with activities on monocytes, eosinophils, and
basophils
induced in allergic and non-allergic inflammation that signals
through the CC chemokine receptors CCR-2 and 3
JOURNAL J. Immunol. 158 (1996) In press
REFERENCE 2 (bases 1 to 825)
AUTHORS Garcia-Zepeda, E.A. and Luster, A.D.
TITLE Direct Submission
JOURNAL Submitted (22-JAN-1996) Eduardo A. Garcia-Zepeda, Infectious
Disease Unit, Massachusetts General Hospital, 149 13th St.,
Charlestown, MA 02129, USA
FEATURES
source Location/Qualifiers
1..825
/organism="Homo sapiens"
/db_xref="taxon:9606"
/tissue_type="heart"
/clone_lib="EG3.16"
sig_peptide 34..102
/ gene="MCP-4"
CDS 34..330
/ gene="MCP-4"
/ note="small cytokine; intercrine/chemokine; C-C
subfamily signature; chemoattractant for monocytes, eosinophils"
/codon_start=1
/product="monocyte chemoattractant protein-4
precursor"
/db_xref="PID:g1732123"

/translation="MKVSAVLLCLLLMTAAFNPOGLAQPDALNVPSTCCFTFSSKKIS

```

```

LQRLKSYVITTSRCPQKAVIFRTKLGKEICADPKEKWVQNYMKHLGRKAHTLKT"
  gene                34..330
                     /gene="MCP-4"
  mat_peptide         103..327
                     /gene="MCP-4"
BASE COUNT          221 a    175 c    185 g    244 t
ORIGIN
    1 acattgtgaa atctccaact cttaaccttc aacatgaaag tctctgcagt gcttctgtgc
   61 ctgctgctca tgacagcagc tttcaacccc cagggacttg ctcagccaga tgcactcaac
  121 gtcccatcta cttgctgctt cacatttagc agtaagaaga tctccttgca gaggctgaag
  181 agctatgtga tcaccaccag caggtgtccc cagaaggctg tcattctcag aaccaaactg
  241 ggcaaggaga tctgtgctga cccaaaggag aagtgggtcc agaattatat gaaacacctg
  301 ggccggaaag ctcacaccct gaagacttga actctgttac ccctactgaa atcaagctgg
  361 agtacgtgaa atgacttttc cattctcctc tggcctcctc ttctatgctt tgggaatactt
  421 ctaccataat tttcaaatag gatgcattcg gttttgtgat tcaaaatgta ctatgtgtta
  481 agtaatatgg gctattatgt gacttggtgc tggtttgagg tttatttgag tattgctgat
  541 cttttctaaa gcaaggcctt gagcaagtag gttgctgtct ctaagcccc ttcccttcca
  601 ctatgagctg ctggcagtggt gttgtattcg gttcccaggg gttgagagca tgcctgtggg
  661 agtcatggac atgaagggat gctgcaatgt aggaaggaga gctctttgtg aatgtgaggt
  721 tgttgctaaa ttattgttta ttgtggaaag atgaatgcaa tagtaggact gctgacattt
  781 tgcagaaaaat acattttatt taaaatctcc taaaaaaaaa aaaaa
//LOCUS          HSAMAC1      803 bp    RNA          PRI          10-AUG-1997
DEFINITION      Homo sapiens mRNA for alternative activated macrophage specific
CC
               chemokine 1.
ACCESSION      Y13710
NID            g2326515
KEYWORDS       AMAC-1 gene; CC-chemokine 1.
SOURCE         human. ORGANISM Homo sapiens
               Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
               Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
Hominidae;
               Homo.
REFERENCE      1 (bases 1 to 803)
AUTHORS       Politz,O.
TITLE         Direct Submission
JOURNAL       Submitted (10-JUN-1997) Politz O., Dermatology, Free University
               Benjamin Franklin Medical Center, Hindenburgdamm 30; 12200
Berlin
               GERMANY
REFERENCE      2 (bases 1 to 803)
AUTHORS       Kodelja,V., Mueller,C., Politz,O., Hakiy,N., Orfanos,C.E. and
               Goerdts,S.
TITLE         Cloning of alternative activated macrophage associated CC
               chemokine
               1 (AMAC-1)
JOURNAL       Unpublished
FEATURES
  source       Location/Qualifiers
               1..803
               /organism="Homo sapiens"
               /db_xref="taxon:9606"
               /cell_type="macrophage"
  sig_peptide  71..133
               /gene="amac-1"
  CDS          71..340
               /gene="amac-1"
               /note="macrophage specific"
               /codon_start=1
               /product="CC-chemokine 1"
               /db_xref="PID:e321838"
               /db_xref="PID:g2326516"
/translation="MKGLAAALLVLVCTMALCSCAQVGTNKELCCLVYTSWQIPQKFI
               VDYSETSPQCPKPGVILLTKRGRQICADPNKKWVQKYISDLKLNA"
  gene                71..340
                     /gene="amac-1"
  mat_peptide         134..337
                     /gene="amac-1"
BASE COUNT          214 a    213 c    160 g    216 t
ORIGIN

```



```

      1 ccggcagcag aggagttgtg agtttccaag cccagctca ctctgaccac ttctctgcct
    61 gcccagcatc atgaagggcc ttgcagctgc cctccttgtc ctctgtctgca ccattggcctt
   121 ctgtctcctgt gcacaagttg gtaccaacaa agagctctgc tgcctcgtct atacctcctg
   181 gcagattcca caaaagttca tagttgacta ttctgaaacc agccccaggt gccccaagcc
   241 aggtgtcatc ctcttaacca agagaggccg gcagatctgt gctgacccca ataagaagtg
   301 ggtccagaaa tacatcagcg acctgaagct gaatgcctga ggggcctgga agctgcgagg
   361 gcccagtgaa cttggtgggc ccaggaggga acaggagcct gagccagggc aatggccctg
   421 ccaccctgga gggcacctct tctaagagtc ccatctgcta tgcccagcca cattaactaa
   481 ctttaatctt agtttatgca tcatatttca ttttgaaatt gatttctatt gttgagctgc
   541 attatgaaat tagtattttc tctgacatct catgacattg tctttatcat cctttcccct
   601 ttcccttcaa ctcttcgtac attcaatgca tggatcaatc agtgtgatta gctttctcag
   661 cagacattgt gccatatgta tcaaattgaca aatctttatt gaatggtttt gctcagcacc
   721 accttttaat atattggcag tactttattat ataaaaggta aaccagcatt ctcactgtga
   781 aaaaaaaaaa aaaaaaaaaa aaa

```

```

//
LOCUS      HUMLD78A      3176 bp      DNA      PRI      17-JAN-1992
DEFINITION Human LD78 alpha gene.
ACCESSION  D90144
NID        g219905
KEYWORDS   LD78; LD78 alpha; cytokine; inducible gene family; secreted
           peptide.
SOURCE     Human blood lymphocyte DNA, clone Lm LD-3.
ORGANISM   Homo sapiens
           Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
           Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
Hominidae; Homo.
REFERENCE  1 (bases 1 to 3176)
AUTHORS   Nakao,M., Nomiya,H. and Shimada,K.
TITLE     Structures of human genes coding for cytokine LD78 and their
           expression
JOURNAL   Mol. Cell. Biol. 10 (7), 3646-3658 (1990)
MEDLINE   90287155
COMMENT   These data kindly submitted in computer readable form by:
Hisayuki

```

```

Nomiya
Department of Biochemistry
Kumamoto University Medical School
2-2-1 Honjo, Kumamoto 860
Japan
Phone: 096-344-2111
Fax: 096-372-6140.
FEATURES   Location/Qualifiers
           source          1..3176
                           /organism="Homo sapiens"
                           /db_xref="taxon:9606"
           TATA_signal     1041..1045
           exon            1069..1227
                           /number=1
           prim_transcript 1069..2957
                           /note="LD78 alpha mRNA and introns"
           sig_peptide     1155..1220
                           /note="LD78 alpha signal peptide"
           CDS             join(1155..1227,1916..2030,2451..2541)
                           /codon_start=1
                           /product="LD78 alpha precursor"
                           /db_xref="PID:d1014875"
                           /db_xref="PID:g219906"

```

```

/translation="MQVSTAALAVLLCTMALCNQFSASLAADTPTACCFSYTSRQIPQ
NFIADYFETSSQCSKPGVIFLTKRSRQVCADPSEEWQKYVSDLELSA"
           mat_peptide     join(1218..1227,1916..2030,2451..2538)
                           /partial
                           /note="LD78 alpha mature peptide"
           intron          1228..1915
           exon            1916..2030
                           /partial
                           /number=2
           intron          2031..2450
           exon            2451..2957
                           /number=3

```

```

BASE COUNT      833 a      741 c      752 g      850 t
ORIGIN
1  acccagggac  ctatcacaca  aatataagaa  ctattcattc  ttttaaggcat  gtattttccaa
61  gcctttgtat  ttttttccat  gcttaggggt  ggcaaggaat  atatatatat  ttgtacaaat
121  atatatgtgt  atatgtacaa  atacatgtat  atatagtaca  aatatatata  tatattttgta
181  caattcttca  gactttgtag  aattttgtata  atgtcgtatc  ttgctttttt  taaccactga
241  tgttataaagc  atattttatgc  cacttcattc  atttttagaga  cttaataata  aatgatctag
301  tggataattt  atcattccct  gatggagaaa  aatttagctt  tgtttatttt  agagtataaa
361  acgatgctgg  gtcaggtatc  tttatgtttg  aagatggctc  catatttggg  ttgtttccac
421  agaactcttt  cctagaaatg  ctttttctag  gttaatggct  acagatattt  ctaggcacct
481  gacatatgta  caccacctc  taaagtattt  ttatgatcca  caactagcgt  ttaacacagc
541  gccctagtca  ctacatgact  aataaataga  caaatgactg  aaacatgacc  tcattgctttc
601  tattcctcca  gctttcattc  agttccttgc  ctctgggagg  aggaaggggt  gtgcagccct
661  ccacagcatc  agcccatcaa  ccctatccct  gtggttatag  cagctgagga  agcagaattg
721  cagctctgtg  ggaaggaatg  gggctggaga  gttcatgcac  agaccagttc  ttatgagaag
781  ggactgacta  agaatagcct  tgggttgaca  tatacccttc  ttcacactca  caggagaaa
841  catttcccta  tgaaactata  acaagtcatg  agttgagagc  tgagagttag  agaatagctc
901  aaagatgcta  ttcttgagata  tcctgagccc  ctgtgggtcac  cagggacctc  gagttgtgca
961  acttagcatg  acagcatcac  tacgttaaaa  aatttccctc  ctcaccccca  gattccattt
1021  ccccatccgc  cagggtgccc  tataaagagg  agagctgggt  tcagacttca  gaaggacacg
1081  ggcagcagac  agtggtcagt  cctttcttgg  ctctgctgac  actcgagccc  acattccgtc
1141  acctgctcag  aatcatgcag  gtctccactg  ctgcccttgc  tgcctcctc  tgcaccatgg
1201  ctctctgcaa  ccagttctct  gcatcacgtg  agtctgagtt  tcgttgtggg  tatcaccact
1261  ctctggccat  ggtagacca  catcaatctt  ttcttgtggc  ctaaaagccc  ccaagataaa
1321  agagaacttc  ttaaagggtc  gccaaacatc  ttggtctttc  tctttaagac  ttttattttt
1381  atctctagaa  ggggtcttag  ccccttagtc  tcagggtatg  agaacttagg  caggggcagg
1441  ggagttacag  tcccttttac  agatagaaaa  acaggggtcg  aaacgaatca  gttagcaaga
1501  ggagaaatcc  agggctgctt  acttcccagt  ggggtatggt  gttcacttca  caggtcctc
1561  taggtctccc  aggagctctg  tcccttggat  gtcttatgag  agatgtccaa  ggcttctctt
1621  ggggtggggg  atgacttctt  gaaccagaca  aaattccctg  aagagaactg  agataagaga
1681  acagtccgtt  caggtatctg  gatcacacag  agaaacagag  aaccactat  gaagagtcaa
1741  ggagaaagaa  ggatacacag  agaaacaaag  agacatttct  cagcaaaaa  gccaaaatgc
1801  ctccagtc  ctgtgtctga  gcaagcctgc  ctctctcaac  tgctcgggga  tcagaagctg
1861  cctggccttt  tctctgagc  tgtgactcgg  gctcattctc  ttctttctc  cacagttgct
1921  gctgacacgc  cgaccgcctg  ctgcttcagc  tacacctccc  ggcagattcc  acagaatttc
1981  atagctgact  actttgagac  gagcagccag  tgctccaagc  ccggtgtcat  gtaagtcca
2041  gtcttctg  tcacctctat  ggaggtaggg  aggggtcagg  ttggggcaga  gacaggccag
2101  aaggctatcc  tggaaaggcc  cagccttcag  gagcctatcg  gggatacagg  acgcagggct
2161  ccgaggtgtg  acctgacttg  gagctggagt  gaggcattgt  ttacagagtc  aggaagggct
2221  gccccagccc  agaggaaagg  gacaggaaga  aggaggcagc  gggacactct  gagggccacc
2281  cctactgagt  cactgagaga  agctctctag  acagagatag  gcagggggcc  cctgaaagag
2341  gagcaagccc  tgagctgccc  aggacagaga  gcagaatggt  ggggccatgg  tgggccagg
2401  attcccctgc  tggattcccc  agtgcttaac  tcttctccc  ttctccacag  ctctctaacc
2461  aagcgaaagc  ggcaggctct  tgctgacccc  agtgaggagt  ggggtccagaa  atatgtcagc
2521  gacctggagc  tgagtgcctg  aggggtccag  aagcttcgag  gcccgagcag  ctcggtgggc
2581  ccagtgggga  ggagcaggag  cctgagcctt  gggaacatgc  gtgtgacctc  cacagctacc
2641  tcttctatgg  actggttgtt  gccaaacagc  cacactgtgg  gactcttctt  aacttaaat
2701  ttaactttatt  tatactattt  agtttttcta  atttatttct  gatttcacag  tgtgtttgtg
2761  attgtttgct  ctgagagttc  ccctgtcccc  tcccccttcc  ctacaccgcg  gtctgtgac
2821  aaccgagtg  ctgtcatcag  cctgtgttag  cagtcatggc  accaaagcca  ccagactgac
2881  aaatgtgtat  cggatgcttt  tgttcagggc  tgtgatcggc  ctggggaaat  aataaagatg
2941  ctcttttaaa  aggtaaacca  gtattgagtt  tggttttgtt  tttctggcaa  atcaaaatca
3001  ctggttaaga  ggaatcatag  gcaaagatta  ggaagaggtg  aaatggaggg  aaattgggag
3061  agatggggag  ggctaccaca  gagttatcca  cttacaacg  gagacacagt  tctggaacat
3121  tgaactacg  aatatgttat  aactcaaadc  ataacatgca  tgctctagga  gaattc

```

```

//
LOCUS      AF043339      225 bp      mRNA      PRI      23-FEB-1998
DEFINITION Homo sapiens macrophage inflammatory protein 1 alpha (MIP1a)
mRNA,
partial cds.
ACCESSION  AF043339
NID        g2905627
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 225)
AUTHORS    Jang, J.S. and Kim, B.E.
TITLE      Direct Submission
JOURNAL     Submitted (15-JAN-1998) Protein Engineering, General Institute

```

of Technology, Hyundai Pharm. Ind. Co., Ltd., 213 Sosa Bon 1-dong, Sosa-gu, Bucheon 422-231, Kor a

COMMENT forward primer (5'-tgcgcatcacttgctgctgaca-3')
reverse primer (5'-cttctggacccctcaggcact-3').

FEATURES Location/Qualifiers

source 1..225
/organism="Homo sapiens"
/db_xref="taxon:9606"
/cell_type="PHA-treated peripheral blood leukocyte"

gene <1..225
/gene="MIP1a"

primer_bind <1..19
/gene="MIP1a"
/PCR_conditions="94C-1min, 50C-1min, 72C-3min, 30 cycles;

DeltaCycler II from Ericomp"

CDS <1..213
/gene="MIP1a"
/function="CC chemokine"
/function="proinflammatory cytokine involved in inflammation"
/note="8-10 kDa"
/codon_start=1
/product="macrophage inflammatory protein 1 alpha"
/db_xref="PID:g2905628"

/translation="ASLAADTPTACCFSTSRQIPQNFADYFETSSQCSKPGVIFLT
KRSRQVCADPSEEWVQKYVSDLELSA"

primer_bind complement(205..225)
/gene="MIP1a"

BASE COUNT 50 a 68 c 62 g 45 t

ORIGIN

1 gcatcacttg ctgctgacac gccgaccgcc tgctgcttca gctacacctc ccggcagatt
61 ccacagaatt tcatagctga ctactttgag acgagcagcc agtgctccaa gcccgggtgc
121 atcttcctaa ccaagcgaag ccggcaggtc tgtgctgacc ccagtgagga gtgggtccag
181 aaatatgtca gcgacctgga gctgagtgcc tgaggggtcc agaag

//

LOCUS HUMLD78B 3112 bp DNA PRI 17-JAN-1992

DEFINITION Human LD78 beta gene.

ACCESSION D90145

NID g219907

KEYWORDS LD78; LD78 beta; cytokine; inducible gene family; secreted peptide.

SOURCE Human placenta DNA, clone Lm LD-1.

ORGANISM Homo sapiens
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
Hominidae;
Homo.

REFERENCE 1 (bases 1 to 3112)

AUTHORS Nakao,M., Nomiya,H. and Shimada,K.

TITLE Structures of human genes coding for cytokine LD78 and their expression

JOURNAL Mol. Cell. Biol. 10 (7), 3646-3658 (1990)

MEDLINE 90287155

COMMENT These data kindly submitted in computer readable form by:
Hisayuki Nomiya
Department of Biochemistry
Kumamoto University Medical School
2-2-1 Honjo, Kumamoto 860
Japan
Phone: 096-344-2111
Fax: 096-372-6140.

FEATURES Location/Qualifiers

source 1..3112
/organism="Homo sapiens"
/db_xref="taxon:9606"

repeat_unit 498..797
/note="Alu repeat"

```

TATA_signal      1078..1082
prim_transcript  1106..2995
                  /note="LD78 beta mRNA and introns"
exon              1106..1267
                  /note="LD78 beta precursor, coding region of exon 1"
                  /number=1
CDS               join(1192..1267,1953..2067,2488..2578)
                  /partial
                  /codon_start=1
                  /product="LD78 beta precursor"
                  /db_xref="PID:d1014876"
                  /db_xref="PID:g219908"

/translation="MQVSTAALAVLLCTMALCNQVLSAPLAADTPTACCFSYTSRQIP
              QNFIADYFETSSQCSKPSVIFLTRGRQVCADPSEEWQKYVSDLELSA"
sig_peptide      1192..1260
                  /partial
                  /note="LD78 beta signal peptide"
mat_peptide       join(1258..1267,1953..2067,2488..2575)
                  /partial
                  /note="LD78 beta mature peptide"
intron            1268..1952
exon              1953..2067
                  /number=2
intron            2068..2487
exon              2488..2955
                  /number=3
BASE COUNT       756 a      775 c      780 g      801 t
ORIGIN
1   ttagagactt aataataaag gatcttgtgg ataatttatt attccctgat agagaaaaat
61  ttagctttgc ttattttaga gttataaatg atgctgggtc aggtatcttt atgtttgaag
121 atggctccat atttgggttg ttccacaga actctttccc agaaatgctt tttctaggtt
181 aatggctaca catatttcta ggcacctgac atactgacac ccacctctaa agtattttta
241 tgatccacaa ctagegttta acacagcgcc ccagtcactc cgagactaat aaatagacaa
301 atgactgaaa cgtgacctca tgctttctat tctccagctt tcatttgagt tcctttcctc
361 tgggaggact gggggttgtc tagccctcca cagcatcagc ccattgacct tatccttggt
421 gttatagcag ctgaggaagc agaattacag ctctgtggga aggaatgggg ctggagagtt
481 catgcataga ccaattcttt tttttttttt tttttgagat ggagtttcac ttttgttgcc
541 caggctggag tgcaatggca tgatctcagc tcaccacagc cccacacctc tgggttcaag
601 cgattctcct gccctcagcc tcccgagtag ctgggattac aggcattgtc caccacgcct
661 gactactttt gtatttttag tagagatgga gtttctcttt ctgggtcagg ttggtctcaa
721 actcctgacc tcagtgatc cgagcctcg gcctcccaaa gtgttgggat tacaggtgtg
781 agcgaccatg cctggctgca tagaccagtt cttatgagaa gggatcaact aagaatagcc
841 ttgggttgac acacaccctt cttcacactc acaggagaaa ccccatgaag ctagaaccag
901 tcatgagttg agagctgaga gttagagagt agctcagaga tgctattctt ggatactctg
961 agccctgtg gtcaccaggg accctgagtt gtgcaacact cagcatgaca gcatcactac
1021 acttaaaaat ttccctcctc accccagatg tccatttccc catccgccag ggctgcctat
1081 aaaggagaga gatggcttca gacatcagaa ggacgcaggc agcaaagagt agtcagtcct
1141 ttcttggctc tgctgacact cgagcccaac ttccatcacc tgctcccaat catgcaggtc
1201 tccactgctg cccttgccgt cctcctctgc accatggctc tctgcaacca ggtcctctct
1261 gcaccacgtg agtccatgtt gttgttgtgg gtatcaccac tctctggcca tgggttagacc
1321 acatcagtct tttttgctg cctgagagcc ccgaagagaa aagaaggaag ttcttaaagc
1381 gctgccaaac accctgggtc tttctctcac aacttttatt tttatctcta gaagggtctt
1441 tagccctcct agtctccagg tatgagaatc taggcagggg caggggagtt acagtcctct
1501 gtacagatag aaaaacaggg ttcaaaacga atcagtttgc aagaggcaga atccagggtc
1561 gcttacttcc cagtgggggtc tgtgtgtcac tctccagctc accctagggtc tcccaggagc
1621 cctgtccctt ggatgtctta tgagagatgt ccagggtctt tcttgggctg gggatagact
1681 tcttgaaccg acaaaattcc atgaagagag ctaagagaa cagtcattca ggtatctgga
1741 tcacatagag aaacagagaa cccactatga agagtcaagg ggaagagga atatagacag
1801 aaacaaagag acatttctct gcaaaacccc ccaaatgcct tgcagtcact tgggtctgagc
1861 aagcctgccc tcctcaacca ctcagggtac agaagctgcc tggccttttc tcttgagctg
1921 tgactcgggc ttattctctc ctttctccgc agttgctgct gacacgcga ccgctgctg
1981 cttcagctac acctcccgac agattccaca gaatttcata gctgactact ttgagacgag
2041 cagccagtgc tccaagccca gtgtcatgta agtgccagtc ttccgtctca cctctaggga
2101 ggtaggaggt gtcagggttg gggcagaaac aggccagaag gccatcctgg aaaggcccag
2161 ccttcaggag cctatcggtg atacaggagc cagggcactg aggtgtgacc tgacttgggg
2221 ctggagttag gtgggtgtta cagagtcagg aagggtctgc ccaggccaga ggaaggaac
2281 aggaagaagg aggcagcagg acactcttag ggcccccttg cctggagtca ctgagagaag
2341 ctctctagac ggagataggc agggggcccc tgagagagga gcaggccttg agtgcgccag
2401 gacagagagc aggatgtcag gccatgggtg gccaggatt ccccggtctg attcccgagt
2461 gcttaactct tcctcccttc tccacagctt cctaaccaag agaggccggc aggtctgtgc

```

```

2521 tgacccccagt gaggagtggg tccagaaata cgtcagtgc ctggagctga gtgcctgagg
2581 ggtccagaag ctctcaggcc cagcgacctc agtgggccc gtggggagga gcaggagcct
2641 gagccttggg aacatgcgtg tgacctctac agctacctct tctatggact gggtattgcc
2701 aaacagccac actgtgggac tcttcttaac ttaaatttta atttattat actatttagt
2761 ttttataatt tatttttgat ttcacagtgt gtttgtgatt gtttgctctg agagttcccc
2821 ctgtccccctc caccttcctt cacagtgtgt ctgggtgacg ccgagtggct gtcctcgcc
2881 tgtgtaggca gtcattggc caaagccacc agactgacaa atgtgtatca gatgcttttg
2941 ttcagggtcg tgatcggcct ggggaaataa taaagatgtt cttttaaacg gtaaaccagt
3001 attgagtttg gttttgtttt tctggcaaat caaatcact agttaagagg aatcataggc
3061 aaagattagg aagaggtgaa atggagggaa actgggagag atggggagcg ct

//
LOCUS      HUMACT2A      696 bp      mRNA      PRI      30-OCT-1994
DEFINITION Human activation (Act-2) mRNA, complete cds.
ACCESSION  J04130
NID        g178017
KEYWORDS   act2 gene; immune activation gene.
SOURCE     Human (Hut-102B2 library) activated T cells, cDNA to mRNA.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 696)
AUTHORS    Lipes,M.A., Napolitano,M., Jeang,K.T., Chang,N.T. and
Leonard,W.J.
TITLE      Identification, cloning, and characterization of an immune
            activation gene
JOURNAL    Proc. Natl. Acad. Sci. U.S.A. 85 (24), 9704-9708 (1988)
MEDLINE    89071764
COMMENT     Draft entry and computer-readable sequence [1] kindly submitted
            by
            W.Leonard, 09-JAN-1989.
FEATURES   Location/Qualifiers
            source          1..696
                                /organism="Homo sapiens"
                                /db_xref="taxon:9606"
                                /map="Unassigned"
            mRNA            <1..696
                                /note="act-2 mRNA"
            sig_peptide     109..177
                                /gene="LAG2"
                                /note="act-2 protein signal peptide"
            gene            109..387
                                /gene="LAG2"
            CDS             109..387
                                /gene="LAG2"
                                /note="act-2 protein precursor"
                                /codon_start=1
                                /db_xref="GDB:G00-127-452"
                                /db_xref="PID:g178018"

/translation="MKLCVTVL SLLMLVA AFCSPAL SAPMGSDPPTACCF SYTARKLP
            RNFVVDYYETSS LCSQPAVVFQTKRSKQVCADPSESWVQEYVYDLELN"
            mat_peptide     178..384
                                /gene="LAG2"
                                /note="act-2 protein"
BASE COUNT 157 a      203 c      139 g      197 t
ORIGIN      Unreported.
            1 ttccccccc ccccccccc ccccgccga gcacaggaca cagctgggtt ctgaagcttc
            61 tgagttctgc agcctcacct ctgagaaaac ctcttttcca ccaataccat gaagctctgc
            121 gtgactgtcc tgtctctcct catgctagta gctgccttct gctctccagc gctctcagca
            181 ccaatgggct cagaccctcc caccgcctgc tgcttttctt acaccgagag gaagcttcct
            241 cgcaactttg tggtagatta ctatgagacc agcagcctct gctcccagcc agctgtggta
            301 ttccaaacca aaagaagcaa gcaagtctgt gctgatccca gtgaatcctg ggtccaggag
            361 tacgtgtatg acctggaact gaactgagct gctcagagac aggaagtctt caggggaagg
            421 caccctgagc cggtgcttc tccatgagac acatctcttc catactcagg actcctctcc
            481 gcagttcctg tcccttctct taatttaac ttttttatgt gccgtgttat tgtattaggt
            541 gtcatttcca ttatttatat tagtttagcc aaaggataag tgtcctatgg ggatgggtcca
            601 ctgtcactgt ttctctgctg ttgcaaatat atggataaca catttgattc tgtgtgtttt
            661 ccataataaa actttaaaat aaaatgcaga cagtta

//
LOCUS      AF031587      481 bp      mRNA      PRI      02-JAN-1998
DEFINITION Homo sapiens MIP-1 delta mRNA, complete cds.

```

ACCESSION AF031587
 NID g2739163
 KEYWORDS .
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
 Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 481)
 AUTHORS Wang, W.
 TITLE Molecular cloning and characterization of a new CC chemokine
 MIP-1
 delta
 JOURNAL Unpublished
 REFERENCE 2 (bases 1 to 481)
 AUTHORS Wang, W.
 TITLE Direct Submission
 JOURNAL Submitted (27-OCT-1997) Immunobiology, DNAX Research Institute,
 901
 California Ave, Palo Alto, CA 94304, USA
 FEATURES Location/Qualifiers
 source 1..481
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /chromosome="17"
 CDS 1..342
 /note="CC or beta chemokine"
 /codon_start=1
 /product="MIP-1 delta"
 /db_xref="PID:g2739164"
 /translation="MKVSVAAALSCLMLVAVLGSQAQFINDAETELMMSKLPLENPVVL
 NSFHFAADCCTSYISQSI PCSLMKSYFETSSECSKPGVIFLTKKGRQVCAKPSGPGVQ
 DCMKKLKPYSI"
 BASE COUNT 140 a 112 c 100 g 129 t
 ORIGIN
 1 atgaaggtct ccgtggctgc cctctcctgc ctcatgcttg ttgctgtcct tggatcccag
 61 gcccagttca taaatgatgc agagacagag ttaatgatgt caaagcttcc actggaaaat
 121 ccagtagttc tgaacagctt tcactttgct gctgactgct gcacctccta catctcacia
 181 agcatcccggt gttcactcat gaaaagttat tttgaaacga gcagcgagtg ctccaagcca
 241 ggtgtcatat tcctcaccaa gaaggggagg caagtctgtg ccaaaccag tgggccggga
 301 gttcaggatt gcatgaaaaa gctgaagccc tactcaatat aataataaag agacaaaaga
 361 gggcagccac ccacctcaa cacctcctgt gaggttcttg gtctgaaata cttaaaaaat
 421 atatatattg ttgtgtcttg taatgaaagt aatgcatcta ataaagagta ttcaattttt
 481 t
 //
 LOCUS AF043340 234 bp mRNA PRI 23-FEB-1998
 DEFINITION Homo sapiens macrophage inflammatory protein 2 alpha (MIP2a)
 mRNA,
 partial cds.
 ACCESSION AF043340
 NID g2905629
 KEYWORDS .
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
 Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 234)
 AUTHORS Jang, J.S. and Kim, B.E.
 TITLE Direct Submission
 JOURNAL Submitted (15-JAN-1998) Protein Engineering, General Institute
 of
 Technology, Hyundai Pharm. Ind. Co., Ltd., 213 Sosa Bon 1-dong,
 Sosa-gu, Bucheon 422-231, Korea
 COMMENT forward primer (5'-tgcgccaccctggccactgaactg-3')
 reverse primer (5'-ccttccttctggtcagttgga-3').
 FEATURES Location/Qualifiers
 source 1..234
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /cell_type="PHA-treated peripheral blood leukocyte"

```

gene          <1..234
              /gene="MIP2a"
primer_bind   <1..21
              /gene="MIP2a"
              /PCR_conditions="94C-1min, 50C-1min, 72C-3min, 30
cycles;
              DeltaCycler II from Ericomp"
CDS           <1..222
              /gene="MIP2a"
              /function="CXC chemokine"
              /function="proinflammatory cytokine involved in
inflammation"
              /note="8-10 kDa"
              /codon_start=1
              /product="macrophage inflammatory protein 2 alpha"
              /db_xref="PID:g2905630"

/translation="APLATELRCQCLQTLQGIHLKNIQSVKVKSPGPHCAQTEVIATL
              KNGQKACLNPA SPMVKKIIIEKMLKNGKSN"
              complement(214..234)
primer_bind   /gene="MIP2a"
BASE COUNT    74 a    70 c    54 g    36 t
ORIGIN
      1 gcacccctgg ccactgaact gcgctgccag tgcttgccaga ccctgcaggg aattcacctc
     61 aagaacatcc aaagtgtgaa ggtgaagtcc cccggacccc actgcgcccc aaccgaagtc
    121 atagccacac tcaagaatgg gcagaaagct tgtctcaacc ccgcatcgcc catgggttaag
    181 aaaatcatcg aaaagatgct gaaaaatgyc aaatccaact gaccagaagg aagg

//
LOCUS         HSU77035      764 bp      mRNA          PRI      23-JAN-1997
DEFINITION    Human macrophage inflammatory protein 3 alpha (MIP-3a) mRNA,
              complete cds.
ACCESSION     U77035
NID           g1790924
KEYWORDS      .
SOURCE        human.
ORGANISM      Homo sapiens
              Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
              Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE     1 (bases 1 to 764)
AUTHORS       Rossi,D.L., Vicari,A.P., Franz-Bacon,K., McClanahan,T.K. and
              Zlotnik,A.
TITLE         Identification through bioinformatics of two new macrophage
              proinflammatory human chemokines: MIP-3alpha and MIP-3beta
JOURNAL       J. Immunol. 158 (3), 1033-1036 (1997)
MEDLINE       97166046
REFERENCE     2 (bases 1 to 764)
AUTHORS       Rossi,D.L. and Zlotnik,A.
TITLE         Direct Submission
JOURNAL       Submitted (31-OCT-1996) Immunology, DNAX Research Institute,
901
              California Ave., Palo Alto, CA 94304, USA
FEATURES
  source      Location/Qualifiers
              1..764
              /organism="Homo sapiens"
              /db_xref="taxon:9606"
              /cell_type="elutriated monocytes activated with
              LPS/IFN-GAMMA"
  gene        1..291
              /gene="MIP-3a"
  CDS         1..291
              /gene="MIP-3a"
              /note="chemokine"
              /codon_start=1
              /product="macrophage inflammatory protein 3 alpha"
              /db_xref="PID:g1790925"

/translation="MCCTKSLLLAALMSVLLHLGGESEAASNFDCCCLGYTDRILHPK
              FIVGFTRQLANEGCDINAIIFHTKKKLSVCANPKQTWVKYIVRLLSKKVKNM"
BASE COUNT    235 a    121 c    146 g    260 t    2 others
ORIGIN
      1 atgtgctgta ccaagagttt gctcctggct gctttgatgt cagtgcctgct actccacctc

```

```

61  tgcggcgaat  cagaagcagc  aagcaacttt  gactgctgtc  ttggatacac  agaccgtatt
121 cttcatccta  aatttattgt  gggcttcaca  cggcagctgg  ccaatgaagg  ctgtgacatc
181 aatgctatca  tctttcacac  aaagaaaaag  ttgtctgtgt  gcgcaaatcc  aaaacagact
241 tgggtgaaat  atattgtgcg  tctcctcagt  aaaaaagtca  agaacatgta  aaaactgtgg
301 cttttctgga  atggaattgg  acatagccca  agaacagaaa  gaaccttgct  ggggttggag
361 gtttcacttg  cacatcatgg  agggtttagt  gcttatctaa  ttgtgcctc  actggacttg
421 tccaattaat  gaagttgatt  catattgcat  catagtttgc  ttgtttaag  catcacatta
481 aaggtaaact  gtattttatg  ttatttatag  ctgtagggtt  tctgtgttta  gctatttaat
541 actaattttc  cataagctat  ttgggttag  tgcaaagtat  aaaattatat  ttggggggga
601 ataagattat  atggactttt  ttgcaagcaa  caagctattt  tttaaaamma  actatttaac
661 attcctttgt  ttatattgtt  ttgtctccta  aattgttgta  attgcattat  aaaataagaa
721 aaatattaat  aagacaaata  ttgaaataaa  agaaacaaaa  agtt

```

```

//
LOCUS      HSU77180      545 bp      mRNA      PRI      23-JAN-1997
DEFINITION Human macrophage inflammatory protein 3 beta (MIP-3beta) mRNA,
            complete cds.
ACCESSION  U77180
NID        gl791002
KEYWORDS   .
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 545)
AUTHORS    Rossi,D.L., Vicari,A.P., Franz-Bacon,K., McClanahan,T.K. and
            Zlotnik,A.
TITLE      Identification through bioinformatics of two new macrophage
            proinflammatory human chemokines: MIP-3alpha and MIP-3beta
JOURNAL    J. Immunol. 158 (3), 1033-1036 (1997)
MEDLINE    97166046
REFERENCE  2 (bases 1 to 545)
AUTHORS    Vicari,A. and Zlotnik,A.
TITLE      Direct Submission
JOURNAL    Submitted (01-NOV-1996) Immunology, DNAX Research Institute,
801
            California Ave, Palo Alto, CA 94304, USA
FEATURES   Location/Qualifiers
            source          1..545
                           /organism="Homo sapiens"
                           /db_xref="taxon:9606"
                           /cell_type="macrophages activated with LPS or IFNg"
                           /chromosome="9"
            gene            1..297
                           /gene="MIP-3beta"
            CDS              1..297
                           /gene="MIP-3beta"
                           /function="chemokine"
                           /codon_start=1
                           /product="macrophage inflammatory protein 3 beta"
                           /db_xref="PID:gl791003"

```

/translation="MALLLALSLVLWTSPAPTLSGTNDACCLSVTQKPIPGYIVR"

NFHYLLIKDGCVRPAVVFTTLRGRQLCAPDQPWVERIIQRLQRTSAKMKRRSS"

BASE COUNT 125 a 160 c 153 g 107 t

```

ORIGIN
1  atggccctgc  tactggccct  cagcctgctg  gttctctgga  cttccccagc  cccaactctg
61  agtggcacca  atgatgctga  agactgctgc  ctgtctgtga  cccagaaaac  catccctggg
121  tacatcgtga  ggaacttcca  ctaccttctc  atcaaggatg  gctgcagggt  gctgtctgta
181  gtgttcacca  cactgagggg  ccgccagctc  tgtgcacccc  cagaccagcc  ctgggtagaa
241  cgcacatccc  agagactgca  gaggacctca  gccaaagatg  agcgccgtag  cagttaacct
301  atgaccgtgc  agagggagcc  cggagtccga  gtcaagcatt  gtgaattatt  acctaacctg
361  gggaaaccgag  gaccagaagg  aaggaccagg  cttccagctc  ctctgcacca  gacctgacca
421  gccaggacag  ggcttgggg  gtgtgtgagt  gtgagtgtga  gcgagagggt  gagtgtggtc
481  tagagtaaag  ctgctccacc  ccagattgca  aatgctacca  ataaagccgc  ctggtgttta
541  caact

```

```

//
LOCUS      HUMTCSM      1160 bp      mRNA      PRI      15-JUN-1989
DEFINITION Human T cell-specific protein (RANTES) mRNA, complete cds.
ACCESSION  M21121
NID        g339420

```


KEYWORDS Alu repeat; T-cell-specific protein.

SOURCE Human peripheral blood (T lymphocyte) cell line AH2, cDNA to mRNA,
clone 228.

ORGANISM Homo sapiens
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 1160)

AUTHORS Schall,T.J., Jongstra,J., Dyer,B.J., Jorgensen,J.,
Clayberger,C.,
Davis,M.M. and Krensky,A.M.

TITLE A human T cell-specific molecule is a member of a new gene family

JOURNAL J. Immunol. 141, 1018-1025 (1988)

MEDLINE 88285659

COMMENT Draft entry and computer-readable sequence for [1] kindly provided
by A.M.Krensky, 24-OCT-1988.

FEATURES Location/Qualifiers

source 1..1160
/organism="Homo sapiens"
/db_xref="taxon:9606"

CDS 27..302
/note="T cell-specific protein precursor"
/codon_start=1
/db_xref="PID:g339421"

/translation="MKVSAARLAVILIATLALCAPASAPYSSDTTPCCFAYIARPLPR
AHIKEYFYTSGKCSNPVVFVTRKNRQVCANPEKKWVREYINSLEMS"

sig_peptide 27..95
/note="T cell-specific protein signal peptide"

mat_peptide 96..299
/note="T cell-specific protein"

repeat_region 450..950
/note="Alu-related repeats"

BASE COUNT 298 a 332 c 295 g 235 t

ORIGIN 276 bp upstream of RsaI site.

```

1 cctccgacag cctctccaca ggtaccatga aggtctccgc ggcacgcctc gctgtcatcc
61 tcattgctac tgccctctgc gctcctgcat ctgcctcccc atattcctcg gacaccacac
121 cctgctgctt tgccctacatt gcccgcccac tgccccgtgc ccacatcaag gagtatttct
181 acaccagtgg caagtgtctc aaccacagcag tcgtctttgt cacccgaaag aaccgccaaag
241 tgtgtgccaa ccagagagaag aaatgggttc gggagtacat caactctttg gagatgagct
301 aggatggaga gtccttgaac ctgaacttac acaaatttgc ctgtttctgc ttgctcttgt
361 cctagcttgg gaggtcttcc ctcactatcc taccaccacc gctccttgaa gggcccgat
421 tctgaccacg acgagcagca gttacaaaaa ccttccccag gctggacgtg gtggctcagc
481 cttgtaatcc cagcactttg ggaggccaag gtgggtggat cacttgaggt caggagttcg
541 agacagcctg gccaacatga tgaaacccca tgtgtactaa aaatacaaaa aattagcccg
601 gcgtggtagc gggcgctgtg agtcccagct actcgggagg ctgaggcagg agaattggcg
661 gaacccggga gcggagcttg cagtgcgcgc agatcgcgcc actgcactcc agcctgggcy
721 acagagcgag actccgtctc aaaaaaaaaa aaaaaaaaaa aaaaaataca aaaattagcc
781 gcgtgggtgc ccacgcctgt aatcccagct actcgggagg ctaaggcagg aaaattgttt
841 gaacccagga ggtggaggct gcagtgcgtc gagattgtgc cacttcactc cagcctgggt
901 gacaaagtga gactccgtca caacaacaac aacaaaaagc tcccccaact aaagcctaga
961 agagcttctg aggcgctgct ttgtcaaaag gaagtctcta ggttctgagc tctggctttg
1021 ccttggtctt gcaagggctc tgtgacaagg aaggaagtca gcatgcctct agaggcaagg
1081 aagggaggaa cactgcactc ttaagcttcc gccgtctcaa cccctcacag gagcttactg
1141 gcaaacatga aaaatcgggg

```

//

LOCUS HUMTLI309 520 bp mRNA PRI 14-JAN-1995

DEFINITION Human secreted protein (I-309) mRNA, complete cds.

ACCESSION M57502

NID g339728

KEYWORDS secreted protein.

SOURCE Human T-cell, cDNA to mRNA.

ORGANISM Homo sapiens
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 520)

AUTHORS Miller,M.D., Hata,S., De Waal Malefyt,R. and Krangel,M.S.

TITLE A nov l polyp ptide secreted by activated human T lymphocytes

JOURNAL J. Immunol. 143 (9), 2907-2916 (1989)

MEDLINE 90038522

FEATURES

source Location/Qualifiers

1..520

/organism="Homo sapiens"

/db_xref="taxon:9606"

/cell_type="T-cell"

/germline

/map="17"

mRNA

<1..520

/gene="SCYA1"

/note="G00-118-872"

gene

1..520

/gene="SCYA1"

CDS

51..341

/gene="SCYA1"

/codon_start=1

/db_xref="GDB:G00-118-872"

/product="secreted protein I-309"

/db_xref="PID:g339729"

/translation="MQIIITTAIVCLLLAGMWPEDVDSKSMQVPPFSRCCFSFAEQEIPL
RAILCYRNTSSICSNEGLIFKLKRGKEACALDTVGWVQRHRKMLRHCPSKRK"

BASE COUNT 140 a 137 c 122 g 121 t

ORIGIN

1 accaggctca tcaaagctgc tccaggaagg cccaagccag accagaagac atgcagatca

61 tcaccacagc cctggtgtgc ttgctgctag ctgggatgtg gccggaagat gtggacagca

121 agagcatgca ggtacccttc tccagatgtt gcttctcatt tgcggagcaa gagattcccc

181 tgagggcaat cctgtgttac agaaatacca gctccatctg ctccaatgag ggcttaatat

241 tcaagctgaa gagaggcaaa gaggcctgcg ccttggacac agttggatgg gttcagaggc

301 acagaaaaat gctgaggcac tgcccgtaaa aaagaaaatg agcagatttc ttccatttgt

361 gggctctgga aaccacatgg cttcacctgt ccccgaaact accagcccta caccattcct

421 tctgccctgc ttttgctagg tcacagagga tctgcttggt cttgataagc tatgttggtg

481 cactttaaac atttaaatta tacaatcatc aacccccaac

//

LOCUS AB000887 687 bp mRNA PRI 05-JUN-1997

DEFINITION Human mRNA for EB11-ligand chemokine, complete cds.

ACCESSION AB000887

NID g2189952

KEYWORDS EB11-ligand chemokine; ELC.

SOURCE Homo sapiens fetal tissue_lib:lung cDNA to mRNA.

ORGANISM Homo sapiens

Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;

Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;

Hominidae;

Homo.

REFERENCE 1 (bases 1 to 687)

AUTHORS Yoshida,R., Imai,T., Hieshima,K., Kusuda,J., Baba,M.,

Kitaura,M.,

Nishimura,M., Kakizaki,M., Nomiya,H. and Yoshie,O.

TITLE Direct Submission

JOURNAL Submitted (05-FEB-1997) to the DDBJ/EMBL/GenBank databases.

Hisayuki Nomiya, Kumamoto University Medical School,

Department

of Biochemistry; Honjo 2-2-1, Kumamoto, Kumamoto 860, Japan

(E-mail:nomiya@gpo.kumamoto-u.ac.jp, Tel:+81-96-373-5063)

REFERENCE 2 (sites)

AUTHORS Yoshida,R., Imai,T., Hieshima,K., Kusuda,J., Baba,M.,

Kitaura,M.,

Nishimura,M., Kakizaki,M., Nomiya,H. and Yoshie,O.

TITLE Molecular cloning of a novel human CC chemokine EB11-ligand

chemokine that is a specific functional ligand for EB11, CCR7

J. Biol. Chem. 272 (21), 13803-13809 (1997)

MEDLINE 97298088

FEATURES

source Location/Qualifiers

1..687

/organism="Homo sapiens"

/db_xref="taxon:9606"

/dev_stage="fetal"

/tissue_lib="lung"

gene

139..435

/gene="ELC"

```

CDS             139..435
                /g ne="ELC"
                /note="CC chemokine"
                /codon_start=1
                /product="EBI1-ligand chemokine"
                /db_xref="PID:d1021215"
                /db_xref="PID:g2189953"

/translation="MALLLALLSLVLWTSPAPTLSGTNDACCLSVTQKPIPGYIVR
NFHYLLIKDGRVPAVVFTTLRGRQLCAPDQPWVERIIQRLQRTSAKMKRRSS"
mat_peptide     202..432
                /gene="ELC"
                /product="EBI1-ligand chemokine"
polyA_signal     657..662
BASE COUNT      154 a    223 c    173 g    137 t
ORIGIN
    1 cattcccagc ctcacatcac tcacaccttg catttcaccc ctgcatccca gtcgccctgc
   61 agcctcacac agatcctgca cacaccaga cagctggcgc tcacacattc accgttggcc
  121 tgcctctgtt caccctccat ggccctgcta ctggccctca gcctgctggg tctctggact
  181 tccccagccc caactctgag tggcaccaat gatgctgaag actgctgcct gtctgtgacc
  241 cagaaaccca tccctgggta catcgtgagg aacttccact accttctcat caaggatggc
  301 tgcagggtgc ctgctgtagt gttcaccaca ctgagggggc gccagctctg tgcaccccca
  361 gaccagccct gggtagaacg catcatccag agactgcaga ggacctcagc caagatgaag
  421 cgccgcagca gttaacctat gaccgtgcag agggagcccg gagtccgagt caagcattgt
  481 gaattattac ctaacctggg gaaccgagga ccagaaggaa ggaccaggct tccagctcct
  541 ctgcaccaga cctgaccagc caggacaggg cctgggggtg gtgtgagtg gtgtgtgagc
  601 gagagggtga gtgtggtcag agtaaagctg ctccaccccc agattgcaat gctaccaata
  661 aagccgctg gtgtttacaa ctaattg

//
LOCUS           AB000221       760 bp    mRNA             PRI       31-JUL-1997
DEFINITION      Homo sapiens mRNA for CC chemokine, complete cds.
ACCESSION       AB000221
NID             g2289718
KEYWORDS        CC chemokine; PARC; pulmonary and activation-regulated
chemokine.
SOURCE          Homo sapiens lung cDNA to mRNA.
ORGANISM        Homo sapiens
                Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
                Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
                Hominidae;
                Homo.
REFERENCE       1 (bases 1 to 760)
AUTHORS         Nomiyama,H.
TITLE           Direct Submission
JOURNAL         Submitted (04-JAN-1997) to the DDBJ/EMBL/GenBank databases.
                Hisayuki Nomiyama, Kumamoto University Medical School,
                Department
                of Biochemistry; Honjo 2-2-1, Kumamoto, Kumamoto 860, Japan
                (E-mail:nomiyama@gpo.kumamoto-u.ac.jp, Tel:81-96-373-5063,
                Fax:81-96-372-6140)
REFERENCE       2 (sites)
AUTHORS         Hieshima,K., Imai,T., Baba,M., Shoudai,K., Ishizuka,K.,
                Nakagawa,T., Tsuruta,J., Takeya,M., Sakaki,Y., Takatsuki,K.,
                Miura,R., Opdenakker,G., Damme,J., Yoshie,O. and Nomiyama,H.
TITLE           A novel human CC chemokine PARC that is most homologous to
chemotactic     macrophage-inflammatory protein-1alpha/LD78alpha and
                for T lymphocytes, but not for monocytes
JOURNAL         J. Immunol. 159 (3), 1140-1149 (1997)
MEDLINE         97376836
FEATURES        Location/Qualifiers
                source             1..760
                                /organism="Homo sapiens"
                                /db_xref="taxon:9606"
                                /tissue_type="lung"
                gene               64..333
                                /gene="PARC"
                CDS                64..333
                                /gene="PARC"
                                /note="pulmonary and activation-regulated chemokine"

```

/codon_start=1
 /product="CC chemokine"
 /db_xref="PID:d1022520"
 /db_xref="PID:g2289719"

/translation="MKGLAAALLVLVCTMALCSCAQVGTNKLCLVYTSWQIPQKFI
 VDYSETSPQCPKPGVILLTKRGRQICADPNKKWVQKYISDLKLNA"

BASE COUNT 186 a 208 c 155 g 211 t

ORIGIN

```

1 gccaggagtt gtgagtttcc aagccccagc tcactctgac cacttctctg cctgcccagc
61 atcatgaagg gccttgacgc tgccctcctt gtccctcgct gcaccatggc cctctgctcc
121 tgtgcacaag ttggtaccaa caaagagctc tgctgcctcg tctatacctc ctggcagatt
181 ccacaaaagt tcatagttga ctattctgaa accagcccc agtgcccaa gccagggtgtc
241 atcctcctaa ccaagagagg ccggcagatc tgtgctgacc ccaataagaa gtgggtccag
301 aaatacatca gcgacctgaa gctgaatgcc tgaggggcct ggaagctgcg agggcccagt
361 gaacttggtg ggcccaggag ggaacaggag cctgagccag ggcaatggcc ctgccaccct
421 ggaggccacc tcttctaaga gtcccatctg ctatgccag ccaatataac taactttaat
481 cttagtttat gcatcatatt tcatcttgaa attgatttct attggtgacc tgcattatga
541 aattagtatt ttctctgaca tctcatgaca ttgtctttat catcctttcc cctttccctt
601 caactcttcg tacattcaat gcatggatca atcagtgtga ttagctttct cagcagacat
661 tgtgccatat gtatcaaata acaaatcttt attgaatggt ttgctcagc accacctttt
721 aatatattgg cagtacttat tatataaaag gtaaaccagc

```

//

LOCUS D86955 799 bp mRNA PRI 06-MAR-1997
 DEFINITION Human mRNA for CC chemokine LARC precursor, complete cds.
 ACCESSION D86955
 NID gl871138
 KEYWORDS CC chemokine LARC precursor.
 SOURCE Homo sapiens cDNA to mRNA.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
 Hominidae;
 Homo.
 REFERENCE 1 (sites)
 AUTHORS Hieshima,K., Imai,T., Opdenakker,G., Van Damme,J., Kusuda,J.,
 Tei,H., Sakaki,Y., Takatsuki,K., Miura,R., Yoshie,O. and
 Nomiyama,H.
 TITLE Molecular cloning of a novel human CC chemokine liver and
 activation-regulated chemokine (LARC) expressed in liver.
 Chemotactic activity for lymphocytes and gene localization on
 chromosome 2
 JOURNAL J. Biol. Chem. 272 (9), 5846-5853 (1997)
 MEDLINE 97190319
 REFERENCE 2 (bases 1 to 799)
 AUTHORS Hieshima,K., Imai,T., Opdenakker,G., Van Damme,J., Kusuda,J.,
 Tei,H., Sakaki,Y., Takatsuki,K., Miura,R., Yoshie,O. and
 Nomiyama,H.
 JOURNAL Unpublished (1996)
 REFERENCE 3 (bases 1 to 799)
 AUTHORS Nomiyama,H.
 TITLE Direct Submission
 JOURNAL Submitted (08-AUG-1996) to the DDBJ/EMBL/GenBank databases.
 Hisayuki Nomiyama, Kumamoto University Medical School,

Department

of Biochemistry; Honjo 2-2-1, Kumamoto, Kumamoto 860, Japan
 (E-mail:nomiyama@gpo.kumamoto-u.ac.jp, Tel:+81-96-373-5063)

FEATURES

source

Location/Qualifiers

1..799

/organism="Homo sapiens"

/db_xref="taxon:9606"

/chromosome="2"

/map="q33-37"

sig_peptide

59..136

/gene="LARC"

CDS

59..349

/gene="LARC"

/codon_start=1

/product="CC chemokine LARC precursor"

/db_xref="PID:d1013880"

/db_xref="PID:gl871139"

```

/translation="MCCTKSLLLAALMSVLLLHLGGESEASNFDCCLGYTDRILHPK
              FIVGFTRQLANEGCDINAIIFHTKKKLSVCANPKQTVWKYIVRLLSKVKVNM"
gene          59..349
              /gene="LARC"
mat_peptide   137..346
              /gene="LARC"
              /product="CC chemokine LARC"
BASE COUNT    240 a    138 c    153 g    268 t
ORIGIN
      1 cactcccaaa gaactgggta ctcaacactg agcagatctg ttctttgagc taaaaacccat
     61 gtgctgtacc aagagtttgc tcctggctgc tttgatgtca gtgctgtacc tccacctctg
    121 cggcgcaatca gaagcagcaa gcaactttga ctgctgtcct ggatacacag accgtattct
    181 tcacctaataa ttattgtggg gcttcacacg gcagctggcc aatgaaggct gtgacatcaa
    241 tgctatcatc tttcacacaa agaaaaagtt gtctgtgtgc gcaaatccaa aacagacttg
    301 ggtgaaatat attgtgcgtc tcctcagtaa aaaagtcaag aacatgtaaa aactgtggct
    361 tttctggaat ggaattggac atagcccaag aacagaaaga accttgctgg ggttggaggt
    421 ttcacttgca catcatggag ggtttagtgc ttatctaatt tgtgcctcac tggacttgtc
    481 caattaatga agttgattca tattgcatca tagtttgctt tgtttaagca tcacattaaa
    541 gttaaaactgt attttatggt atttatagct gtaggttttc tgtgttagc tatttaatac
    601 taattttcca taagctatatt tggtttagtg caaagtataa aattataatt gggggggaat
    661 aagattatat ggactttctt gcaagcaaca agctattttt taaaaaaact atttaacatt
    721 cttttgttta tattgttttg tctcctaaat tgttgtaatt gcattataaa ataagaaaaa
    781 cattaataag acaaatatt

//
LOCUS          HUMAR          538 bp    mRNA          PRI          11-SEP-1996
DEFINITION     Human mRNA for chemokine, complete cds.
ACCESSION      D43767
NID            g1536878
KEYWORDS       chemokine, thymus and activation-regulated; chemokine.
SOURCE         Homo sapiens male peripheral blood cDNA to mRNA, clone:D3A.
               ORGANISM
               Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
               Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
               Hominidae;
               Homo.
REFERENCE      1 (sites)
AUTHORS        Imai,T., Yoshida,T., Baba,M., Nishimura,M., Kakizaki,M. and
               Yoshie,O.
TITLE          Molecular cloning of a novel T cell-directed CC chemokine
expressed      in thymus by signal sequence trap using Epstein-Barr virus
vector
JOURNAL        J. Biol. Chem. 271 (35), 21514-21521 (1996)
MEDLINE        96355526
REFERENCE      2 (bases 1 to 538)
AUTHORS        Imai,T.
JOURNAL        Unpublished (1996)
REFERENCE      3 (bases 1 to 538)
AUTHORS        Imai,T.
TITLE          Direct Submission
JOURNAL        Submitted (07-DEC-1994) to the DDBJ/EMBL/GenBank databases.
Toshio
               Imai, Shionogi Institute for Medical Science; 2-5-1 Mishima,
               Settsu, Osaka 566, Japan (Tel:06-382-2612, Fax:06-382-2598)
FEATURES
  source       1..538
               /organism="Homo sapiens"
               /db_xref="taxon:9606"
               /clone="D3A"
               /sex="male"
               /tissue_type="peripheral blood"
  CDS          53..337
               /note="thymus and activation regulated"
               /codon_start=1
               /product="chemokine"
               /db_xref="PID:d1008410"
               /db_xref="PID:g1536879"

/translation="MAPLKMLALVTL LLGASLQHIHAARGTNVGRECCLEYFKGAIPL
              RKLKTWYQTS EDCSRDAIVFVTVQGRAICSDPNKRVKNAV KYLQSLERS"

```

```

BASE COUNT      118 a      168 c      149 g      103 t
ORIGIN
    1 cccctgagcag agggacctgc acacagagac tccctcctgg gctcctggca ccatggcccc
   61 actgaagatg ctggccctgg tcacctctct cctgggggct tctctgcagc acatccacgc
  121 agctcgaggg accaatgtgg gccgggagtg ctgcctggag tacttcaagg gagccattcc
  181 ccttagaaag ctgaagacgt ggtaccagac atctgaggac tgctccaggg atgccatcgt
  241 ttttgtaact gtgcagggca gggccatctg ttcggacccc aacaacaaga gagtgaagaa
  301 tgcagttaaa tacctgcaaa gccttgagag gtcttgaagc ctctcacc cagactcctg
  361 actgtctccc gggactacct gggacctcca ccgttggtgt tcaccgcccc caccctgagc
  421 gcctgggtcc aggggaggcc ttccagggac gaagaagagc cacagtgagg gagatcccat
  481 ccccttgtct gaactggagc catgggcaca aagggcccag attaaagtct ttatcctc

```

//

```

LOCUS      HUMEOTAXIN      807 bp      mRNA      PRI      25-SEP-1996
DEFINITION Human mRNA for eotaxin, complete cds.
ACCESSION  D49372
NID        gl552240
KEYWORDS   eotaxin; eosinophil-selective CC chemokine; chemoattractant.
SOURCE     Homo sapiens Small intestine, proximal cDNA to mRNA, clone:141.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
Hominidae; Homo.
REFERENCE  1 (bases 1 to 807)
AUTHORS   Kitaura,M., Nakajima,T., Imai,T., Harada,S., Combadiere,C.,
            Tiffany,H.L., Murphy,P.M. and Yoshie,O.
TITLE     Molecular cloning of human eotaxin, an eosinophil-selective CC
            chemokine, and identification of a specific eosinophil eotaxin
            receptor, CC chemokine receptor 3
JOURNAL   J. Biol. Chem. 271 (13), 7725-7730 (1996)
MEDLINE   96205964
REFERENCE  2 (bases 1 to 807)
AUTHORS   Yoshie,O.
TITLE     Direct Submission
JOURNAL   Submitted (15-FEB-1995) to the DDBJ/EMBL/GenBank databases.
Osamu
            Yoshie, Shionogi Institute for Medical Science; 2-5-1 Mishima,
            Settsu, Osaka 566, Japan (E-mail:osamu.yoshie@shionogi.co.jp,
            Tel:06-382-2612, Fax:06-382-2598)
COMMENT   On Sep 20, 1996 this sequence version replaced gi:1313900.
FEATURES
    source          1..807
                    /organism="Homo sapiens"
                    /db_xref="taxon:9606"
                    /clone="141"
                    /tissue_type="Small intestine, proximal"
    CDS             99..392
                    /codon_start=1
                    /product="eotaxin"
                    /db_xref="PID:d1008966"
                    /db_xref="PID:gl552241"

/translation="MKVSAALLWLLLIAAAFSPQGLAGPASVPTTCCFNLANRKIPLQ
            RLESYRRITSGKCPQKAVIFKTKLAKDICADPKKKWVQDSMKYLDQKSPTPKP"
    misc_signal     548..557
                    /note="mRNA destabilization signal"
    polyA_signal    775..780
    polyA_site      807

```

```

BASE COUNT      229 a      198 c      147 g      233 t
ORIGIN
    1 gcattttttc aagttttatg atttatttaa cttgtggaac aaaaataaac cagaaaccac
   61 cacctctcac gccaaagctc acaccttcag cctccaacat gaaggtctcc gcagcacttc
  121 tgtggctgct gctcatagca gctgccttca gccccaggg gctcgctggg ccagcttctg
  181 tcccaaccac ctgctgcttt aacctggcca ataggaagat accccttcag cgactagaga
  241 gctacaggag aatcaccagt ggcaaatgtc ccagaaaagc tgtgatcttc aagaccaaac
  301 tggccaagga tatctgtgcc gacccaaga agaagtgggt gcaggattcc atgaagtatc
  361 tggacaaaaa atctccaact ccaaagccat aaataatcac catttttgaa accaaaccag
  421 agcctgagtg ttgcctaatt tgttttcctt tcttacaatg cattctgagg taacctcatt
  481 atcagtccaa agggcatggg ttttattata tatatatata tttttttttt aaaaaaaaac
  541 gtattgcatt taattttatt aggctttaaa acttatcctc catgaatatc agttattttt

```

```

601 aaactgtaaa gctttgtgca gattctttac ccctgggag cccaattcg atccccgtgc
661 acgtgtgggc aatgttcccc ctctcctctc ttctccctg gaattctgta aaggctcctgg
721 caaagatgat cagtatgaaa atgtcattgt tcttggaac ccaaagtggt actcattaaa
781 tggaagtaaa tgtgtttta ggaatac

//
LOCUS       HSCCHEMA      232 bp      RNA                      PRI      10-SEP-1996
DEFINITION  H.sapiens mRNA for CC-chemokine.
ACCESSION   Z69291
NID         g1181148
KEYWORDS    CC-chemokine.
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1 (bases 1 to 232)
AUTHORS     Bartels,J.H., Schlueter,C., Richter,E., Christophers,E. and
            Schroeder,J.M.
TITLE       Cloning of a novel human chemokine homologous to human monocyte
            chemoattractant proteins and rodent eotaxins
JOURNAL      Unpublished
REFERENCE   2 (bases 1 to 232)
AUTHORS     Bartels,J.H.
TITLE       Direct Submission
JOURNAL      Submitted (01-FEB-1996) Bartels J. H.,
            Christian-Albrechts-Universitaet          zu          Kiel,
            Dermatology/Hautklinik,
            Mol.Biol.Lab.609, Schittenhelmstr. 7, Kiel, Schleswig-Holstein,
            Germany, D-24105
REFERENCE   3 (bases 1 to 232)
AUTHORS     Bartels,J., Schluter,C., Richter,E., Noso,N., Kulke,R.,
            Christophers,E. and Schroder,J.M.
TITLE       Human dermal fibroblasts express eotaxin: molecular cloning,
mRNA         expression, and identification of eotaxin sequence variants
JOURNAL      Biochem. Biophys. Res. Commun. 225 (3), 1045-1051 (1996)
MEDLINE      96374440
FEATURES             Location/Qualifiers
     source          1..232
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /clone="clones 4(9512),
                     14(9512),15(9512),10(9601),11(9601)"
                     /tissue_type="foreskin"
                     /cell_type="fibroblast"
                     /sex="Male"
     mRNA            <1..>232
                     /citation=[1]
                     /product="CC-chemokine"
     sig_peptide     56..109
                     /citation=[1]
     CDS             56..>232
                     /function="putative chemoattractant protein"
                     /note="sequence homology to human MCP-1, MCP-2 and
MCP-3              and to rodent eotaxins"
                     /citation=[1]
                     /codon_start=1
                     /product="CC-chemokine, preprotein"
                     /db_xref="PID:e221070"
                     /db_xref="PID:g1181149"
                     /db_xref="SWISS-PROT:P50877"

/translation="MKVSAALLWLLLIAAAFSPQGLAGPASVPTTCCFNLANRKIPLQ
             RLESYRRITSGKCPQ"
     mat_peptide     110..>232
                     /citation=[1]
                     /function="putative chemoattractant protein"
                     /product="CC-chemokine"
BASE COUNT      55 a      82 c      50 g      42 t      3 others
ORIGIN          1 accaaaccag aaaccwccam ytctcagcc aaagctcaca ctttcagcct ccaacatgaa

```

```

61 ggtctccgca ggcgttctgt ggctgctgct catagcggt gccttcagcc cccaggggct
121 cgctgggcca gcttctgtcc caaccacctg ctgctttaac ctggccaata ggaagatacc
181 ccttcagcga ctagagagct acaggagaat caccagtggc aaatgtcccc ag

//
LOCUS      HSHCC1GEN      4037 bp      DNA      PRI      01-OCT-1995
DEFINITION H.sapiens gene for chemokine HCC-1.
ACCESSION  Z49269
NID        g1004266
KEYWORDS   chemokine.
SOURCE     human.
  ORGANISM Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 4037)
AUTHORS    Pardigol,A., Maegert,H.J., Cieslak,A., Hill,O., Schulz-
Knappe,P.
            and Forssmann,W.G.
TITLE      Nucleotide Sequence of the Gene for the Human Chemokine HCC-1
JOURNAL    Unpublished
REFERENCE  2 (bases 1 to 4037)
AUTHORS    Pardigol,A.
TITLE      Direct Submission
JOURNAL    Submitted (18-MAY-1995) Andreas Pardigol, Molecular Biology,
Lower
            Saxony Institute for Peptide Research, Feodor-Lynen-Strasse 31,
            Hannover, Lower Saxon, 30625, Germany
FEATURES   Location/Qualifiers
            source          1..4037
                           /organism="Homo sapiens"
                           /db_xref="taxon:9606"
                           /clone="ph3b7"
                           /dev_stage="adult"
                           /tissue_type="placenta"
                           /clone_lib="lambda FIX II, Cat.Nr. 946203, Stratagene"
                           /sex="male"
            TATA_signal     727..733
                           /note="putative, determined by consensus rules."
            5'UTR           764..833
                           /note="first base determined by means of consensus
rules"
            exon            764..912
                           /note="first base determined by means of consensus
rules;
                           base 780 is the first base of cDNA (Z49270)"
                           /number=1
            CDS              join(834..912,3021..3135,3585..3672)
                           /codon_start=1
                           /product="chemokine HCC-1"
                           /db_xref="PID:g1004267"

/translation="MKISVAAIPFFLLITIALGKTESSSRGPYHPSECCFTYTTYKI
PRQRIMDYETNSQCSKPGIVFITKRGHSVCTNPSDKWVQDYIKDMKEN"
            intron          913..3020
                           /number=1
            exon            3021..3135
                           /number=2
            intron          3136..3584
                           /number=2
            exon            3585..3817
                           /number=3
            3'UTR           3673..3817
BASE COUNT  1023 a   1048 c   1004 g   962 t
ORIGIN
1 gagctccggtt gggagtcacca tgtttcttta tggcataatg ggtgagaaca cagacttgga
61 agccaaacca cctgaatttg aacccagtt ccatttacca actgtcaaaa gcttaggctt
121 tgattctaag cctgtttctt caactgctgt tctaaagatt aaataggcta atattcataa
181 ggcaactggg acagtggctt gtgtgtatag caaccattat ataagtgaat tatctactga
241 gcaccacagc atttcttcac tccatgggtg ggtgaccaga atggagatga gacagagaac
301 tgcaggttct gcttcgagtt taagtttaga ttcccttga ccaatgagac ctgacttgga
361 ggagtcctgg cctcattcca ttaccccaaa caccctctag tctctagatg aacagatcct
421 gaatgtccag gccccacgtg gcctgttcta aggcctgaga tggaattgga tacaggacac

```



```

481 atccagcctt gagatctttt gctaagtgtg acacagtggc cccagccctg tgctcatgtt
541 catgcctagg gaaaggcttc tatcaaaaaga gttgaacttc tccccactgg ggatggaaga
601 ccatttcctc ccttaaacct tggctctccc tgcttccttc aggccacca caacacatgt
661 gcaggatatg aaattgctga ggcatcactg ctttctact tcccttccaa gtctcagctc
721 ccttatttta aaaaatattt ggccctcaatg atcatttctc aacaattcct caccgcagga
781 gccctgaag ctcccaccag gccagctctc ctcccacaac agcttcccac agcatgaaga
841 tctccgtggc tgccattccc ttcttctccc tcatcccat cgccctaggg accaagactg
901 aatcctcctc acgtgagtgc aatgccttgt cttccttcca acctagagcc tgcaggga
961 taagcaggag tgaggttggg gctcagggga agaccaggag cagggactca gaaaggaggg
1021 ctggtatctt cttgaaattg tgtgtatagc aacattatat aaatgaatta tctactgagc
1081 accacagcac ttcaccccat ggtgtggtga gcaggatgga gatgagactt aggactgtag
1141 gttctgctta agagttaag ttgggactct ccagccttga ccaatgagac tggacttggg
1201 agactccagg cttcattcca ctaccccaaa tgccctctag tctccaaata aacagatcct
1261 gaatctccag gcctcacatg gccttgatct ctatcattg cccccaggga ccagtcctcc
1321 cttgcccctc aggacatgga gtgagaccag cctgcctctc tactcctcca atttctctct
1381 attagcgtcc aagcaaaaaga gtggccacc ccatttgggg tatatttctt caggagattt
1441 aggagcagtg tcttgagccc ctcaagggca tttttctatt ggccctctga ggttggggcc
1501 cagcctgctt ccagcgtcac ctgtgcccag tgagtgcagc attgcttggg tatgggctgg
1561 ggggaaacac gacagtgtgg ggtccatcct agggccctct ttctcagctg atttcttaga
1621 ataagctgcc tttagagata accaaaacta ttatcactc ttcatttta cctactctcc
1681 ttttcagaaa ctggggggaa accgaaggtt gttaaaatac agctaagtat ggtgggtatg
1741 tgcacagttt gacttgccct ctccgatgtc atttgtcagc tcagaggaa aaggtgggag
1801 agtataggag ctctgactgg gtctcaggaa acagggggcc cttatgccgt tctttggatc
1861 gtgtaaaaac aacttggaat tgcttggaat ggagctgga gaccttcca ccagacatc
1921 tggccaccct cagtgcctc tgaggccatt gtgatgcaca tccatgattc tatgagcag
1981 ggtcacataa catgcacaca cctgatttct ccactccata accacaacat gtgcctgttt
2041 gtacagggtc cttggcctac aatgtccttc ctgctacctc tataattcaa gcttgggggtg
2101 cttgctgtca ccttgcttct cctataaaag ccatgaaact tctcaatcag aaaaatagatg
2161 aaaaaatcac ccaatccagt gatttttaaa actttttaga ccacaaaacc tttcttcaa
2221 gcaatatctt ccacagaggc ccaatatgta aaacagaaaa aatgggttga gtagggtaca
2281 agacaccact ctcaaagtga gcaaggcctc cacaatagtc cctgaggccc ccagagctca
2341 gtgtaaaaac cactgatgca gtccaaggcc ctcatttaca gaggagggaa cagggggaaa
2401 gtaaaatggc cacagtacac aggaagcaca ggcaagggtt ggttaggatt tgggtgccct
2461 gactctgtgg cctttgtcct tggggcttgc tgtgggcatc ctgctctctc tgcaggttgt
2521 cggttcaatg gggacatggg cagggtggag cactaggagg ggctgggttt gcattcccaa
2581 atggcactgc tccaaatccc tattgggatt tcttccaat attcctcta tttggagc
2641 ctttcccgaa taaggcatga aggtctgatg atattggcca agtccctagc cttctctgcc
2701 agtcggcccc cagagatggt gtaagaagat ctgagtgtgc tgctctcaa tcctggagtt
2761 gaaagtcac caccagtctt tccaagagg gttgaagaaa agggagaagg gtgattgatg
2821 atgaggagg agaaaaagaa gagccaggga gtaccatgga gaaggagaag agaagatgag
2881 gaaagcctac tctcccctcc aagtctctgag gggctgtctc ctctctcct cctcctcca
2941 tgccctcagc ttgcaggagc agccaatggt atggccttta acaaggggcc cctcctcagc
3001 atctgatgct ctctctcag ggggacctta ccacctca gagtgtgct tcacctacac
3061 tacctacaag atcccgcgtc agcggattat ggattactat gagaccaaca gccagtgtc
3121 caagcccggg attgtgtagg ttgtacacac acatcacact ggggggagag ggagccagca
3181 gggcctcctg gagggaaagca gggagtgtg gtggaatggg gacccccagc gtacctcca
3241 ggtgtgacta catggggaga ggcagctgag gggcaatctg agcgtttct ggctggagcc
3301 tgcaggagcc atggggaaac tgaccctat gatggggaga tgacagagaa gggagaagaa
3361 ggcaagaggg cacttctca gggggacaca gagactagat ggtctagggt gtcttaggaa
3421 ccgaagagta tgtctcagag aggagactgg ctctaagctg cctctgtgga agaaaggaaa
3481 agcagtatag gtcaggtggg gaatttagga gggagggaag atgggctgtc tcttccggcc
3541 actggggccc tcggttgtg atccttctcc ctctgtctc acagcttcat caccaaaagg
3601 ggccattccg tctgtacca cccagtgac aagtgggtcc aggaactat caaggacatg
3661 aaggagaact gagtgacca gaaggggtg cgaaggcaca gctcagagac ataaagagaa
3721 gatgccaagg cccctcctc caccaccgc taactctcag cccagtcac cctctggag
3781 ctteccgtct ttgaattaaa gaccactcat gctcttccct ggctcattc ctttctacgg
3841 gatttactca ttggccatgc actgaggaca ccagggtgtg gcacctcgg catcaagcct
3901 cgctctgcag aagttttggg ggagcctggt acaaaaaata ggtcaggcct gcaatgcagg
3961 tagtgagaag cagaaagtga gaaagaaaag cagtgtaaag accgtctcct cctcagcagc
4021 aacagtagca gaccccc

```

//

```

LOCUS       HSCC21           925 bp      mRNA           PRI           30-JUN-1998
DEFINITION   H.sapiens mRNA for chemokine CC-2 and CC-1.
ACCESSION   Z70292
NID         g1296608
KEYWORDS     chemokine CC-1; chemokine CC-2.
SOURCE      human.
  ORGANISM   Homo sapiens
              Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
              Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 925)

```

AUTHORS Pardigol,A., Forssmann,U., Zucht,H.D., Loetscher,P.,
Schulz-Knappe,P., Baggiolini,M., Forssmann,W.G. and Magert,H.J.

TITLE HCC-2, a human chemokine: gene structure, expression pattern,
and biological activity

JOURNAL Proc. Natl. Acad. Sci. U.S.A. 95 (11), 6308-6313 (1998)

MEDLINE 98263352

REFERENCE 2 (bases 1 to 925)

AUTHORS Pardigol,A.

TITLE Direct Submission

JOURNAL Submitted (25-MAR-1996) Andreas Pardigol, IV - Molecular
Biology, Lower Saxony Institute for Peptide Research, Feodor-Lynen-
Strasse 31, Hannover, Lower Saxony, 30625, Germany

FEATURES
source Location/Qualifiers
1..925
/organism="Homo sapiens"
/db_xref="taxon:9606"
/dev_stage="adult"
/tissue_type="liver"
/clone_lib="PCR fragments"

5'UTR 1..55

CDS 56..397
/note="putative; first coding region of a bicistronic
mRNA"
/codon_start=1
/product="chemokine CC-2"
/db_xref="PID:e233855"
/db_xref="PID:g1296609"
/db_xref="SWISS-PROT:Q16663"

/translation="MKVSVAALSCLMLVAVLGSSQAQFTNDAETELMMSKLPLENPVVL
NSFHFAADCCTSYISQSIPCSLMKSYFETSSECSKPGVIFLTKKGRQVCAKPSGPGVQ
DCMKLKPYSI"
misc_feature 398..498
/note="spacing region between two coding regions of
the bicistronic mRNA"

CDS 499..780
/codon_start=1
/evidence=experimental
/product="chemokine CC-1"
/db_xref="PID:e233856"
/db_xref="PID:g1296610"
/db_xref="SWISS-PROT:Q16627"

/translation="MKISVAAIPFFLLITIALGKTESSSRGYPHPSECCFTYTTYKI
PRQRIMDYETNSQCSKPGIVFITKRGHVCTNPSPDKWVQDYIKDMKEN"

3'UTR 781..925

polyA_signal 902..908

BASE COUNT 240 a 296 c 199 g 190 t

ORIGIN
1 ccaggaagca gtgagcccag gagtcctcgg ccagccctgc ctgcccacca ggaggatgaa
61 ggtctccgtg gctgccctct cctgcctcat gcttggtgct gtccttggat ccagggccca
121 gttcacaaat gatgcagaga cagagttaat gatgtcaaag ctccactgag aaaatccagt
181 agttctgaac agctttcact ttgctgctga ctgctgcacc tcctacatct cacaaagcat
241 cccgtgttca ctcatgaaaa gttattttga aacgagcagc gagtgctcca agccagggtg
301 catattcctc accaagaagg ggcggcaagt ctgtgccaaa ccagtggtc cgggagttca
361 ggattgcatg aaaaagctga agccctactc aatataataa taaagagaca aaagaggcca
421 gccacccacc tccaacacct cctgagcctc tgaagctccc accaggccag ctctcctccc
481 acaacagctt cccacagcat gaagatctcc gtggctgcca ttcccttctt cctcctcatc
541 accatcgccc tagggaccaa gactgaatcc tcctcacggg gaccttacca cccctcagag
601 tgctgcttca cctacactac ctacaagatc ccgcgtcagc ggattatgga ttactatgag
661 accaacagcc agtgctccaa gcccggaatt gtcttcatca ccaaaagggg ccattccgtc
721 tgtaccaacc ccagtgacaa gtgggtccag gactatatca aggacatgaa ggagaactga
781 gtgacccaga aggggtggcg aaggcacagc tcagagacat aaagagaaga tgccaaggcc
841 cctcctccta cccaccgcta actctgagcc ccagtcaccc tcttgagct tccctgcttt
901 gaattaaaga ccactcatgc tcttc

//

LOCUS HSCC23 973 bp RNA PRI 03-MAY-1996
 DEFINITION H.sapiens mRNA for chemokine CC-2 and CC-3.
 ACCESSION Z70293
 NID g1296611
 KEYWORDS Human chemokine CC-2; Human chemokine CC-3.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 973)
 AUTHORS Pardigol,A., Maegert,H.J., Zucht,HD., Forssmann,W.G. and Schulz-Knappe,P.
 TITLE Transcription of a Human Tandem Gene results in a Mature Bicistronic mRNA encoding two Novel CC-Chemokines
 JOURNAL Unpublished
 REFERENCE 2 (bases 1 to 973)
 AUTHORS Pardigol,A.
 TITLE Direct Submission
 JOURNAL Submitted (25-MAR-1996) Andreas Pardigol, IV - Molecular Biology,
 Lower Saxony Institute for Peptide Research, Feodor-Lynen-Strasse
 31. Hannover, Lower Saxony, 30625, Germany
 FEATURES
 source Location/Qualifiers
 1..973
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /dev_stage="adult"
 /tissue_type="liver"
 /clone_lib="PCR fragments"
 5'UTR 1..55
 CDS 56..397
 /note="putative; first coding region of a bicistronic mRNA"
 /codon_start=1
 /product="chemokine CC-2"
 /db_xref="PID:e233857"
 /db_xref="PID:g1296612"
 /translation="MKVSVAALSCLMLVAVLGSQAQFTNDAETELMMSKLPLENFVVL
 NSFHFAADCCTSYISQSI PCSLMKSYFETSSSECSKPGVIFLTKKGRQVCAKPSGPGVQ
 DCMKKLKPYSI"
 misc_feature 398..498
 /note="spacing region between two coding regions of
 the
 bicistronic mRNA"
 CDS 499..828
 /note="putative"
 /codon_start=1
 /product="chemokine CC-3"
 /db_xref="PID:e233858"
 /db_xref="PID:g1296613"
 /translation="MKISVAAIPFFLLITIALGKTESSSQTGGKPKVVKIQLKLVGG
 PYHPSECCFTYTTYKIPRQRIMDYETNSQCSKPGIVFITKRGHSVCTNP SDKWVQDY
 IKDMKEN"
 3'UTR 829..973
 polyA_signal 950..956
 BASE COUNT 257 a 301 c 215 g 200 t
 ORIGIN
 1 ccaggaagca gtgagcccag gagtctcgg ccagccctgc ctgccacca ggaggatgaa
 61 ggtctccgtg gctgccctct cctgcctcat gcttggtgct gtccttgat ccaggccca
 121 gttcacaat gatgcagaga cagagttaat gatgtcaaag cttccactgg aaaatccagt
 181 agttctgaac agctttcact ttgctgctga ctgctgcacc tcctacatct cacaaagcat
 241 cccgtgttca ctcatgaaaa gttattttga aacgagcagc gagtgtctca agccagggtg
 301 catattcttc accaagaagg ggcggcaagt ctgtgccaaa cccagtgggc cgggagttca
 361 ggattgcatg aaaaagctga agccctactc aatataataa taaagagaca aaagaggcca
 421 gccacccacc tccaacacct cctgagcctc tgaagctccc accaggccag ctctcctccc

```

481 acaacagctt cccacagcat gaagatctcc gtggctgcca ttccttctt cctcctcacc
541 accatcgccc tagggaccaa gactgaatcc tcctcacaaa ctgggggggaa accgaaggtt
601 gttaaaatac agctaaagtt ggtgggggga ccttaccacc cctcagagtg ctgcttcacc
661 tacactacct acaagatccc gcgtcagcgg attatggatt actatgagac caacagccag
721 tgctccaagc ccggaattgt cttcatcacc aaaaggggccc attccgtctg taccaacccc
781 agtgacaagt ggggccagga ctatatcaag gacatgaagg agaactgagt gacccagaag
841 ggggtggcgaa ggcacagctc agagacataa agagaagatg ccaaggcccc ctccctccacc
901 caccgctaac tctcagcccc agtcaccctc ttggagcttc cctgctttga attaaagacc
961 actcatgctc ttc

```

//

```

LOCUS      HSU91746      1430 bp      mRNA      PRI      12-MAR-1998
DEFINITION Homo sapiens IL-10-inducible chemokine (HCC-4) mRNA, complete
cds.
ACCESSION  U91746
NID        g2581780
KEYWORDS   .
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 1430)
AUTHORS    Hedrick,J.A., Helms,A., Gorman,D. and Zlotnik,A.
TITLE      Identification of a novel human CC chemokine upregulated by IL-
10
JOURNAL     Blood (1998) In press
REFERENCE  2 (bases 1 to 1430)
AUTHORS    Hedrick,J.A., Helms,A., Gorman,D. and Zlotnik,A.
TITLE      Direct Submission
JOURNAL     Submitted (02-MAR-1997) Immunology, DNAX Research Institute,
901
            California Ave, Palo Alto, CA 94304, USA
FEATURES   Location/Qualifiers
            source          1..1430
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /chromosome="17"
            gene            1..1430
                        /gene="HCC-4"
            CDS              1..363
                        /gene="HCC-4"
                        /note="CC or beta chemokine family member"
                        /codon_start=1
                        /product="IL-10-inducible chemokine"
                        /db_xref="PID:g2581781"

```

/translation="MKVSEALSLVLILIITSASRSQPKVPEWVNTPTCCLKYEEK

VLPRRLVVGYSKALNCHLPAIIFVTKRNRVCTNPNDWVQEYIKDPNLPPLPTRNLS
TVKIIITAKNGQPQLLSQ"

BASE COUNT 401 a 351 c 293 g 385 t
ORIGIN

```

1 atgaaggtct ccgaggctgc cctgtctctc cttgtcctca tccttatcat tacttcgggt
61 tctcgcagcc agccaaaagt tcctgagtgg gtgaacaccc catccacctg ctgcctgaag
121 tattatgaga aagtgttgcc aaggagacta gtgggtgggac acagaaaggc cctcaactgt
181 cacctgccag caatcatctt cgtcaccaag aggaaccgag aagtctgcac caaccccaat
241 gacgactggg tccaagagta catcaaggat cccaacctac ctttgctgcc taccaggaaac
301 ttgtccacgg ttaaaattat tacagcaaag aatgggtcaac cccagctcct caactcccag
361 tgatgaccag gcttttagtg aagcccttgt ttacagaaga gaggggtaaa cctatgaaaa
421 caggggaagc cttattagtc tgaaactagc cagtcacatt gagagaagca gaacaatgat
481 caaaataaag gagaagtatt tcgaatatct tctcaatctt aggaggaaat accaaagtta
541 agggacgtgg gcagaggtac gctcttttat ttttatattt atatttttat tttttgaga
601 taggtcttac tctgtcacc aggtctggag gcagtggtgt gatcttggtt cacttgatct
661 tggctcactg taacctccac ctcccaggct caagtgtacc tcccacccca gcctcccgag
721 tagctgggac tacaggcttg cgccaccaca cctggctaag ttttgtattt ttggtagaga
781 cggtattcta ccattgtgac caggctggtc tcaaactcgt gtgcccagc aatccacctg
841 cctcagcctt ccaaaagtgc tgggattaca ggcgtgagcc accacatccg gccagtgcac
901 tcttaataca cagaaaaata tatttcacat ccttctcctg ctctctttca attcctcact
961 tcacaccagt acacaagcca ttctaaatac ttagccagtt tccagccttc cagatgatct
1021 ttgccctctg ggtcttgacc cattagaagc cccatagaac tcttgatttt tcctgtccat
1081 ctttatggat ttttctggat ctatattttc ttcaattatt ctttcatttt ataattgcaac

```

```

1141 tttttcatag gaagtcgga tgggaatatt cacattaatc atttttgcag agactttgct
1201 agatcctctc atattttgtc ttcctcaggg tggcaggggt acagagagtg cctgattgga
1261 aaaaaaaaaa aaagagagag agagagaaga agaagaagaa gagacacaaa tctctacctc
1321 ccattgttaag ctttgcagga cagggaaga aagggtatga gacacggcta ggggtaaact
1381 cttagtccaa aaccaagca tgcaataaat aaaactccct tatttgacaa

```

//

LOCUS AB007454 1503 bp mRNA PRI 09-APR-1998
 DEFINITION Homo sapiens mRNA for chemokine LEC precursor, complete cds.
 ACCESSION AB007454
 NID g2723285
 KEYWORDS chemokine LEC precursor.
 SOURCE Homo sapiens liver cDNA to mRNA.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
 Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (sites)
 AUTHORS Shoudai,K., Hieshima,K., Fukuda,S., Iio,M., Miura,R., Imai,T.,
 Yoshie,O. and Nomiyama,H.
 TITLE Isolation of cDNA encoding a novel human CC chemokine NCC-4/LEC
 JOURNAL Biochim. Biophys. Acta 1396 (3), 273-277 (1998)
 MEDLINE 98207719
 REFERENCE 2 (bases 1 to 1503)
 AUTHORS Nomiyama,H.
 TITLE Direct Submission
 JOURNAL Submitted (19-SEP-1997) to the DDBJ/EMBL/GenBank databases.
 Hisayuki Nomiyama, Kumamoto University Medical School,
 Department of Biochemistry; Honjo 2-2-1, Kumamoto, Kumamoto 860-0811,
 Japan
 (E-mail:nomiyama@gpo.kumamoto-u.ac.jp, Tel:81-96-373-5063,
 Fax:81-96-372-6140)

FEATURES Location/Qualifiers
 source 1..1503
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /tissue_type="liver"
 sig_peptide 77..145
 CDS 77..439
 /codon_start=1
 /product="chemokine LEC precursor"
 /db_xref="PID:d1024963"
 /db_xref="PID:g2723286"

/translation="MKVSEAALSLVLILIIITSASRSQPKVPEWVNTPTCCLKYEK

VLPRRLVVG YRKALNCHLPAIIFVTKRNREVCTNPNDWVQEIYKDPNLPLLPTRNLS
 TVKIIITAKNGQPQLNSQ"

mat_peptide 146..436
 polyA_signal 560..565
 polyA_signal 1485..1490

BASE COUNT 417 a 374 c 312 g 400 t
 ORIGIN

```

1 gttggcaagc ggaccaccag caacagacaa catcttcatt cggctctccc tgaagctgta
61 ctgcctcgct gagaggatga aggtctccga ggctgccctg tctctccttg tcctcatcct
121 tatcattact tcggcttctc gcagccagcc aaaagttcct gagtgggtga acaccccatc
181 cacctgctgc ctgaagtatt atgagaaagt gttgccaaagg agactagtgg tgggatacag
241 aaaggccctc aactgtcacc tgccagcaat catcttcgtc accaagagga accgagaagt
301 ctgcaccaac cccaatgacg actgggtcca agagtacatc aaggatccca acctaccttt
361 gctgcctacc aggaacttgt ccacggttaa aattattaca gcaaagaatg gtcaacccca
421 gctcctcaac tcccagtgat gaccaggctt tagtggaagc ccttgtttac agaagagagg
481 ggtaaaccta tgaaaacagg ggaagcctta ttaggctgaa actagccagt cacattgaga
541 gaagcagaac aatgatcaaa ataaaggaga agtatcttca atattttctc aatcttagga
601 ggaaatacca aagttaaggg acgtgggcag aggtacgctc ttttattttt atatttatat
661 ttttattttt ttgagatagg gtcttactct gtcacccagg ctggagtgtg gtgggtgtgat
721 cttggctcac ttgatcttgg ctactgttaa cctccacctc ccaggctcaa gtgatcctcc
781 caccaccagc tcccagtag ctgggactac aggtctgcgc caccacacct ggctaatttt
841 tgtatttttg gtagagacgg gattctacca tgttgcccag gctggtctca aactcgtgtg
901 cccaagcaat ccacctgcct cagccttcca aaagtgcctg gattacaggc gtgagccacc
961 acatccggcc agtgcactct taatacacag aaaaaatata ttcacatcct tctctgtctc
1021 tctttcaatt cctcacttca caccagtaca caagccattc taaatactta gccagtttcc

```

```

1081 agccttccag atgatctttg ccctctgggt cttgacccat taagagcccc atagaactct
1141 tgatttttcc tgtccatctt tatggatttt tctggatcta tattttcttc aattattctt
1201 tcattttata atgcaacttt ttcataaggaa gtccggatgg gaatattcac attaatcatt
1261 tttgcagaga ctttgctaga tcctctcata ttttgtcttc ctcagggtgg caggggtaca
1321 gagatgtcct gattggaaaa aaaaaaaaaa gagagagaga gagaagaaga agaagaagag
1381 acacaaatct ctacctcca tgtaagctt tgcaggacag ggaaagaagag ggtatgagac
1441 acggctaggg gtaaactctt agtccaaaac ccaagcatgc aataaataaa actcccttat
1501 ttg

```

//

```

LOCUS      AF001979      800 bp      mRNA      PRI      20-NOV-1997
DEFINITION Homo sapiens beta chemokine mRNA, complete cds.
ACCESSION  AF001979
NID        g2624924
KEYWORDS   .
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 800)
AUTHORS    Hedrick, J.A. and Zlotnik, A.
TITLE      Identification and characterization of a novel beta chemokine
            containing six conserved cysteines
JOURNAL    J. Immunol. 159 (4), 1589-1593 (1997)
MEDLINE    97400322
REFERENCE  2 (bases 1 to 800)
AUTHORS    Hedrick, J.A. and Zlotnik, A.
TITLE      Direct Submission
JOURNAL    Submitted (01-MAY-1997) Immunobiology, DNAX Research Institute,
901

```

California Ave, Palo Alto, CA 94304, USA

```

FEATURES             Location/Qualifiers
     source            1..800
                       /organism="Homo sapiens"
                       /db_xref="taxon:9606"
     CDS                1..405
                       /note="6Ckine; CC chemokine"
                       /codon_start=1
                       /product="beta chemokine"
                       /db_xref="PID:g2624925"

```

/translation="MAQSLALSLILVLAFGIPRTQGS DGG AQDCCLKYSQRKIPAKV

```

VRSYRKQEPSLGCSIPAILFLPRKRSQAELCADPKELWVQQLMQHLDKTPSPQKPAQG
CRKDRGASKTGKKGKSGKCKRTERSQTPKGP"

```

```

BASE COUNT      203 a      248 c      210 g      139 t
ORIGIN

```

```

1 atggctcagt cactggctct gagcctcctt atcctgggtc tggcctttgg aatccccagg
61 acccaaggca gtgatggagg ggctcaggac tgttgctca agtacagcca aaggaagatt
121 cccgccaagg ttgtccgcag ctaccggaag caggaaccaa gcttaggctg ctccatccca
181 gctatcctgt tcttgccccg caagcgctct caggcagagc tatgtgcaga cccaaggag
241 ctctgggtgc agcagctgat gcagcatctg gacaagacac catccccaca gaaaccagcc
301 cagggctgca ggaaggacag gggggcctcc aagactggca agaaaggaaa gggctccaaa
361 ggctgcaaga ggactgagcg gtcacagacc cctaaagggc catagcccag tgagcagcct
421 ggagccctgg agaccccacc agcttcacca gcgcttgaag cctgaacca agatgcaaga
481 aggaggctat gctcaggggc cctggagcag ccaccccatg ctggccttgc cacactctt
541 ctctgctttt aaccacccca tctgcattcc cagctctacc ctgcatggct gagctgcccc
601 cagcaggcca ggtccagaga gaccgaggag ggagagtctc ccaggagca tgagaggagg
661 cagcaggact gtccccttga aggagaatca tcaggaccct ggacctgata cggctcccca
721 gtacacccca cctcttcctt gtaaataatga ttatacctta actgaataaa aagctgttct
781 gtcttcccac ccaaaaaaaaa

```

//

```

LOCUS      HSU64197      821 bp      mRNA      PRI      25-JUN-1997
DEFINITION Homo sapiens chemokine exodus-1 mRNA, complete cds.
ACCESSION  U64197
NID        g1778716
KEYWORDS   .
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;

```

Hominidae; Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
 Homo.
 REFERENCE 1 (bases 1 to 821)
 AUTHORS Hromas,R., Gray,P.W., Chantry,D., Godiska,R., Krathwohl,M.,
 Fife,K., Bell,G.I., Takeda,J., Aronica,S., Gordon,M.,
 Cooper,S., Broxmeyer,H.E. and Klemsz,M.J.
 TITLE Cloning and characterization of exodus, a novel beta-chemokine
 JOURNAL Blood 89 (9), 3315-3322 (1997)
 MEDLINE 97275143
 REFERENCE 2 (bases 1 to 821)
 AUTHORS Hromas,R.A.
 TITLE Direct Submission
 JOURNAL Submitted (17-JUL-1996) Indiana University Medical Center,
 Medicine, 975 W. Walnut St., Indianapolis, IN 46202, USA
 FEATURES Location/Qualifiers
 source 1..821
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="Exodus-1"
 /cell_type="islet"
 /tissue_type="pancreas"
 /dev_stage="adult"
 CDS 43..330
 /function="inhibits proliferation of hematopoietic
 progenitors and HIV"
 /codon_start=1
 /product="chemokine exodus-1"
 /db_xref="PID:g1778717"
 /translation="MCCTKSLLLAALMSVLLHLGGESEASNFDCCLGYTDRILHPKF
 IVGFTRQLANEGCDINAIIFHTKKLSVCANPKQTWVKYIVRLLSKVKNM"
 variation 121^122
 /note="insertion of an extra codon GCA at nt 121,
 encoding for an alanine after the alanine at amino acid
 position 26, represents the allelic difference of the
 transcript isolated from macrophages"
 BASE COUNT 258 a 134 c 156 g 273 t
 ORIGIN
 1 ggtactcaac actgagcaga tctgttcttt gagctaaaaa ccatgtgctg taccaagagt
 61 ttgctcctgg ctgctttgat gtcagtgtcg ctactccacc tctgcccga atcagaagca
 121 agcaactttg actgctgtct tggatacaca gaccgtattc ttcaccta atttattgtg
 181 ggcttcacac ggcagctggc caatgaaggc tgtgacatca atgctatcat ctttcacaca
 241 aagaaaaagt tgtctgtgtg cgcaaatcca aaacagactt gggtgaaata tattgtgcgt
 301 ctctctagta aaaaagtcaa gaacatgtaa aaactgtggc ttttctggaa tggaattgga
 361 catagcccaa gaacagaaaag aacctgtgtg gggttggagg ttccacttgc acatcatgga
 421 gggtttagtg cttatcta atgtgcctca cctggacttg tccaattaat gaagttgatt
 481 catattgcat catagtttgc tttgtttaag catcacatta aagtgaact gtattttatg
 541 ttatttatag ctgtaggttt tctgtgttta gctattta atactaatttc cataagctat
 601 tttggtttag tgcaaagtat aaaattatat ttggggggga ataagattat atggactttc
 661 ttgcaagcaa caagctattt tttaaaaaaa actatttaac attcttttgt ttatattgtt
 721 ttgtctccta aattgttgta atgtcattat aaaataagaa aaatattaat aagacaaata
 781 ttgaaaataa agaaacaaaa agtgcttctg ttaaaaaaaa a
 //
 LOCUS HSU88320 828 bp mRNA PRI 18-DEC-1997
 DEFINITION Human beta chemokine Exodus-2 mRNA, complete cds.
 ACCESSION U88320
 NID g2196919
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
 Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 828)
 AUTHORS Hromas,R., Kim,C.H., Klemsz,M., Krathwohl,M., Fife,K.,
 Cooper,S.,

TITLE Schnizlein-Bick, C. and Broxmeyer, H.E.
 chemokine Isolation and characterization of Exodus-2, a novel C-C
 with a unique 37-amino acid carboxyl-terminal extension
 JOURNAL J. Immunol. 159 (6), 2554-2558 (1997)
 MEDLINE 97444139
 REFERENCE 2 (bases 1 to 828)
 AUTHORS Hromas, R.A.
 TITLE Direct Submission
 JOURNAL Submitted (04-FEB-1997) Medicine, Indiana University Medical
 Center, 975 West Walnut, Indianapolis, IN 46202, USA
 FEATURES Location/Qualifiers
 source 1..828
 /organism="Homo sapiens"
 /note="PCR amplified from activated THP-1 cells"
 /db_xref="taxon:9606"
 /clone_lib="Soares human placenta cDNA"
 /cell_line="THP-1"
 /cell_type="monoblast"
 CDS 15..419
 /codon_start=1
 /product="beta chemokine Exodus-2"
 /db_xref="PID:g2196920"

/translation="MAQSLALSLLILVLAFGIPRTQGSDDGAQDCCLKYSQRKIPAKV

VRSYRKQEPSLGCSIPAILFLPRKRSQAELCADPKELWVQQLMQHLDKTPSPQKPAQG
 CRKDRGASKTGKKGKSGCKRTERSQTPKGP"

BASE COUNT 218 a 255 c 216 g 139 t

ORIGIN

```

1 ggcacgagggc agacatggct cagtcactgg ctctgagcct ccttatcctg gttctggcct
61 ttggcatccc caggacccaa ggcagtgatg gaggggctca ggactgttgc ctcaagtaca
121 gccaaaggaa gattcccgcc aaggttgctc gcagctaccg gaagcaggaa ccaagcttag
181 gctgctccat ccagctatc ctgttcttgc cccgcaagcg ctctcaggca gagctatgtg
241 cagacccaaa ggagctcttg gtgcagcagc tgatgcagca tctggacaag acaccatccc
301 cacagaaacc agcccagggc tgcaggaagg acaggggggc ctccaagact ggcaagaaag
361 gaaagggctc caaaggctgc aagaggactg agcggtcaca gaccctctaa gggccatagc
421 ccagtgcagc gcctggagcc ctggagaccc caccagcctc accagcgctt gaagcctgaa
481 cccaagatgc aagaaggagg ctatgtctag gggccctgga gcagccaccc catgctggcc
541 ttgccacact ctttctcctg ctttaaccac cccatctgca ttcccagctc tcaccctgca
601 tggctgagtc tgcccacagc aggccaggctc cagagagacc gaggagggag agtctcccag
661 ggagcatgag aggaggcagc aggactgtcc ccttgaagga gaatcatcag gaccctggac
721 ctgatacggc tccccagtag accccacctc ttccttgtaa atatgattta tacctaactg
781 aataaaaaagc tgttctgtct tcccacccaa aaaaaaaaaa aaaaaaaaaa
  
```

//

LOCUS HSU88321 502 bp mRNA PRI 22-JUN-1998
 DEFINITION Human beta chemokine Exodus-3 mRNA, complete cds.
 ACCESSION U88321
 NID g2196921
 KEYWORDS .
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
 Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 502)
 AUTHORS Hromas, R.A., Gray, P., Klemsz, M., Fife, K. and Broxmeyer, H.
 TITLE DCCL chemokines represent a novel beta chemokine subfamily
 JOURNAL Unpublished
 REFERENCE 2 (bases 1 to 502)
 AUTHORS Hromas, R.A.
 TITLE Direct Submission
 JOURNAL Submitted (04-FEB-1997) Medicine, Indiana University Medical
 Center, 975 West Walnut, Indianapolis, IN 46202, USA
 REFERENCE 3 (bases 1 to 502)
 AUTHORS Hromas, R.A.
 TITLE Direct Submission
 JOURNAL Submitted (22-JUN-1998) Medicine, Indiana University Medical
 Center, 975 West Walnut, Indianapolis, IN 46202, USA
 REMARK Amino acid sequence updated by submitter
 FEATURES Location/Qualifiers
 source 1..502


```

/organism="Homo sapiens"
/note="PCR amplified from THP-1 cells"
/db_xref="taxon:9606"
/cell_line="THP-1"
/cell_type="monoblast"
/dev_stage="adult"
CDS
120..416
/note="Mip-3alpha/ELC/CKbeta1"
/codon_start=1
/product="beta chemokine Exodus-3"
/db_xref="PID:g3243080"

/translation="MALLLALLLVLTSPAPTLSGTNDACCLSVTQKPIPGYIVR

NFHYLLIKDGCRVPAVVFTTLRGRQLCAPPDQPWVERIIQRLQRTSAKMKRRSS"
BASE COUNT      113 a      170 c      121 g      98 t
ORIGIN
    1 ctcacacctt gcatttcacc cctgcatccc atgcgccctg cagcctcaca cagatcctgc
   61 acacacccag acagctggcg ctcacacatt caccgttggc ctgcctctgt tcaccctcca
  121 tggccctgct actggccctc agcctgctgg ttctctggac ttccccagcc ccaactctga
  181 gtggcaccaa tgatgctgaa gactgctgcc tgtctgtgac ccagaaaccc atccctgggt
  241 acatcgtgag gaacttcac taccttctca tcaaggatgg ctgcaggggt cctgctgtag
  301 tgttcaccac actgaggggc cgccagctct gtgcaccccc agaccagccc tgggtagaac
  361 gcacatcca gagactgcag aggactccag ccaagatgaa gcgccgcagc agttaacctt
  421 tgaccgtgca gagggagccc cgagtccgag tcaagcattg tgaattatta ctaactggga
  481 acgaggacag aaggaaggac ag
//

LOCUS      HSU86358      879 bp      mRNA      PRI      11-SEP-1997
DEFINITION Human chemokine (TECK) mRNA, complete cds.
ACCESSION  U86358
NID        g2388626
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 879)
AUTHORS    Vicari,A.P., Figueroa,D.J., Hedrick,J.A., Foster,J.S.,
Singh,K.P.,
and        Menon,S., Copeland,N.G., Gilbert,D.J., Jenkins,N.A., Bacon,K.B.
            Ziotnik,A.
TITLE      TECK: a novel cc chemokine specifically expressed by thymic
            dendritic cells and potentially involved in T cell development
JOURNAL     Immunology 7, 291-301 (1997)
REFERENCE  2 (bases 1 to 879)
AUTHORS    Vicari,A.P. and Zlotnik,A.
TITLE      Direct Submission
JOURNAL     Submitted (21-JAN-1997) Immunology, DNAX Research Institute,
901        California Ave., Palo Alto, CA 94304, USA
FEATURES
            Location/Qualifiers
            source      1..879
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /chromosome="4"
                        /tissue_type="thymus"
            gene        1..879
                        /gene="TECK"
            CDS          1..453
                        /gene="TECK"
                        /codon_start=1
                        /product="chemokine"
                        /db_xref="PID:g2388627"

/translation="MNLWLLACLVLGAWAPAVHTQGVFEDCCLAYHYPIGWAVLR

RAWTYRIQEVSGSCNLPAAIFYLPKRHRKVCGNPKSREVQRAMKLLDARNKVFAKLHH
NMQTFQAGPHAVKKLSSGNSKLSSSKFSNPISSSKRNVSLLISANSGL"
BASE COUNT      191 a      264 c      218 g      206 t

```

ORIGIN

```

1 atgaacctgt ggctcctggc ctgcctgggtg gccggcttcc tgggagcctg ggcccccgct
61 gtccacaccc aaggtgtctt tgaggactgc tgcctggcct accactacc cattgggtgg
121 gctgtgctcc ggcgcgctg gacttaccgg atccaggagg tgagcgggag ctgcaatctg
181 cctgctgcga tattctacct ccccaagaga cacaggaagg tgtgtgggaa ccccaaaagc
241 agggaggtgc agagagccat gaagctcctg gatgctcgaa ataaggtttt tgcaaagctc
301 caccacaaca tgcagacctt ccaagcaggc cctcatgctg taaagaagtt gagttctgga
361 aactccaagt tatcatcatc caagtttagc aatcccatca gcagcagcaa gaggaatgtc
421 tccctcctga tatcagctaa ttcaggactg tgagccggct catttctggg ctccatcggc
481 acaggagggg ccggatcttt ctccgataaa accgtcgccc tacagaccca gctgtcccca
541 cgctctgtc ttttgggtca agtcttaate cctgcacctg agttggctct ccctctgcac
601 cccaccacc tcctgccgt ctggcaactg gaaagaagga gttggcctga ttttaacctt
661 ttgccgctcc gggaacagc acaatcctgg gcagccagt gctctttag agaaaactta
721 ggatacctct ctactttct gtttcttgcc gtccaccccg ggccatgcc gctgtgctc
781 tgggtccct ccaaaaatct ggtcattcaa ggtacccctc ccaaggctat gcttttctat
841 aacttttaaa taaaccttgg ggggtgaatg gaataaaaa

```

//

```

LOCUS      AB002409      852 bp      mRNA      PRI      15-AUG-1997
DEFINITION Homo sapiens mRNA for SLC, complete cds.
ACCESSION  AB002409
NID        g2335034
KEYWORDS   SLC; mature ELC.
SOURCE      Homo sapiens cDNA to mRNA.
ORGANISM    Homo sapiens
             Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
             Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
Hominidae; Homo.
REFERENCE  1 (bases 1 to 852)
AUTHORS    Nomiya, H.
TITLE      Direct Submission
JOURNAL     Submitted (28-MAR-1997) to the DDBJ/EMBL/GenBank databases.
             Hisayuki Nomiya, Kumamoto University Medical School,
Department of Biochemistry; Honjo 2-2-1, Kumamoto, Kumamoto 860, Japan
             (E-mail:nomiyama@gpo.kumamoto-u.ac.jp, Tel:81-96-373-5063,
             Fax:81-96-372-6140)
REFERENCE  2 (bases 1 to 852)
AUTHORS    Nagira, M., Imai, T., Hieshima, K., Kusuda, J., Ridanpaa, M.,
Takagi, S., Nishimura, M., Kakizaki, M., Nomiya, H. and Yoshie, O.
TITLE      Molecular Cloning of a Novel Human CC Chemokine Secondary
             Lymphoid-Tissue Chemokine (SLC) That is an Efficient
             Chemoattractant for Lymphocytes and Mapped to Chromosome 9p13
JOURNAL     Unpublished (1997)
FEATURES    Location/Qualifiers
             source      1..852
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
             CDS          59..463
                     /codon_start=1
                     /product="SLC"
                     /db_xref="PID:d1022673"
                     /db_xref="PID:g2335035"

/translation="MAQSLALSLILVLAFGIPRTQGSDDGAQDCLKYSQRKIPAKV
VRSYRKQEPSLGCSIPAILFLPRKRSQAELCADPKELWVQQLMQHLDKTPSPQKPAQG
CRKDRGASKTGKKGKSGCKRTERSQTPKGP"
             mat_peptide  <107..460
                     /product="mature ELC"
             polyA_site   823..828
BASE COUNT  205 a      279 c      217 g      151 t
ORIGIN

```

```

1 cttgcagctg cccacctcac cctcagctct ggctctttac tcacctcta ccacagacat
61 ggctcagtc ctggctctga gcctccttat cctggttctg gcctttggca tccccaggac
121 ccaaggcagt gatggagggg ctcaggactg ttgcctcaag tacagccaa ggaagattcc
181 cgccaagggt gtccgcagct accggaagca ggaaccaagc ttaggctgct ccatccagc
241 taccctgttc ttgccccgca agcgtcttca ggagagctat tgtgcagacc caaaggagct
301 ctgggtgcag cagctgatgc agcatctgga caagacacca tccccacaga aaccagccca

```

```

361 gggctgcagg aaggacaggg gggcctccaa gactggcaag aaaggaaagg gctccaaagg
421 ctgcaagagg actgagcggg cacagacccc taaagggcca tagccagtg agcagcctgg
481 agccctggag accccaccag cctcaccacg gcttgaagcc tgaaccaag atgcaagaag
541 gaggtatgc tcagggggcc tggagcagcc accccatgct ggccttgcca cactcttct
601 cctgctttaa ccaccccatc tgcattccca gctctaccct gcatggctga gctgcccaca
661 gcaggccagg tccagagaga ccgaggaggg agagtctccc agggagcatg agaggaggca
721 gcaggactgt ccccttgaag gagaatcatc aggaccctgg acctgatacg gctccccagt
781 acaccccacc tcttccttgt aaatatgatt tatacctaac tgaataaaaa gctgttctgt
841 cttcccaccc gc

```

//

```

LOCUS      AF055467      1481 bp      mRNA                      PRI      06-AUG-1998
DEFINITION Homo sapiens monotactin-1 mRNA, complete cds.
ACCESSION  AF055467
NID        g3395775
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 1481)
AUTHORS    Youn,B.S., Zhang,S., Broxmeyer,H.E., Antol,K., Fraser,M.J. Jr.,
            Hangoc,G. and Kwon,B.S.
TITLE      Isolation and characterization of LMC, a novel lymphocyte and
            monocyte chemoattractant human CC chemokine, with
            myelosuppressive
            activity
JOURNAL     Biochem. Biophys. Res. Commun. 247 (2), 217-222 (1998)
MEDLINE     98308096
REFERENCE  2 (bases 1 to 1481)
AUTHORS    Youn,B.S. and Kwon,B.S.
TITLE      Direct Submission
JOURNAL     Submitted (24-MAR-1998) Microbiology and Immunology, Indiana
            University, School of Medicine, 605 Barnhill Dr. Medical
            Science
            Bldg., Indianapolis, IN 46202, USA
FEATURES
            Location/Qualifiers
            source          1..1481
                           /organism="Homo sapiens"
                           /db_xref="taxon:9606"
                           /chromosome="17"
            5'UTR          1..34
            CDS             35..397
                           /note="Mtn-1; LMC; lymphocyte and monocyte
            chemoattractant
                           CC chemokine"
                           /codon_start=1
                           /product="monotactin-1"
                           /db_xref="PID:g3395776"

```

/translation="MKVSEAALSLVLILIIITSASRSQPKVPEWVNTPTSCCLKYYEK

VLPRRLVVGGRKALNCHLPAIIFVTKRNREVCTNPNDWVQEYIKDPLNPLLPTRNLS

TVKIIITAKNGQPQLLSQ"

```

3'UTR      398..1481
BASE COUNT 412 a    362 c    302 g    405 t
ORIGIN

```

```

1 gcacgagctg aagctgtact gcctcgctga gaggatgaag gtctccgagg ctgccctgtc
61 tctccttgct ctcacacctta tcattacttc ggcttctcgc agccagccaa aagttcctga
121 gtgggtgaac accccatcca cctgctgcct gaagtattat gagaaagtgt tgccaaggag
181 actagtgggt ggatacagaa aggccctcaa ctgtcacctg ccagcaatca tcttcgtcac
241 caagaggaa cagagaagtct gcaccaaccc caatgacgac tgggtccaag agtacatcaa
301 ggatcccaac ctacctttgc tgccctaccag gaacttgccc acggttaaaa ttattacagc
361 aaagaatggt caaccccagc tcctcaactc ccagtgtatga ccaagcttta gtggaagccc
421 ttgtttacag aagagagggg taaactatga aaacagggga agccttatta ggctgaaact
481 agccagtcac attgagagaa gcagaacaat gatcaaaata aaggagaagt atttcgaata
541 ttttctcaat cttaggagga aataccaaag ttaagggacg tgggcagagg tacgtcttt
601 tatttttata tttatatattt tatttttttg agataggggt ttactctgtc acccaggctg
661 gagtgcagtg gtgtgatctt ggctcacttg atcttggtc actgtaacct ccactcccca
721 ggctcaagtg atcctccacc cccaccctcc cgagttagctg ggactacagg cttgctccac
781 cacacctggc taatttttgt attttttgta gagacgggat tctaccatgt tgcccaggct

```

```

841 ggtctcaaac tcgtgtgccc aagcaatcca cctgcctcag ccttccaaaa gtgctgggct
901 tacaggcgtg agccaccaca tccggccagt ccactcttaa tacacagaaa aatatatttc
961 acatccttct cctgctctct ttcaattcct cacttcacac cagtacacaa gccattctaa
1021 atacttagcc agtttccagc cttccagatg atctttgccc tctgggtctt gacccattaa
1081 gagccccata gaactcttga ttttctctgt ccactcttat gggatttttc tggatctata
1141 ttttcttcaa ttattctttc attttataat gcaacttttt cataggaagt ccggtaggga
1201 atattcacat taatcatttt tgcagagact ttgctagatc ctctcatatt ttgtcttcct
1261 cagggtggca ggggtacaga agtgcctgat tggttttttt tttttttgag agagagagag
1321 aagaagaaga agaagagaca caaatctcta cctcccatgt taagctttgc aggacaggga
1381 aagaaagggg atgagacacg gctagggtaa actcttagtc caaaacccaa gcatgcaata
1441 aataaaactc cttattttga caaaaaaaaa aaaaaaaaaa a

```

//

```

LOCUS      HSRNAATAC      557 bp      RNA      PRI      06-JUL-1995
DEFINITION H.sapiens mRNA for ATAC protein.
ACCESSION  X86474
NID        g895846
KEYWORDS   ATAC gene.
SOURCE     human.
  ORGANISM Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 557)
AUTHORS   Muller,S., Dorner,B., Korthauer,U., Mages,H.W., D'Apuzzo,M.,
            Senger,G. and KroczeK,R.A.
TITLE      Cloning of ATAC, an activation-induced, chemokine-related
molecule
            exclusively expressed in CD8+ T lymphocytes
JOURNAL    Eur. J. Immunol. 25 (6), 1744-1748 (1995)
MEDLINE    95339892
REFERENCE  2 (bases 1 to 557)
AUTHORS   KroczeK,R.A.
TITLE      Direct Submission
JOURNAL    Submitted (20-APR-1995) R.A. KroczeK, Molecular Immunology,
            Robert-Koch-Institute, Nordufer 20, 13353 Berlin, FRG
FEATURES   Location/Qualifiers
    source      1..557
                /organism="Homo sapiens"
                /db_xref="taxon:9606"
                /tissue_type="peripheral blood"
                /cell_type="lymphocyte"
                /chromosome="1"
                /map="q23"
    gene        25..369
                /gene="ATAC"
    CDS         25..369
                /gene="ATAC"
                /codon_start=1
                /product="CD8+T cell specific protein"
                /db_xref="PID:g895847"
                /db_xref="SWISS-PROT:P47992"

```

/translation="MRLILALLGICSLTAYIVEGVGSEVSDKRTCVSLLTQRLPVSR

IKTYTITEGSLRAVIFITKRLKVCADPQATWVRDVVRSMDRKSNTNRNMIQTKPTGT

QQSTNTAVTLTG'

polyA_signal 469..474

polyA_signal 534..539

BASE COUNT 157 a 139 c 112 g 149 t

ORIGIN

```

1 gcacagctca gcaggacctc agccatgaga cttctcatcc tggccctcct tggcatctgc
61 tctctcactg catacattgt ggaaggtgta gggagtgaag tctcagataa gaggacctgt
121 gtgagcctca ctaccagcg actgccggtt agcagaatca agacctacac catcacggaa
181 ggctccttga gagcagtaat ttttattacc aaacgtggcc taaaagtctg tgctgatcca
241 caagccacat gggtagaga cgtggtcagg agcatggaca ggaaatccaa caccagaaat
301 aacatgatcc agaccaagcc aacaggaaacc cagcaatcga ccaatacagc tgtgactctg
361 actggctagt agtctctggc accctgtccg tctccagcca gccagctcat ttactttac
421 acgctcatgg actgagttta tactcgcttt ttatgaaagc actgcatgaa taaaattatt
481 cctttgtatt tttactttta aatgtcttct gtattcactt atatgttcta attaataaat
541 tatttattat taagaat

```

//

LOCUS HSU85767 563 bp mRNA PRI 01-APR-1997
 DEFINITION Human myeloid progenitor inhibitory factor-1 MPIF-1 mRNA, complete
 cds.
 ACCESSION U85767
 NID g1916249
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata; Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 563)
 AUTHORS Patel,V.P., Kreider,B.L., Li,Y., Li,H., Leung,K., Salcedo,T., Nardelli,B., Pippalla,V., Gentz,S., Thotakura,R., Parmelee,D., Gentz,R. and Garotta,G.
 TITLE Molecular and functional characterization of two novel human C-
 chemokines as inhibitors of two distinct classes of myeloid progenitors
 J. Exp. Med. (1997) In press
 REFERENCE 2 (bases 1 to 563)
 AUTHORS Li,H. and Patel,V.P.
 TITLE Direct Submission
 JOURNAL Submitted (17-JAN-1997) Cell Biology, Human Genome Sciences, 9410
 Keywest Ave., Rockville, MD 20850, USA
 FEATURES
 source Location/Qualifiers
 1..563
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 CDS 31..393
 /note="myeloid progenitor inhibitory factor-1"
 /codon_start=1
 /product="MPIF-1"
 /db_xref="PID:g1916250"
 /translation="MKVSVAAALSCMLVLTALGSQARVTKDAETEFMMSKLPLENPVLL
 DRFHATSADCCISYTPRSIPCSLLESYFETNSECSKPGVIFLTKKGRRFCANPSDKQV
 QVCMRMLKLDTRIKTRKN"
 BASE COUNT 164 a 143 c 117 g 139 t
 ORIGIN
 1 ctcagccagc cctgcctgcc caccaggagg atgaagggtc cctgtggctgc cctctcctgc
 61 ctcatgcttg ttactgccct tggatccag gcccggtca caaaagatgc agagacagag
 121 ttcatgatgt caaagcttcc attggaaaat ccagtacttc tggacagatt ccatgctact
 181 agtgcgtgact gctgcatctc ctacacccca cgaagcatcc cgtgttcact cctggagagt
 241 tactttgaaa cgaacagcga gtgctccaag ccgggtgtca tcttcctcac caagaagggg
 301 cgacgtttct gtgccaaccc cagtgataag caagttcagg ttgcatgag aatgctgaag
 361 ctggacacac ggatcaagac caggaagaat tgaacttgtc aagggtgaagg gacacaagtt
 421 gccagccacc aactttcttg cctcaactac cttcctgaat tattttttta agaagcattt
 481 attcttgtgt tctggattta gagcaattca tctaataaac agtttctcac ttttaaaaaa
 541 aaaaaaaaaa aaaaaaaaaa aaa

//

LOCUS HSU85768 360 bp mRNA PRI 01-APR-1997
 DEFINITION Human myeloid progenitor inhibitory factor-1 MPIF-2 mRNA, complete
 cds.
 ACCESSION U85768
 NID g1916251
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata; Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 360)
 AUTHORS Patel,V.P., Kreider,B.L., Li,Y., Li,H., Leung,K., Salcedo,T., Nardelli,B., Pippalla,V., Gentz,S., Thotakura,R., Parmelee,D., Gentz,R. and Garotta,G.
 TITLE Molecular and functional characterization of two novel human C-

C

chemokines as inhibitors of two distinct classes of myeloid progenitors

JOURNAL J. Exp. Med. (1997) In press

REFERENCE 2 (bases 1 to 360)

AUTHORS Li, H. and Patel, V.P.

TITLE Direct Submission

JOURNAL Submitted (17-JAN-1997) Cell Biology, Human Genome Sciences, 9410

Keywest Ave., Rockville, MD 20850, USA

FEATURES Location/Qualifiers

source 1..360

/organism="Homo sapiens"

/db_xref="taxon:9606"

CDS 1..360

/note="myeloid progenitor inhibitory factor-2"

/codon_start=1

/product="MPIF-2"

/db_xref="PID:g1916252"

/translation="MAGLMTIVTSLFLGVCAHHIIPTGSVVIPSPCCMFFVSKRIPE

NRVVS YQLSSRSTCLKGGVIFTTKKGQQFCGDPKQEWVQRYMKNLDAKQKKASPRARA

VAVKGPVQRYPGNQTTTC"

BASE COUNT 85 a 106 c 96 g 73 t

ORIGIN

1 atggcaggcc tgatgacat agtaaccagc cttctgttcc ttggtgtctg tgcccaccac

61 atcatcccta cgggctctgt ggtcataccc tctccctgct gcatgttctt tgtttccaag

121 agaattcctg agaaccgagt ggtcagctac cagctgtcca gcaggagcac atgcctcaag

181 ggaggagtga tcttcaccac caagaagggc cagcagttct gtggcgaccc caagcaggag

241 tgggtccaga ggtacatgaa gaacctggac gccaaagcaga agaaggcttc ccctagggcc

301 agggcagtggt ctgtcaaggg ccctgtccag agatatcctg gcaaccaaac cacctgctaa

//

LOCUS HUMSDF1A 1847 bp mRNA PRI 26-DEC-1996

DEFINITION Human pre-B cell stimulating factor homologue (SDF1a) mRNA, complete cds.

ACCESSION L36034

NID g1220363

KEYWORDS intercrine; intercrine CXC subfamily; pre-B cell stimulating factor

homologue; alpha-chemokine.

SOURCE human.

ORGANISM Homo sapiens

Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata; Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 1847)

AUTHORS Shirozu, M., Nakano, T., Inazawa, J., Tashiro, K., Tada, H., Shinohara, T. and Honjo, T.

TITLE Structure and chromosomal localization of the human stromal cell-derived factor 1 (SDF1) gene

JOURNAL Genomics 28 (3), 495-500 (1995)

MEDLINE 96039262

FEATURES Location/Qualifiers

source 1..1847

/organism="Homo sapiens"

/db_xref="taxon:9606"

/clone="h5"

/cell_line="FLEB14-14"

sig_peptide 80..142

/gene="SDF1a"

CDS 80..349

/codon_start=1

/product="pre-B cell stimulating factor homologue"

/db_xref="PID:g1220364"

/translation="MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANV

KHLKILNTPNCALQIVARLKNNNRQVCIDPKLKWIQEYLEKALNK"

gene 80..346

/gene="SDF1a"

mat_peptide 143..346

```

                /gene="SDF1a"
                /product="pre-B cell stimulating factor homologue"
BASE COUNT      459 a      471 c      417 g      500 t
ORIGIN
1  tctccgtcag cgcattgcc cgctcggcgt cgggcccccg acccgtgctc gtccgcccgc
61 cgcgccgccc gccgcgcgcca tgaacgccaa ggtcgtggtc gtgctgggtc tcgtgctgac
121 cgcgctctgc ctccagcgacg ggaagccccg cagcctgagc tacagatgcc catgccgatt
181 cttcgaaagc catgttgcca gagccaacgt caagcatctc aaaattctca acactccaaa
241 ctgtgccctt cagattgtag cccggctgaa gaacaacaac agacaagtgt gcattgaccc
301 gaagctaaag tggattcagg agtacctgga gaaagcttta aacaagtaag cacaacagcc
361 aaaaaggact ttccgctaga cccactcgag gaaaactaaa accttgtgag agatgaaagg
421 gcaaagacgt gggggagggg gccttaacca tgaggaccag gtgtgtgtgt ggggtgggca
481 cattgatctg ggatcgggcc tgagggttgc agcatttaga ccctgcattt atagcatacg
541 gtatgatatt gcagcttata ttcatccatg ccctgtacct gtgcacgttg gaacttttat
601 tactggggtt ttcttaagaa agaaattgta ttatcaacag cattttcaag cagttagttc
661 cttcatgata atcacaatca tcatcattct cattctcatt ttttaaatca acgatactt
721 caagatctga atttggcttg ttggagcat ctctctgctt cccctgggga gtctgggcac
781 agtcagggtg tggcttaaca gggagctgga aaaagtgtcc ttctctcaga cactgaggct
841 cccgcagcag cgcctctccc aagagaaagg cctctgtggc actcagatac cgactggggc
901 tggggcgccg ccactgcctt cacctcctct ttcaaaccct agtgattggc tctgtgggct
961 ccatgtagaa gccactatta ctgggactgt ctccagagacc cctctcccag ctattcctac
1021 tctctccccg actccgagag catgcttaat cttgcttctg cttctcattt ctgtagcctg
1081 atcagcgccg caccagccgg gaagagggtg attgctgggg ctgctgacct gcacccctct
1141 cctcccaggg cctgccccac agctcggggc ctctgtgaga tccgtctttg gccctctcca
1201 gaatggagct ggcctctctc tggggatgtg taatggtccc cctgcttacc cgcaaaagac
1261 aagtccttac agaatacaat gcaattttaa atctgagagc tcgcttgagt gactgggttt
1321 gtgattgcct ctgaagccta tgtatgcat ggaggcacta acaaaactct aggtttccga
1381 aatcagaagc gaaaaaatca gtgaataaac catcatcttg ccactacccc ctctggaagc
1441 cacagcaggg gttcagggtc caatcagaac tgttggcaag gtgacatttc catgcataga
1501 tgcgatccac agaaggtcct ggtggtattt gtaacttttt gcaaggcatt tttttatata
1561 tattttttgt cacatttttt ttacgattc tttagaaaac aaatgtattt caaaatatat
1621 ttatagtcga acaagtcata tatatgaatg agagccatat gaatgtcagt agtttatact
1681 tctctattat ctcaaaactac tggcaatttg taaagaaata tatatgatat ataaatgtga
1741 ttgcagcttt tcaatgttag ccacagtgtt ttttttctac tgtactaaaa ttgtatcaaa
1801 tgtgacatta tatgcactag caataaaatg ctaattgttt catggtta

```

//

```

LOCUS      HUMSDF1B      3524 bp      mRNA      PRI      26-DEC-1996
DEFINITION Human pre-B cell stimulating factor homologue (SDF1b) mRNA,
            complete cds.
ACCESSION  L36033
NID        gl220365
KEYWORDS   intercrine; intercrine CXC subfamily; pre-B cell stimulating
            factor
SOURCE     homologue; alpha-chemokine.
ORGANISM   human.
            Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 3524)
AUTHORS    Shirozu,M., Nakano,T., Inazawa,J., Tashiro,K., Tada,H.,
            Shinohara,T. and Honjo,T.
TITLE      Structure and chromosomal localization of the human stromal
            cell-derived factor 1 (SDF1) gene
JOURNAL    Genomics 28 (3), 495-500 (1995)
MEDLINE    96039262
FEATURES   Location/Qualifiers
            source      1..3524
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /clone="h17"
                        /cell_line="FLEB14-14"
            sig_peptide  80..142
                        /gene="SDF1b"
            CDS          80..361
                        /codon_start=1
                        /product="pre-B cell stimulating factor homologue"
                        /db_xref="PID:gl220365"

```

```

/translation="MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPFRFFESHVARANV
            KHLKILNTPNCALQIVARLKNNNRQVCIDPKLKWIQEYLEKALNKRFRKM"

```

```

gene      80..358
          /gene="SDF1b"
mat_peptide 143..358
          /gene="SDF1b"
          /product="pre-B cell stimulating factor homologue"
BASE COUNT 903 a 886 c 793 g 942 t
ORIGIN
1 tctccgctcag ccgcattgcc cgctcggcgt cgggcccccg acccgtgctc gtccgccccg
61 cgcggcgccc gcccgcgcca tgaacgccaa ggctcgtggc gtgctggctc tcgtgctgac
121 cgcgctctgc ctcagcgacg ggaagcccg cagcctgagc tacagatgcc catgccgatt
181 cttcgaaagc catgttgcca gagccaacgt caagcatctc aaaattctca acactccaaa
241 ctgtgccctt cagattgtag cccggctgaa gaacaacaac agacaagtgt gcattgaccc
301 gaagctaaag tggattcagg agtacctgga gaaagcttta aacaagaggt tcaagatgtg
361 agaggggtcag acgcctgagg aacctttaca gtaggagccc agctctgaaa ccagtgttag
421 ggaagggcct gccacagcct cccctgccag ggcagggcc caggcattgc caagggcttt
481 gttttgcaca ctttgccata ttttcaccat ttgattatgt agcaaaatac atgacattta
541 tttttcattt agtttgatta ttcagtgtca ctggcgacac gtagcagctt agactaaggc
601 cattattgta cttgccttat tagagtgtct ttccacggag ccactcctct gactcagggc
661 tcctgggttt tgtattctct gagctgtgtc ggtagggaga ctgggctgag ggagcctggc
721 cccatgggta gccctagggt ggagagccac caagagggac gcctgggggt gccaggacca
781 gtcaacctgg gcaaagccta gtgaaggctt ctctctgtgg gatgggatgg tggaggcca
841 catggggagg tcacccccct ctccatccac atgggagccg ggtctgcctc tctctggagg
901 gcagcagggc taccctgagc tgaggcagca gtgtgaggcc agggcagagc gagaccagc
961 cctccatccc agcacctcca catcctccac gttctgtcta tcattctctg tctcatccat
1021 catcatgtgt gtccacgact gtctccatgg ccccgcaaaa ggactctcag gaccaaaagt
1081 tcatgtataa ctgtgcacca agcaggaaat gaaaatgtct tgggttacct gaaaacactg
1141 tgcacatctg tgtcttgtgt ggaatatgtt ccattgtcca atcctatggt tttgttcaaa
1201 gtcagcgccc tctctgtgta ccaatgtctt gatgcattga ctgttcccc tgtcagccg
1261 ctgagcgagg agatgtctct tgggcccttt gagtgcagtc ctgatcagag ccgtggctct
1321 ttggggtgaa ctaccttggg tccccactg atcacaaaaa catggtgggt ccatgggcag
1381 agcccaaggg aattcgggtg gcaccagggt tgacccaga ggattgtctg ccatcagtg
1441 ctcctgcaca tgtcagtacc ttcaaactag ggccaagccc agcactgctt gaggaaaaca
1501 agcattcaca acttgttttt gggttttaaa acccagtcca caaaaatacc aatcctggac
1561 atgaagattc ttccccaatt cacatctaac ctcatcttct tcaccatttg gcaatgccat
1621 catctcctgc ctctcctctg ggccctctct gctctgcgtg tcacctgtct ttcgggcctc
1681 tcccacagga catttctcta agagaacaat gtgctatgtg aagagtaagt caacctgcct
1741 gacatttgga gtgttcccc cccactgagg gcagtcgata gagctgtatt aagccactta
1801 aaatgttcac ttttgacaaa ggcaagcact tgtgggtttt tgttttgtt ttcatcagt
1861 cttacgaata cttttgcctt ttgattaaag actccagtta aaaaaaatt taatgaagaa
1921 agtggaataa aaggaagtca aagcaaggaa actatgtaac atgtaggaag taggaagtaa
1981 attatagtga tgtaactctt aattgttaact gtctgtgaat ttaataatct gtagggtaat
2041 tagtaacatg tgttaagtat ttccataagt atttcaaat ggagcttcat ggcagaaggc
2101 aaacccatca acaaaaattg tcccttaaac aaaaattaaa atcctcaatc agctatggt
2161 atattgaaaa aatagagcct gagggatctt tactagtatt aaagatacag aactctttca
2221 aaaccttttg aaattaacct ctactatac cagtataatt gagttttcag tggggcagtc
2281 attatccagg taatccaaga tattttaaaa tctgtcacgt agaacttga tgtacctgcc
2341 cccaatccat gaaccaagac cattgaattc ttgggtgagg aaacaaacat gacctaaat
2401 cttgactaca gtcaggaaaag gaatcatttc tatttctct ccatgggaga aaatagataa
2461 gactagaaac tgcagggaac attatttgca taacaattcc tctactaaca atcagctcct
2521 tcttgagagc tgcccagcta aagcaatatg catttaataa cagtcttcca ttgcaaggg
2581 aaaagtctct tgtaatccga atctcttttt gctttcgaac tgctagtcaa gtgcgtccac
2641 gagctgttta ctagggatcc ctcatctgtc cctccgggac ctgggtctgc ctctacctga
2701 cactcccttg ggctccctgt aacctcttca gaggccctcg ctgccagctc tgtatcagga
2761 ccagaggaaa ggggccagag gctcgttgac tggctgtgtg ttgggattga gtctgtgcca
2821 cgtgtatgtg ctgtgggtgt tccccctctg tccaggcact gagataccag cgaggaggct
2881 ccagagggca ctctgcttgt tattagagat tacctcctga gaaaaaagct tccgcttggg
2941 gcagaggggc tgaatagcag aagggtgcac ctcccccaac cttagatgtt ctaagtcttt
3001 ccattggatc tcattggacc ctccatgggt gtgatcgtct gactggtgtt atcaccgtgg
3061 gctccctgac tgggagttga tcgcctttcc cagggtgtac acccttttcc agctggatga
3121 gaatttgagt gctctgatcc ctctacagag ctctcctgac tcattctgaa ggagcccat
3181 tcctgggaaa tattccctag aaacttccaa atccccaaag cagaccactg ataaaaccat
3241 gtgaaaaatt tgttattttg caacctcgct ggactctcag tctctgagca gtgaatgatt
3301 cagtgttaaa tgtgatgaat actgtatttt gtattgtttc aagtgcattc ccagataaat
3361 gtgaaaatgg tccaggagaa ggccaatttc tatacgagc gtgctttaa aaataataa
3421 gaaacaactc tttgagaaa aacaatttct actttgaagt cataccaatg aaaaaatgta
3481 tatgcactta taattttctt aataaagttc tgtactcaaa tgta

```

//

```

LOCUS      HSJ002211      663 bp      mRNA      PRI      11-MAR-1998
DEFINITION Homo sapiens cDNA for a CXC chemokine.
ACCESSION  AJ002211

```


NID g2832410
 KEYWORDS CXC chemokine.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
 Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 663)
 AUTHORS Legler,D.F., Loetscher,M., Roos,R.S., Clark-Lewis,I.,
 Baggiolini,M.
 and Moser,B.
 TITLE B cell-attracting chemokine 1, a human CXC chemokine expressed
 in lymphoid tissues, selectively attracts B lymphocytes via
 BLR1/CXCR5
 JOURNAL J. Exp. Med. 187 (4), 655-660 (1998)
 MEDLINE 98130629
 REFERENCE 2 (bases 1 to 663)
 AUTHORS Moser,B.
 TITLE Direct Submission
 JOURNAL Submitted (05-NOV-1997) Moser B., University of Bern, Theodor
 Kocher Institute, Freiestrasse 1, CH-3012 Bern, SWITZERLAND
 FEATURES Location/Qualifiers
 source 1..663
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /cell_type="PBL"
 sig_peptide 35..100
 /gene="BCA-1"
 CDS 35..364
 /gene="BCA-1"
 /codon_start=1
 /product="CXC chemokine"
 /db_xref="PID:e1249325"
 /db_xref="PID:g2832411"

/translation="MKFISTSLLLMLLVSSLSFVQGVLEVYYTSLRCRCVQESSVFIP

RRFIDRIQILPRGNCPKKEIIVWKNKSIVCVDPQAEWIQRMMEVLRKRSSSTLPVP

VFKRKIP"
 gene 35..364
 /gene="BCA-1"
 mat_peptide 101..361
 /gene="BCA-1"
 BASE COUNT 176 a 136 c 145 g 198 t 8 others
 ORIGIN

```

1 cagagctcaa gtctgaactc tacctccaga cagaatgaag ttcattctga catctctgct
61 tctcatgctg ctggctcagca gcctctctcc agtccaaggt gttctggagg tctattacac
121 aagcttgagg tgtagatgtg tccaagagag ctcagctctt atccctagac gcttcattga
181 tcgaattcaa atcttgcccc gtgggaatgg ttgtccaaga aaagaaatca tagtctggaa
241 gaagaacaag tcaattgtgt gtgtggaccc tcaagctgaa tggatacaaa gaatgatgga
301 agtattgaga aaaagaagtt ctccaactct accagttcca gtgtttaaga gaaagattcc
361 ctgatgctga tatttccact aagaacacct gcattcttcc cttatccctg ctctgggatt
421 ttagttttgt gcttagttaa atcttttcca gggagaaaga acttccccat acaaataagg
481 catgaggact atgtaaaaat aaccttcgag gagctggatg gggggccaaa ctcaagcttc
541 ttctactcca caggcaccct attntacact tgggggtttt gcnttctttn tttcntcagg
601 gggggggaaa gtttcttttg gaaantagtt ntccaggttn ttaggtatta cagggttntt
661 ttt
  
```

//

LOCUS HSHUMIG 2545 bp RNA PRI 16-NOV-1993
 DEFINITION H.sapiens Humig mRNA.
 ACCESSION X72755 S60728
 NID g311375
 KEYWORDS chemokine; cytokine; Humig gene; secreted protein.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 2545)
 AUTHORS Farber,J.M.
 TITLE Direct Submission
 JOURNAL Submitted (22-MAR-1993) J.M. Farber, Johns Hopkins Univ. School

of
 USA Medicine, Ross 1147, 720 Rutland Avenue, Baltimore, MD 21205,
 REFERENCE 2 (bases 1 to 2545)
 AUTHORS Farber, J.M.
 TITLE HuMig: a new human member of the chemokine family of cytokines
 JOURNAL Biochem. Biophys. Res. Commun. 192 (1), 223-230 (1993)
 MEDLINE 93236577
 FEATURES Location/Qualifiers
 source 1..2545
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /germline
 /dev_stage="child"
 /tissue_type="leukaemia"
 /cell_type="monocyte"
 /cell_line="THP-1"
 /clone_lib="THP-1/IFN-gamma cDNA"
 /clone="H-1-3"
 misc_feature 13..19
 /note="cis-acting element; putative"
 gene 40..417
 /gene="Humig"
 CDS 40..417
 /gene="Humig"
 /codon_start=1
 /db_xref="PID:g311376"
 /db_xref="SWISS-PROT:Q07325"

/translation="MKKSGVLFLLGIILLVLIGVQGTPVVRKGRCSISTNQGTIHLQ

SLKDLKQFAPSPSCEKIEIIATLKNQVQTCLNPDSADVKELIKKEKQVSQKKKQKNG

KKHQKKKVLKVRKSQRSRQKKTT"

BASE COUNT 755 a 581 c 457 g 752 t

ORIGIN

```

1 atccaatata ggagtgactt ggaactccat tctatcacta tgaagaaaag tgggtgttctt
61 ttcctcttgg gcatcatctt gctgggtctg attggagtgc aaggaacccc agtagtgaga
121 aagggtcgct gttcctgcat cagcaccacac caagggacta tccacctaca atccttgaaa
181 gaccttaaac aatttgcccc aagcccttcc tgcgagaaaa ttgaaatcat tgctacactg
241 aagaatggag ttcaaacatg tctaaaccca gattcagcag atgtgaagga actgattaaa
301 aagtgggaga aacaggtcag ccaaaagaaa aagcaaaaaga atgggaaaaa acatcaaaaa
361 aagaaagtgc tgaaagtgcg aaaatctcaa cgttctcgtc aaaagaagac tacataagag
421 accacttcac caataagtat tctgtgttaa aaatgttcta ttttaattat accgctatca
481 ttccaaagga ggatggcata taatacaaag gcttattaat ttgactagaa aatttaaaac
541 attactctga aattgtaact aaagttagaa agttgatttt aagaatccaa acgttaagaa
601 ttgttaaagg ctatgattgt ctttgttctt ctaccacca ccagttgaat tcatcatgc
661 ttaagcccat gattttagca ataccatgt ctacacagat gtccacccaa ccacatccca
721 ctcaaacag ctgcctggaa gagcagccct aggcctccac gtactgcagc ctccagagag
781 tatctgaggc acatgtcagc aagtcctaaag cctgttagca tgctgggtgag ccaagcagtt
841 tgaaattgag ctggacctca ccaagctgct gtggccatca acctctgtat ttgaatcagc
901 ctacaggcct cacacacaat gtgtctgaga gattcatgct gattgttatt ggggtatcacc
961 actggagatc accagtgtgt ggctttcaga gcctccttcc tggcctttgga agccatgtga
1021 ttccatcttg cccgctcagg ctgaccactt tatttctttt tgttccccct tgcctcattc
1081 aagtcagctc ttctccatcc taccacaatg cagtgccttt cttctctcca gtgcacctgt
1141 catatgctct gatttatctg agtcaactcc tttctcatct tgtccccaac accccacaga
1201 agtgctttct tctcccaatt cactcctcact cagtccagct tagttcaagt cctgcctctt
1261 aaataaacct ttttggacac acaaattatc ttaaaactcc tgtttcactt ggttcagtac
1321 acatgggtg aacactcaat ggttaactaa ttcttgggtg ttatctctat ctctccaacc
1381 agattgtcag ctcttgagg gcaagagcca cagtatatct ccctgtttct tccacagtgc
1441 ctaataatac tgtggaacta ggttttaata attttttaat tgatgttgtt atgggcagga
1501 tggcaaccag accattgtct cagagcaggt gctggctctt tccgtgctac tccatgttgg
1561 ctacgctctg gtaacctctt acttattatc ttcaggacac tcaactacag gaccagggat
1621 gatgcaacat ccttgtcttt ttatgacagg atgtttgtct agcttctcca acaataagaa
1681 gcacgtggta aaacacttgc ggatattctg gactgttttt aaaaaatata cagtttaccg
1741 aaaatcatat aatcttcaa tgaaaaggag tttatagatc agccagtgaac caacctttc
1801 ccaaccatac aaaaattcct ttcccggaag gaaaagggct ttctcaataa gcctcagctt
1861 tctaagatct aacaagatag ccaccgagat ccttatcgaa actcatttta ggcaaatatg
1921 agttttattg tccgtttact tgtttcagag tttgtattgt gattatcaat taccacacca
1981 tctcccatga agaaaggga cgggtgaagta ctaagcgcta gaggaagcag ccaagtcggt
2041 tagtggagc atgattggtg cccagttagc ctctgcagga tgtggaaacc tcttccagg
2101 ggaggttcag tgaattgtgt aggagaggtt gtctgtggcc agaatttaaa cctatactca

```

```

2161 ctttcccaaa ttgaatcact gctcacactg ctgatgattt agagtgtgtt ccggtggaga
2221 tcccacccga acgtcttatac taatcatgaa actccctagt tccttcatgt aacttccctg
2281 aaaaatctaa gtgtttcata aatttgagag tctgtgaccc acttaccttg catctcacag
2341 gtagacagta tataactaac aaccaaagac tacatattgt cactgacaca caggttataa
2401 tcatttatca tatatatata tacatgcata cactctcaaa gcaaataatt tttcacttca
2461 aaacagtatt gacttgata ccttgtaatt tgaaatattt tctttgttaa aatagaatgg
2521 tatcaataaa tagaccatta atcag

```

//

```

LOCUS      HSHUMIG      2545 bp      RNA      PRI      16-NOV-1993
DEFINITION H.sapiens Humig mRNA.
ACCESSION  X72755 S60728
NID        g311375
KEYWORDS   chemokine; cytokine; Humig gene; secreted protein.
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 2545)
AUTHORS    Farber,J.M.
TITLE      Direct Submission
JOURNAL    Submitted (22-MAR-1993) J.M. Farber, Johns Hopkins Univ. School
of
            Medicine, Ross 1147, 720 Rutland Avenue, Baltimore, MD 21205,
            USA
REFERENCE  2 (bases 1 to 2545)
AUTHORS    Farber,J.M.
TITLE      HuMig: a new human member of the chemokine family of cytokines
JOURNAL    Biochem. Biophys. Res. Commun. 192 (1), 223-230 (1993)
MEDLINE    93236577
FEATURES   Location/Qualifiers
            source          1..2545
                           /organism="Homo sapiens"
                           /db_xref="taxon:9606"
                           /germline
                           /dev_stage="child"
                           /tissue_type="leukaemia"
                           /cell_type="monocyte"
                           /cell_line="THP-1"
                           /clone_lib="THP-1/IFN-gamma cDNA"
                           /clone="H-1-3"
            misc_feature    13..19
                           /note="cis-acting element; putative"
            gene            40..417
                           /gene="Humig"
            CDS             40..417
                           /gene="Humig"
                           /codon_start=1
                           /db_xref="PID:g311376"
                           /db_xref="SWISS-PROT:Q07325"

```

/translation="MKKSGVLFLLGIILLVLIGVQGTPVVRKGRCSISTNQGTIHLQ

SLKDLKQFAPSPSCEKIEIIATLKNVQTCLNPDSADVKELIKKEKQVSQKKKQKNG
KKHQKKKVLKVRKSQRSRQKKTT"

BASE COUNT 755 a 581 c 457 g 752 t
ORIGIN

```

1 atccaataca ggagtgcactt ggaactccat tctatcacta tgaagaaaag tgggtgttctt
61 ttccctcttgg gcatcatctt gctgggtctg attggagtgc aaggaacccc agtagtgaga
121 aagggtcgct gttcctgcac cagcaccaac caagggacta tccacctaca atccttgaaa
181 gaccttaaac aatttgcccc aagcccttcc tgcgagaaaa ttgaaatcat tgctacactg
241 aagaatggag ttcaaacatg tctaaaccca gattcagcag atgtgaagga actgtataaa
301 aagtgggaga aacagggtcag ccaaaagaaa aagcaaaaaga atgggaaaaa acatcaaaaa
361 aagaaagtgc tgaaagtgcg aaaatctcaa cgttctcgtc aaaagaagac tacataagag
421 accacttcac caataagtat tctgtgttaa aaatgttcta ttttaattat accgctatca
481 ttccaaaagga ggatggcata taatacaaaag gcttattaat ttgactagaa aatttaaaac
541 attactctga aattgtaact aaagttagaa agttgatttt aagaatccaa acgttaagaa
601 ttgttaaagg ctatgattgt ctttgttctt ctaccacca ccagttgaat ttcatcatgc
661 ttaaggccat gatcttagca ataccatgt ctacacagat gttcacccaa ccacatccca
721 ctcaaacag ctgcctggaa gagcagccct aggtttccac gtactgcagc ctccagagag
781 tatctgaggc acatgtcagc aagtcctaag cctgttagca tgctggtgag ccaagcagtt

```

```

841  tgaaattgag  ctggacctca  ccaagctgct  gtggccatca  acctctgtat  ttgaatcagc
901  ctacaggcct  cacacacaat  gtgtctgaga  gattcatgct  gattgttatt  gggatatcacc
961  actggagatc  accagtgtgt  ggctttcaga  gcctcctttc  tggctttgga  agccatgtga
1021  ttccatcttg  cccgctcagg  ctgaccactt  tatttctttt  tgttccccct  tgcttcattc
1081  aagtcagctc  ttctccatcc  taccacaatg  cagtgccttt  cttctctcca  gtgcacctgt
1141  catatgctct  gatttatctg  agtcaactcc  tttctcatct  tgtccccaac  accccacaga
1201  agtgctttct  tctcccaatt  catcctcact  cagtccagct  tagttcaagt  cctgcctctt
1261  aaataaacct  ttttggacac  acaaattatc  ttaaaaactcc  tgtttcactt  gggtcagtag
1321  ccaactgggtg  aacactcaat  ggtaactaa  ttcttgggtg  tttatcctat  ctctccaacc
1381  agattgtcag  ctcttgagg  gcaagagcca  cagtatattt  ccctgtttct  tccacagtgc
1441  ctaataatac  tgtggaacta  ggttttaata  attttttaat  tgatgttgtt  atgggagga
1501  tggcaaccag  accattgtct  cagagcaggt  gctggctctt  tcctggctac  tccatgttgg
1561  ctagcctctg  gtaacctctt  acttattatc  ttcaggacac  tcactacagg  gaccagggat
1621  gatgcaacat  ccttgtcttt  ttatgacagg  atgtttgctc  agcttctcca  acaataagaa
1681  gcacgtggta  aaacacttgc  ggatattctg  gactgttttt  aaaaaatata  cagtttaccg
1741  aaaatcatat  aatcttaca  tgaaaaggac  tttatagatc  agccagtgc  caaccttttc
1801  ccaaccatac  aaaaattcct  tttcccgaag  gaaaagggtt  ttctcaataa  gcctcagctt
1861  tctaagatct  aacaagatag  ccaccgagat  ccttatcgaa  actcatttta  ggcaaataatg
1921  agttttattg  tccgtttact  tgtttcagag  tttgtattgt  gattatcaat  taccacacca
1981  tctcccatga  agaaagggaa  cgggtgaagta  ctaagcgcta  gaggaagcag  ccaagtcggt
2041  tcttggaagc  atgattgtgt  cccagttagc  ctctgcagga  tgtggaacc  tccttcagg
2101  ggaggttcag  tgaattgtgt  aggagaggtt  gtctgtggcc  agaatttaaa  cctatactca
2161  ctttcccaaa  ttgaatcact  gctcacactg  ctgatgattt  agagtgtgt  ccggtggaga
2221  tcccaccgca  acgtcttatc  taatcatgaa  actccctagt  tccttcatgt  aacttccttg
2281  aaaaatctaa  gtgtttcata  aatttgagag  tctgtgacct  acttaccttg  catctcacag
2341  gtagacagta  tataactaac  aaccaaagac  tacatattgt  cactgacaca  cacgttataa
2401  tcatttatca  tatatatata  tacatgcata  cactctcaaa  gcaataaatt  tttcacttca
2461  aaacagtatt  gacttgata  ccttgtaatt  tgaaatattt  tctttgttaa  aatagaatgg
2521  tatcaataaa  tagaccatta  atcag

```

//

```

LOCUS      AF002985      995 bp      mRNA      PRI      01-NOV-1997
DEFINITION Homo sapiens putative alpha chemokine (H174) mRNA, complete
cds.
ACCESSION  AF002985
NID        g2580585
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 995)
AUTHORS    Jacobs,K.A., Collins-Racie,L.A., Colbert,M., Duckett,M.,
            Golden-Fleet,M., Kelleher,K., Kriz,R., LaVallie,E.R.,
            Merberg,D.,
            Spaulding,V., Stover,J., Williamson,M.J. and McCoy,J.M.
TITLE      A genetic selection for isolating cDNAs encoding secreted
            proteins
JOURNAL    Gene 198 (1-2), 289-296 (1997)
MEDLINE    98036061
REFERENCE  2 (bases 1 to 995)
AUTHORS    Jacobs,K.A., Collins-Racie,L.A., Colbert,M., Duckett,M.,
            Golden-Fleet,M., Kelleher,K., Kriz,R., LaVallie,E.R.,
            Merberg,D.,
            Spaulding,V., Stover,J., Williamson,M.J. and McCoy,J.M.
TITLE      Direct Submission
JOURNAL    Submitted (07-MAY-1997) Genetics Institute, 87 Cambridge Park
            Drive, Cambridge, MA 02140, USA
FEATURES   Location/Qualifiers
            source      1..995
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /cell_type="PHA and PMA activated human peripheral
blood
                        mononuclear cells"
            gene        1..995
                        /gene="H174"
            CDS          88..372
                        /gene="H174"
                        /codon_start=1
                        /product="putative alpha chemokine"

```

/db_xref="PID:g2580586"

/translation="MSVKGMAIALAVILCATVVQGFPMFKRGRCLCIGPGVKAVKQAD
 IEKASIMYPSNNCDKIEVIITLKENKGQRCLNPKSKQARLIKKVERKNF"

BASE COUNT 382 a 170 c 194 g 249 t
 ORIGIN

```

1 gaattcggcc aaagaggcct acttccaaga agagcagcaa agctgaagta gcagcaacag
61 caccagcagc aacagcaaaa aacaaacatg agtgtgaagg gcatggctat agccttggct
121 gtgatattgt gtgctacagt tgttcaaggc ttcccatgt tcaaaaggag acgctgtctt
181 tgcataggcc ctggggtaaa agcagtgaag gtggcagata ttgagaaagc ctccataatg
241 tacccaagta acaactgtga caaaatagaa gtgattatta ccctgaaaga aaataaagga
301 caacgatgcc taaatcccaa atcgaagcaa gcaaggctta taatcaaaaa agttgaaaga
361 aagaattttt aaaaatatca aaacatatga agtcctggaa aaggcatctt gaaaaacctt
421 gaacaagttt aactgtgact actgaaatga caagaattct acagtaggaa actgagactt
481 ttctatgggt ttgtgacttt caacttttgt acagtattgt gaaggatgaa aggtgggtga
541 aaggacaaaa aacagaaata cagtcttctt gaatgaatga caatcagaat tccactgccc
601 aaagaggtcc aacaattaaa tggatttcta ggaagctga ccttaagaaa ggctgtttac
661 catcggagtt tacaaagtgc ttccacgttc ttacttgttg tattatacat tcatgcattt
721 ctaggctaga gaaccttcta gatttgatgc ttacaactat tctgttgtga ctatgagaac
781 atttctgtct ctagaagtta tctgtctgta ttgatcttta tgctatatta ctatctgtgg
841 ttacagtgga gacattgaca ttattactgg agtcaagccc ttataagtca aaagcaccta
901 tgtgtcgtaa agcattcctc aaacatttaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa
961 aaaaaaaaaa aaaaaaaaaa aaaaaaagcg gccgc

```

//

LOCUS AF030514 1371 bp mRNA PRI 17-JUN-1998
 DEFINITION Homo sapiens interferon stimulated T-cell alpha chemoattractant precursor, mRNA, complete cds.
 ACCESSION AF030514
 NID g3219692
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
 Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 1371)
 AUTHORS Cole,K.E., Strick,C.A., Paradis,T.J., Ogborne,K.T.,
 Loetscher,M., Gladue,R.P., Lin,W.; Boyd,J.G., Moser,B., Wood,D.E.,
 Sahagan,B.G. and Neote,K.
 TITLE Interferon-inducible T cell alpha chemoattractant (I-TAC): a
 novel non-ELR CXC chemokine with potent activity on activated T cells
 through selective high affinity binding to CXCR3
 JOURNAL J. Exp. Med. 187 (12), 2009-2021 (1998)
 MEDLINE 98290735
 REFERENCE 2 (bases 1 to 1371)
 AUTHORS Cole,K.E., Strick,C.A. and Sahagan,B.G.
 TITLE Direct Submission
 JOURNAL Submitted (20-OCT-1997) Molecular Sciences, Pfizer, Inc.,
 Eastern Point Road, Groton, CT 06340, USA
 FEATURES Location/Qualifiers
 source 1..1371
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /chromosome="4"
 /cell_type="astrocytes"
 sig_peptide 70..132
 CDS 70..354
 /note="chemokine; I-TAC"
 /codon_start=1
 /product="interferon stimulated T-cell alpha
 chemoattractant precursor"
 /db_xref="PID:g3219693"
 /translation="MSVKGMAIALAVILCATVVQGFPMFKRGRCLCIGPGVKAVKQAD
 IEKASIMYPSNNCDKIEVIITLKENKGQRCLNPKSKQARLIKKVERKNF"
 mat_peptide 133..351
 /evidence=not_experimental

```

                /product="interferon stimulated T-cell alpha
                chemoattractant"
BASE COUNT      487 a      228 c      244 g      411 t      1 others
ORIGIN
1   ctccttccaa gaagagcagc aaagctgaag tagcagcaac agcaccagca gcaacagcaa
61  aaaacaaaca tgagtgtgaa gggcatggct atagccttgg ctgtgatatt gtgtgctaca
121 gttgttcaag gcttcccat  gttcaaaaga ggacgctgtc tttgcatagg ccctggggta
181 aaagcagtga aagtggcaga tattgagaaa gcctccataa tgtacccaag taacaactgt
241 gacaaaatag aagtgattat taccctgaaa gaaaataaag gacaacgatg cctaaatccc
301 aaatcgaagc aagcaaggct tataatcaaa aaagttgaaa gaaagaattt taaaaaatat
361 caaaacatat gaagtcctgg aaaagggcat ctgaaaaaac tagaacaagt ttaactgtga
421 ctactgaaat gacaagaatt ctacagtagg aaactgagac ttttctatgg ttttgtgact
481 ttcaactttt gtacagttaa gtgaaggatg aaagggtggg gaaaggacca aaaacagaaa
541 tacagtcttc ctgaatgaat gacaatcaga attccactgc ccaaaggagt ccagcaatta
601 aatggatttc taggaaaagc taccttaaga aaggctgggt accatcggag tttaaaaagt
661 gctttcacgt tcttacttgt tgtattatac attcatgcat ttctaggcta gagaaccttc
721 tatctttgat gcttacaact attctgttgt gactatgaga acatttctgt ctctagaagt
781 tatctgtctg tattgatctt tatgctatat tactatctgt ggttacagtg gagacattga
841 cattattact ggagtcgaag ccttataagt caaagcatc tatgtgtcgt aaagcattcc
901 tcaaacattt tttcatgcaa atacacaytt ctttcccaa atatcatgta gcacatcaat
961 atgtagggaa acattcttat gcatcatttg gtttgtttta taaccaattg attaaatgta
1021 attcataaaa tgtactatga aaaaaattat acgctatggg atactggcaa cagtgcacat
1081 atttcataac caaattagca gcaccgggtc taatttgatg tttttcaact tttattcatt
1141 gagatgtttt gaagcaatta ggatatttgt gtttactgta ctttttgttt tgatccgttt
1201 gtataaatga tagcaatatc ttggacacat ttgaaataca aaatgttttt gtctacaaaa
1261 gaaaaatgtt gaaaaataag caaatgtata cctagcaatc acttttactt tttgtaattc
1321 tgtctcttag aaaaatacat aatctaatac aaaaaaaaaa aaaaaaaaaa a

```

//

```

LOCUS      AF030514      1371 bp      mRNA                      PRI      17-JUN-1998
DEFINITION Homo sapiens interferon stimulated T-cell alpha chemoattractant
            precursor, mRNA, complete cds.
ACCESSION  AF030514
NID        g3219692
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 1371)
AUTHORS    Cole,K.E., Strick,C.A., Paradis,T.J., Ogborne,K.T.,
Loetscher,M., Gladue,R.P., Lin,W., Boyd,J.G., Moser,B., Wood,D.E.,
Sahagan,B.G. and Neote,K.
TITLE      Interferon-inducible T cell alpha chemoattractant (I-TAC): a
            novel
            non-ELR CXC chemokine with potent activity on activated T cells
            through selective high affinity binding to CXCR3
JOURNAL     J. Exp. Med. 187 (12), 2009-2021 (1998)
MEDLINE     98290735
REFERENCE  2 (bases 1 to 1371)
AUTHORS     Cole,K.E., Strick,C.A. and Sahagan,B.G.
TITLE       Direct Submission
JOURNAL      Submitted (20-OCT-1997) Molecular Sciences, Pfizer, Inc.,
            Eastern
            Point Road, Groton, CT 06340, USA
FEATURES
            Location/Qualifiers
            source          1..1371
                           /organism="Homo sapiens"
                           /db_xref="taxon:9606"
                           /chromosome="4"
                           /cell_type="astrocytes"
            sig_peptide     70..132
            CDS              70..354
                           /note="chemokine; I-TAC"
                           /codon_start=1
                           /product="interferon stimulated T-cell alpha
                           chemoattractant precursor"
                           /db_xref="PID:g3219693"

```

```

/translation="MSVKGMAIALAVILCATVVQGFPMFKRGRCLCIGPGVKAVKQAD
IEKASIMYPSNNCDKIEVITLKENKGQRCLNPKSKQARLIKKVERKNF"
mat_peptide      133..351
/evidence=not_experimental
/product="interferon stimulated T-cell alpha
chemoattractant"
BASE COUNT      487 a    228 c    244 g    411 t    1 others
ORIGIN
    1 ctccttccaa gaagagcagc aaagctgaag tagcagcaac agcaccagca gcaacagcaa
   61 aaaacaaaca tgagtgtgaa gggcatggct atagccttgg ctgtgatatt gtgtgtcata
  121 gttgttcaag gcttccccat gttcaaaaga ggacgctgtc ttgcatagg cctgtgggta
  181 aaagcagtga aagtggcaga tattgagaaa gcctccataa tgtaccaag taacaactgt
  241 gacaaaaatag aagtgattat tacctgaaa gaaaataaag gacaacgatg cctaaatccc
  301 aaatcgaagc aagcaaggct tataatcaaa aaagttgaaa gaaagaattt ttaaaaatat
  361 caaaacatat gaagtccctgg aaaagggcat ctgaaaaacc tagaacaagt ttaactgtga
  421 ctactgaaat gacaagaatt ctacagtagg aaactgagac ttttctatgg ttttgtgact
  481 ttcaactttt gtacagttaa gtgaaggatg aaaggtgggt gaaaggacca aaaacagaaa
  541 ttacagtcttc ctgaatgaat gacaatcaga attccactgc ccaaaggagt ccagcaatta
  601 aatggatttc taggaaaagc taccttaaga aaggctgggt accatcggag ttacaaaagt
  661 gctttcacgt tcttacttgt tgtattatac attcatgcat ttctaggcta gagaaccttc
  721 tagatttgat gcttacaact attctgttgt gactatgaga acatttctgt ctctagaagt
  781 taactgtctg tattgatctt tatgtcttat tactatctgt ggttacagtg gagacattga
  841 cattattact ggagtcagc ccttataagt caaaagcatt tatgtgtcgt aaagcattcc
  901 tcaaacatctt ttctcatgca atacacaytt ctttcccaa atatcatgta gcacatcaat
  961 atgtagggaa acattcttat gcatctttt gttgtttta taaccaattc attaaatgta
 1021 attcataaaa tgtactatga aaaaaattat acgctatggg atactggcaa cagtgcacat
 1081 attcataaac caaattagca gcaccggctc taatttgatg tttttcaact tttattcatt
 1141 gagatgtttt gaagcaatta ggaatagtgt gtttactgta ctttttgttt tgatccgttt
 1201 gtataaatga tagcaatc ttggacacat ttgaaataca aaatgttttt gtctaccaa
 1261 gaaaaatggt gaaaaataag caaatgtata cctagcaatc acttttactt tttgtaattc
 1321 tgtctcttag aaaaatacat aatctaata aaaaaaaaaa aaaaaaaaaa a

```

//

```

LOCUS      AF030514      1371 bp      mRNA      PRI      17-JUN-1998
DEFINITION Homo sapiens interferon stimulated T-cell alpha chemoattractant
precursor, mRNA, complete cds.
ACCESSION  AF030514
NID        g3219692
KEYWORDS   .
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 1371)
AUTHORS    Cole,K.E., Strick,C.A., Paradis,T.J., Ogborne,K.T.,
Loetscher,M., Gladue,R.P., Lin,W., Boyd,J.G., Moser,B., Wood,D.E.,
Sahagan,B.G.
            and Neote,K.
TITLE      Interferon-inducible T cell alpha chemoattractant (I-TAC): a
novel
            non-ELR CXC chemokine with potent activity on activated T cells
            through selective high affinity binding to CXCR3
JOURNAL    J. Exp. Med. 187 (12), 2009-2021 (1998)
MEDLINE    98290735
REFERENCE  2 (bases 1 to 1371)
AUTHORS    Cole,K.E., Strick,C.A. and Sahagan,B.G.
TITLE      Direct Submission
JOURNAL    Submitted (20-OCT-1997) Molecular Sciences, Pfizer, Inc.,
Eastern
            Point Road, Groton, CT 06340, USA
FEATURES   Location/Qualifiers
            source      1..1371
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /chromosome="4"
                        /cell_type="astrocytes"
            sig_peptide  70..132
            CDS          70..354
                        /note="chemokine; I-TAC"
                        /codon_start=1

```

/product="interferon stimulated T-cell alpha
chemoattractant precursor"
/db_xref="PID:g3219693"

/translation="MSVKGMAIALAVILCATVVQGFPMFKRGRCLCIGPGVKAVKVAD
IEKASIMYPSNNDKIEVIITLKENKGQRCLNPKSKQARLI IKKVERKNF"
mat_peptide 133..351

/evidence=not_experimental
/product="interferon stimulated T-cell alpha
chemoattractant"

BASE COUNT 487 a 228 c 244 g 411 t 1 others
ORIGIN

```

1 ctccttccaa gaagagcagc aaagctgaag tagcagcaac agcaccagca gcaacagcaa
61 aaaacaaaca tgagtgtgaa gggcatggct atagccttgg ctgtgatatt gtgtgctaca
121 gttgttcaag gcttccccat gttcaaaaga ggacgctgtc tttgcatagg ccctggggta
181 aaagcagtga aagtggcaga tattgagaaa gcctccataa tgtaccgaag taacaactgt
241 gacaaaatag aagtgattat tacctgaaa gaaaataaag gacaacgatg cctaaatccc
301 aaatcgaagc aagcaaggct tataatcaaa aaagttgaaa gaaagaatct taaaaaatat
361 caaaacatat gaagtcctgg aaaagggcat ctgaaaaaac tagaacaagt ttaactgtga
421 ctactgaaat gacaagaatt ctacagtagg aaactgagac ttttctatgg ttttgtgact
481 ttcaactttt gtacagttat gtgaaggatg aaagggtgggt gaaaggacca aaaacagaaa
541 tacagtcttc ctgaatgaat gacaatcaga attccactgc ccaaaggagt ccagcaatta
601 aatggatttc taggaaaagc taccttaaga aaggctgggt accatcggag tttaaaaagt
661 gctttcacgt tcttacttgt tgtattatac attcatgcat ttctaggcta gagaacctc
721 tgattttgat gcttacaact attctgttgt gactatgaga acatttctgt ctctagaagt
781 tatctgtctg tattgatctt tatgctatat tactatctgt ggttacagtg gagacattga
841 cattattact ggagtcaagc ccttataagt caaaagcatc tatgtgtcgt aaagcattcc
901 tcaaacattt tttcatgcaa atacacaytt ctttcccaa ataatcatgta gcacatcaat
961 atgtagggaa acattcttat gcatcatttg gtttgtttta taaccaattc attaatgta
1021 attcataaaa tgtactatga aaaaaattat acgctatggg atactggcaa cagtgcacat
1081 atttcataac caaattagca gcaccgggtc taatttgatg tttttcaact tttattcatt
1141 gagatgtttt gaagcaatta ggatatttgt gtttactgta ctttttgttt tgatccggtt
1201 gtataaatga tagcaatatc ttggacacat ttgaaataca aaatgttttt gtctaccaa
1261 gaaaaatggt gaaaaataag caaatgtata cctagcaatc acttttactt tttgtaattc
1321 tgtctcttag aaaaatacat aatctaatac aaaaaaaaaa aaaaaaaaaa a

```

//

LOCUS H5MDNCF 1560 bp RNA PRI 31-MAR-1995
DEFINITION Human mRNA for MDNCF (monocyte-derived neutrophil chemotactic factor).
ACCESSION Y00787
NID g34518
KEYWORDS cytokine.
SOURCE human.
ORGANISM Homo sapiens
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata; Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1560)
AUTHORS Matsushima,K.
TITLE Direct Submission
JOURNAL Submitted (03-MAY-1988) Matsushima K., National Cancer Institute,
Bldg 560, Rm 31-19, Frederick, MD 21701
REFERENCE 2 (bases 1 to 1560)
AUTHORS Matsushima,K., Morishita,K., Yoshimura,T., Lavu,S., Kobayashi,Y.,
Lew,W., Appella,E., Kung,H.F., Leonard,E.J. and Oppenheim,J.J.
TITLE Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor
JOURNAL J. Exp. Med. 167 (6), 1883-1893 (1988)
MEDLINE 88258376
COMMENT for overlapping sequence see M17016 - M17017.
FEATURES Location/Qualifiers
source 1..1560
/organism="Homo sapiens"
/db_xref="taxon:9606"
/cell_type="monocyte"
/clone_lib="lambda gt10"
sig_peptide 102..182
/note="signal peptide (AA -27 to -1)"


```

CDS          102..401
             /codon_start=1
             /product="MDNCF precursor (AA -27 to 72)"
             /db_xref="PID:g34519"
             /db_xref="SWISS-PROT:P10145"

/translation="MTSKLAVALLAFLISAALCEGAVLPRSAKELRCQCIKTYSKPF
HPKFIKELRVIESGPHCANTEIIVKLSDGRELCLDPKENWVQRVVEKFLKRAENS"
mat_peptide  183..398
             /note="mat. MDNCF (AA 1 - 72)"
BASE COUNT   526 a    247 c    281 g    506 t
ORIGIN
    1 ctccataagg cacaaacttt cagagacagc agagcacaca agcttctagg acaagagcca
   61 ggaagaaacc accggaagga accatctcac tgtgtgtaaa catgacttcc aagctggccg
  121 tggctctctt ggcagccttc ctgatttctg cagctctgtg tgaagggtga gttttgccaa
  181 ggagtgtctaa agaacttaga tgtcagtgca taaagacata ctccaaacct ttccacccca
  241 aattttatcaa agaactgaga gtgattgaga gtggaccaca ctgcgccaac acagaaatta
  301 ttgtaaagct ttctgatgga agagagctct gtctggaccc caaggaaaac tgggtgcaga
  361 gggttgtgga gaagtttttg aagagggctg agaattcata aaaaaattca ttctctgtgg
  421 tatccaagaa tcagtgaaga tgccagtga acttcaagca aatctacttc aacacttcat
  481 gtattgtgtg ggtctgttgt aggggttgcca gatgcaatac aagattctctg gttaaatttg
  541 aatttcagta aacaatgaat agtttttcat tgtaccatga aatatccaga acatacttat
  601 atgtaaagta ttattttatt gaatctacaa aaaacaacaa ataattttta aatataagga
  661 ttttctagta tattgcacgg gagaatatac aaatagcaaa attgggccaa gggccaagag
  721 aatatccgaa ctttaatttc aggaattgaa tgggtttgct agaattgat atttgaagca
  781 tcacataaaa atgatgggac aataaatttt gccataaagt caaatttagc tggaaatcct
  841 ggattttttt ctgttaaatc tggcaaccct agtctgctag ccaggatcca caagtccttg
  901 ttccactgtg ccttggtttc tcctttattt ctaagtggaa aaagtattag ccaccatctt
  961 acctcacagt gatgttgtga ggacatgtgg aagcacttta agttttttca tcataacata
 1021 aattattttc aagtgttaact tattaaccta tttattattt atgtatttat ttaagcatca
 1081 aatattttgt caagaatttg gaaaaataga agatgaatca ttgattgaat agttataaag
 1141 atgtttatag aaattttatt tattttagat attaaatgat gttttattag ataaatttca
 1201 atcagggttt ttagattaaa caaacaacaa attgggtacc cagttaaatt ttcatctcag
 1261 atatacaaca aataattttt tagtataagt acattattgt ttatctgaaa ttttaattga
 1321 actaacaatc ctagtttgat actcccagtc ttgtcattgc cagctgtgtt ggtagtgctg
 1381 tgttgaatta cggaataatg agttagaact attaaaacag ccaaaactcc acagtcaata
 1441 ttagtaattt cttgctggtt gaaacttggt tattatgtac aaatagattc ttataatatt
 1501 atttaaatga ctgcattttt aaatacaagg ctttatattt ttaactttaa aaaaaaccgg

```

```

//
LOCUS       HSINFGER      1172 bp      RNA              PRI      21-MAR-1995
DEFINITION  Human mRNA for gamma-interferon inducible early response gene
(with
homology to platelet proteins).
ACCESSION   X02530 M17752
NID         g33917
KEYWORDS    interferon response; signal peptide.
SOURCE      human.
ORGANISM    Homo sapiens
             Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
             Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1 (bases 1 to 1172)
AUTHORS     Luster,A.D., Unkeless,J.C. and Ravetch,J.V.
TITLE       Gamma-interferon transcriptionally regulates an early-response
gene
             containing homology to platelet proteins
JOURNAL      Nature 315 (6021), 672-676 (1985)
MEDLINE      85240552
REFERENCE   2 (bases 1 to 1172)
AUTHORS     Luster,A.D.
TITLE       Direct Submission
JOURNAL      Submitted (29-JUL-1986) to the EMBL/GenBank/DBJ databases
COMMENT      Data kindly reviewed (29-JUL-1986) by Luster A.D.
FEATURES
             Location/Qualifiers
             source
               1..1172
               /organism="Homo sapiens"
               /strain="(U 937 histiocytic lymphoma cell line)"
               /db_xref="taxon:9606"
             misc_RNA
               1
               /note="cap site"

```

```

sig_peptide      67..129
                  /note="pot. signal peptide (aa-21 to -1)"
CDS              67..363
                  /note="early response precursor polypeptide (aa-21 to
77)"
                  /codon_start=1
                  /db_xref="PID:g33918"
                  /db_xref="SWISS-PROT:P02778"

/translation="MNQTAILICCLIFLTLSGIQGVPLSRTVRCISISNQPVNPRS
LEKLEIIPASQFCPRVEIIATMKKKGEKRCINPESKAIKNLLKAVSKEMSKRSP"
mat_peptide      130..360
                  /note="mature early response polypeptide (aa 1-77)"
old_sequence     1138..1141
                  /note="ugaa was uga in [1]"
                  /citation=[1]
old_sequence     1146..1148
                  /note="caa was ca in [1]"
                  /citation=[1]
misc_feature     1155..1160
                  /note="pot. polyA signal"
polyA_site       1172
                  /note="polyA site"
BASE COUNT      384 a    231 c    208 g    349 t
ORIGIN
      1 gagacattcc tcaattgctt agacatatcc tgagcctaca gcagaggaac ctccagtctc
     61 agcaccatga atcaaaactgc gattctgatt tgctgcctta tctttctgac tctaagtggc
    121 attcaaggag tacctctctc tagaaccgta cgctgtacct gcatcagcat tagtaatcaa
    181 cctgttaatc caaggctctt agaaaaactt gaaattatcc ctgcaagcca attttgtcca
    241 cgtgttgaga tcattgctac aatgaaaaag aagggtgaga agagatgtct gaatccagaa
    301 tcgaaggcca tcaagaattt actgaaagca gttagcaagg aaatgtctaa aagatctcct
    361 taaaaccaga ggggagcaaa atcgatgcag tgcttccaag gatggaccac acagaggctg
    421 cctctcccat cacttcctta catggagtat atgtcaagcc ataattgttc ttagtttgca
    481 gttacactaa aaggtgacca atgatgggtc ccaaatacagc tgctactact cctgtaggaa
    541 ggттаатгтт catcatccta agctattcag taataactct accctggcac tataatgtaa
    601 gctctactga ggtgctatgt tcttagtgga tgttctgacc ctgcttcaaa tatttccctc
    661 acctttccca tcttccaagg gtactaagga atctttctgc tttgggggtt atcagaatc
    721 tcagaatctc aaataactaa aagggtatgca atcaaactct ctttttaaag aatgctcttt
    781 acttcatgga cttccactgc catcctccca aggggcccac attctttcag tggctaccta
    841 catacaattc caaacacata caggaaggta gaaatatctg aaaatgtatg tgtaagtatt
    901 cttatttaat gaaagactgt acaaagtata agtcttagat gtatatattt cctatatgtt
    961 tttcagtgtg catggaataa catgtaatta agtactatgt atcaatgagt aacaggaaaa
   1021 ttttaaaaaa acagatagat atatgctctg catgttacat aagataaatg tgctgaatgg
   1081 ttttcaataa aaaatgaggt actctctctg aaatattaag aaagactatc taaatgttga
   1141 aagatcaaaa ggттаатааа gтаattataa ct
//

```

```

LOCUS      SYNRP4A      225 bp      DNA      SYN      15-JUN-1989
DEFINITION Human recombinant platelet factor 4 (PF4) gene, complete cds.
ACCESSION  M20901
NID        g209285
KEYWORDS   platelet factor; platelet factor 4.
SOURCE     Synthetic oligonucleotide DNA, clone pIN-III-ompA-2.
  ORGANISM  artificial sequence
            artificial sequence.
REFERENCE  1 (bases 1 to 225)
AUTHORS    Barone,A.D., Ghayeb,J., Hammerling,U., Zucker,M.B. and
            Thorbecke,G.J.
TITLE      The expression in Escherichia coli of recombinant human
platelet   factor 4, a protein with immunoregulatory activity
JOURNAL    J. Biol. Chem. 263, 8710-8715 (1988)
MEDLINE    88243725
FEATURES   Location/Qualifiers
    source  1..225
            /organism="artificial sequence"
            /db_xref="taxon:29278"
    CDS     <1..>225
            /note="recombinant platelet factor 4"
            /codon_start=2

```

/transl_table=11
/db_xref="PID:g209286"

/translation="ASMEAEDGDQLQCLCVKTTTSQVRPRHITSLEVIKAGPHCPTAQL
IATLKDGRKICLDLQAPLYKKI IKKLLSESGS"

BASE COUNT 59 a 59 c 51 g 56 t

ORIGIN HindIII site.

1 agcttctatg gaagctgaag aagacgggtga cctgcagtgc ctgtgcgtta aaactacttc
61 tcagggttcgt ccgcgtcata tcaattctct ggaagttatc aaagctgggc cgcattgccc
121 gactgctcag ctgatcgcta ctctcaaaga cggtcgtaaa atctgcctgg acctgcaggc
181 tccgctgtac aaaaaaatca tcaaaaaact gctggaatct ggatc

//

LOCUS HUMGRO 1050 bp mRNA PRI 11-JUN-1993

DEFINITION Human gro (growth regulated) gene.

ACCESSION J03561

NID g183622

KEYWORDS gro gene; tumor cell.

SOURCE Human bladder tumor cell (T24) cDNA to mRNA.

ORGANISM Homo sapiens

Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 1050)

AUTHORS Anisowicz, A., Bardwell, L. and Sager, R.

TITLE Constitutive overexpression of a growth-regulated gene in
transformed Chinese hamster and human cells

JOURNAL Proc. Natl. Acad. Sci. U.S.A. 84, 7188-7192 (1987)

MEDLINE 88041072

COMMENT Draft entry and computer-readable sequence kindly submitted by
R. Sager (20-NOV-1987).

FEATURES Location/Qualifiers

source

1..1050

/organism="Homo sapiens"

/db_xref="taxon:9606"

sig_peptide

54..140

/note="signal peptide (put.); putative"

CDS

54..377

/note="gro protein"

/codon_start=1

/db_xref="PID:g306806"

/translation="MARAALSAAPSNPRLLRVALLLLLLVAAGRRAAGASVATELRQC

CLQTLQGIHPKNIQSVNVKSPGPHCAQTEVIATLKNGRKACLNPAPIVKKIIEKMLN

SDKSN"

mat_peptide 141..374

/note="gro mature protein (put.); putative"

BASE COUNT 270 a 246 c 239 g 295 t

ORIGIN 52 bp upstream of NcoI site.

1 ctgcgcagct ctccgcgtcc tctcacagcc gccagaccgc cctgctgagc cccatggccc
61 gcgctgctct ctccgccgcc cccagcaatc cccggctcct gcgagtggca ctgctgctcc
121 tgctcctggg agccgctggc cggcgcgagc caggagcgtc cgtggccact gaactgcgct
181 gccagtgtct gcagaccctg caggggaattc accccaagaa catccaaagt gtgaacgtga
241 agtcccccg accccactgc gcccaaaccg aagtcatagc cacactcaag aatgggcgga
301 aagcttgctt caatcctgca tcccccatag ttaagaaaat catcgaaaag atgctgaaca
361 gtgacaaatc caactgacca gaaggaggga ggaagctcac tgggtggctgt tcctgaagga
421 ggccctgccc ttataggaac agaagaggaa agagagacac agctgcagag gccacctgga
481 ttgtgcctaa tgtgtttgag catcgcttag gagaagtctt ctattttatt atttattcat
541 tagttttgaa gattctatgt taatatttta ggtgtaaaat aattaagggt atgattaact
601 ctacctgcac actgtcctat tatattcatt ctttttgaaa tgtcaacccc aagttagttc
661 aatctggatt catatttaat ttgaaggtag aatgttttca aatgttctcc agtcattatg
721 ttaatatattc tgaggagcct gcaacatgcc agccactgtg atagaggctg gcggatccaa
781 gcaaatggcc aatgagatca ttgtgaaggc aggggaatgt atgtgcacat ctgttttgta
841 actgtttaga tgaatgtcag ttgttattta ttgaaatgat ttcacagtgt gtggtcaaca
901 tttctcatgt tgaacttta agaactaaaa tgttctaaat atcccttgga cattttatgt
961 ctttcttgta aggcatactg cctgtgttaa tggtagtttt acagtgtttc tggcttagaa
1021 caaaggggct taattattga tgttttcgga

//

LOCUS HUMGROB5 1110 bp mRNA PRI 07-MAR-1995

DEFINITION Human cytokine (GRO-beta) mRNA, complete cds.

ACCESSION M36820
 NID g183628
 KEYWORDS cytokine.
 SOURCE Human lymphocyte, cDNA to mRNA, clone GRO-beta.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 1110)
 AUTHORS Haskill, S., Peace, A., Morris, J., Sporn, S.A., Anisowicz, A.,
 Lee, S.W., Smith, T., Martin, G., Ralph, P. and Sager, R.
 TITLE Identification of three related human GRO genes encoding
 cytokine
 functions
 JOURNAL Proc. Natl. Acad. Sci. U.S.A. 87 (19), 7732-7736 (1990)
 MEDLINE 91017578
 COMMENT Draft entry and computer-readable sequence for [Proc. Natl.
 Acad.
 Sci. U.S.A. (1990) In press] kindly submitted
 by S.Haskill, 20-JUL-1990.
 FEATURES
 source Location/Qualifiers
 1..1110
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="GRO-beta"
 /tissue_type="monocyte and lymphocyte"
 gene 75..398
 /gene="GRO-beta"
 CDS 75..398
 /gene="GRO-beta"
 /codon_start=1
 /product="cytokine gro-beta"
 /db_xref="PID:g183629"

/translation="MARATLSAAPSNPRLRLVALLLLLVAASRRRAAGAPLATELRQC

CLQTLQGIHLKNIQSVKVKSPGPHCAQTEVIATLKNGQKACLNPA SPMVKIIEKMLK
 NGKSN"

BASE COUNT 300 a 247 c 247 g 316 t
 ORIGIN

```

1  gacagagccc gggccacgga gctccttgcc agctctctcc ctcgcacagc cgctcgaacc
61  gcctgctgag ccccatggcc cgcgccacgc tctccgccgc ccccagcaat ccccggtctc
121  tgcgggtggc gctgctgctc ctgctcctgg tggccgccag ccgcccgcga gcaggagcgc
181  ccctggccac tgaactgcgc tgccagtgc tgcagaccct gcagggaatt cacctcaaga
241  acatccaaag tgtgaagggtg aagtcctccg gaccccaactg cgcccaaacc gaagtcatag
301  ccacactcaa gaatgggcag aaagcttgct tcaaccccg ctcgcccata gtttaagaaa
361  tcacgaaaa gatgctgaaa aatggcaaat ccaactgacc agaaggaagg aggaagctta
421  ttggtggctg ttctgaagg aggccttgcc ttacaggaac agaagaggaa agagagacac
481  agctgcagag gccacctggc ttgcgcctaa tgtgtttgag catacttagg agaagtcttc
541  tattttatta ttattttatt ttttggttt ttttagaaga ttctatgta atattttatg
601  tgtaaaataa ggttatgatt gaattactt gcacactctc ccattatatt tattgtttat
661  tttaggtcaa acccaagtta gttcaatcct gattcatatt taatttgaag atagaaggtt
721  tgcagatatt ctctagtcac ttgttaatat ttcttcgtga tgacatatca catgtcagcc
781  actgtgatag aggctgagga atccaagaaa atggccagta agatcaatgt gacggcaggg
841  aaatgtatgt gtgtctatct tgtaactgta aagatgaatg tcagttgta ttatttgaaa
901  tgatttcaca gtgtgtgggc aacattttctc atgttgaaag ttttaagaact aaaatgttct
961  aaatatccct tggcatttta tgtctttctt gtaagatact gccttgttta atgttaatta
1021  tgcagtgttt ccctctgtgt tagagcagag aggtttcgat atttattgat gttttcacaa
1081  agaacaggaa aataaaatat ttaaaatat

```

//

LOCUS HUMGROG5 1064 bp mRNA PRI 07-MAR-1995
 DEFINITION Human cytokine (GRO-gamma) mRNA, complete cds.
 ACCESSION M36821
 NID g183632
 KEYWORDS cytokine.
 SOURCE Human lymphocyte, cDNA to mRNA, clone GRO-gamma.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 1064)
 AUTHORS Haskill, S., Peace, A., Morris, J., Sporn, S.A., Anisowicz, A.,

TITLE Lee, S.W., Smith, T., Martin, G., Ralph, P. and Sager, R.
 Identification of three related human GRO genes encoding
 cytokine functions
 JOURNAL Proc. Natl. Acad. Sci. U.S.A. 87 (19), 7732-7736 (1990)
 MEDLINE 91017578
 COMMENT Draft entry and computer-readable sequence for [Proc. Natl.
 Acad. Sci. U.S.A. (1990) In press] kindly submitted
 by S.Haskill, 20-JUL-1990.
 FEATURES Location/Qualifiers
 source 1..1064
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="GRO-gamma"
 /tissue_type="lymphocyte and monocyte"
 gene 78..398
 /gene="GRO-gamma"
 CDS 78..398
 /gene="GRO-gamma"
 /codon_start=1
 /product="cytokine GRO-gamma"
 /db_xref="PID:g183633"

/translation="MAHATLSAAPSNPRLRLRVALLLLLLVGSRRAGASVVTELRCQC

LQTLQGIHLKNIQSVNVRSPGPHCAQTEVIATLKNGKKACLNPA SPMVQKII EKILNK
 GSTN"

BASE COUNT 281 a 237 c 239 g 305 t 2 others
 ORIGIN

```

1 cacagccggg tcgcaggcac ctccccngcc agctctcccg cattctgcac agcttccgga
61 cgcgtctgct gagccccatg gccacgcca cgctctccgc cgccccagc aatccccggc
121 tcctgcggtt ggcgtgctg ctctgctcc tgggtggcag ccggcgcgca gcaggagcgt
181 ccgtgggtcac tgaactgcgc tgccagtgc tgcagacact gcagggaatt cacctcaaga
241 acatccaaag tgtgaatgta aggtcccccg gacccccact cgcccaaacc gaagtcatag
301 ccacactcaa gaatgggaag aaagcttgct tcaacccgc atccccatg gttcagaaaa
361 tcatcgaaaa gatactgaac aaggggagca ccaactgaca ggagagaagt aagaagctta
421 tcagcgtatc attgacactt cctgcagggt ggtccctgcc cttaccagag ctgaaaatga
481 aaaagagaac agcagcttct tagggacagc tggaaaggga cttaattgtt ttgactattt
541 cttacgaggg ttctacttat ttatgtattt atttttgaaa gcttgatttt taatatttta
601 catgctgtta tttaaagatg tgagtgtgtt tcatcaaaca tagctcagtc ctgattattt
661 aattggaata tgatgggttt taaatgtgtc attaaactaa tatttagtgg gagaccataa
721 tgtgtcagcc accttgataa atgacagggg ggggaactgg agggtnnggg gattgaaatg
781 caagcaatta gtggatcact gttagggttaa gggaatgtat gtacacatct atttttata
841 cttttttttt taaaaaagaa tgtcagttgt tatttattca aattatctca cattatgtgt
901 tcaacatttt tatgctgaag tttcccttag acattttatg tcttgcttgt agggcataat
961 gccttgttta atgtccattc tgacgcgttt ctcttccctt tggaaaagag aatttatcat
1021 tactgtttaca tttgtacaaa tgacatgata ataaaagttt tatg
  
```

//

LOCUS HUMCTAP3 673 bp mRNA PRI 06-MAR-1995
 DEFINITION Human connective tissue activation peptide III mRNA, complete
 cds.
 ACCESSION M54995 M38441
 NID g181175
 KEYWORDS connective tissue activating peptide-III; platelet basic
 protein;
 thromboglobulin.
 SOURCE Human platelet, cDNA to mRNA, clone lambda-c[1,2].
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 673)
 AUTHORS Wenger, R.H., Wicki, A.N., Walz, A., Kieffer, N. and Clemetson, K.J.
 TITLE Cloning of cDNA coding for connective tissue activating peptide
 III
 from a human platelet-derived lambda gt11 expression library
 JOURNAL Blood 73 (6), 1498-1503 (1989)
 MEDLINE 89229374
 FEATURES Location/Qualifiers
 source 1..673

```

/organism="Homo sapiens"
/db_xref="taxon:9606"
/tissue_type="platelet"
/clone="lambda-cl"
/cell_type="platelet"
/tissue_type="blood"
/tissue_lib="lambda-gtl1"
/map="4p13-q21"
gene      67..453
          /gene="PPBP"
sig_peptide 67..168
          /gene="PPBP"
          /note="G00-127-391"
CDS       67..453
          /gene="PPBP"
          /codon_start=1
          /db_xref="GDB:G00-127-391"
          /product="connective tissue activating peptide III"
          /db_xref="PID:g181176"

/translation="MSLRLDTPSCNSARPLHALQVLLLLSLLLTALASSTKGQTKRN
LAKGKEESLSDLYAELRCMCIKTTSGIHPKNIQSLEVIGKGTNCNQVEVIATLKDGR
KICLDPDAPRIKKIVQKKLAGDESAD"
mat_peptide 196..450
          /gene="PPBP"
          /note="G00-127-391"
          /product="connective tissue activating peptide III"
mat_peptide 208..450
          /gene="PPBP"
          /note="G00-127-391"
          /product="beta-thromboglobulin"
polyA_site 673
          /gene="PPBP"
          /note="G00-127-391"
BASE COUNT      202 a      149 c      139 g      183 t
ORIGIN
    1 gggcaactca ccctcactca gaggtcttct ggttcttgaa acaactctag ctcagccttc
   61 tccaccatga gcctcagact tgataccacc ccttcctgta acagtgcgag accactcat
  121 gccttgcaagg tgcgtcgtct tctgtcattg ctgctgactg ctctggcttc ctcacacaaa
  181 ggacaaacta agagaaactt ggcgaaaggc aaagaggaaa gtctagacag tgacttgat
  241 gctgaactcc gctgcatgtg tataaagaca acctctggaa ttcaccccaa aaacatccaa
  301 agtttggaag tgatcgggaa aggaacccat tgcaaccaag tcgaagtgat agccacactg
  361 aaggatggga ggaaaatctg cctggaccca gatgctccca gaatcaagaa aattgtacag
  421 aaaaaattgg cagggtgatga atctgctgat taattgttc tgtttctgcc aaacttcttt
  481 aactcccagg aagggtagaa ttttgaaacc ttgattttct agagttctca tttattcagg
  541 atacctattc ttactgtatt aaaatttgga tatgtgttcc attctgtctc aaaaatcaca
  601 ttttattctg agaagggttg taaaagatg gcagaaagaa gatgaaaata aataagcctg
  661 gtttcaaccc tct

//

LOCUS      HUMENA78A      2177 bp      DNA                      PRI      31-JAN-1996
DEFINITION Homo sapiens neutrophil-activating peptide 78 (ENA-78) gene,
            complete cds.
ACCESSION  L37036 Z46254
NID        g607030
KEYWORDS   ENA-78 gene; homologue; neutrophil-activating factor;
            neutrophil-activating peptide 78.
SOURCE     Homo sapiens DNA.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 2177)
AUTHORS    Walz,A., Burgener,R., Car,B., Baggiolini,M., Kunkel,S.L. and
            Strieter,R.M.
TITLE      Structure and neutrophil-activating properties of a novel
            inflammatory peptide (ENA-78) with homology to interleukin 8
JOURNAL     J. Exp. Med. 174 (6), 1355-1362 (1991)
MEDLINE     92078844
REFERENCE  2 (bases 1 to 2177)
AUTHORS     Walz,A.

```

TITLE Direct Submission
 JOURNAL Submitted (14-OCT-1994) A. Walz, University of Bern, Theodor
 Kocher
 Institute, Freiestr. 1, Bern, Switzerland 3012
 REFERENCE 3 (bases 1 to 2177)
 AUTHORS Corbett,M.S., Schmitt,I., Riess,O. and Walz,A.
 TITLE Characterization of the gene for human neutrophil-activating
 peptide 78 (ENA-78)
 JOURNAL Biochem. Biophys. Res. Commun. 205 (1), 612-617 (1994)
 MEDLINE 95091791

FEATURES
 source Location/Qualifiers
 1..2177
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /cell_type="lymphoblastoid cells"
 /clone="4H2, 178C11, 106C1"
 /chromosome="4"
 /clone_lib="Chromosome 4 cosmid library of Riess et
 al."
 gene 539..1747
 /gene="ENA-78"
 CAAT_signal 539..547
 /gene="ENA-78"
 TATA_signal 675..681
 /gene="ENA-78"
 exon <803..911
 /gene="ENA-78"
 /number=1
 CDS join(803..911,1046..1178,1289..1372,1729..1747)
 /gene="ENA-78"
 /note="homologue to interleukin-8"
 /codon_start=1
 /product="neutrophil-activating peptide 78"
 /db_xref="PID:g607031"

/translation="MSLLSSRAARVPGPSSSLCALLVLLLLLTQPGPIASAGPAAAVL

RELRCVCLQTTQGVHPKMISNLQVFAIGPQCSKVEVVASLKNKEICLDPEAPFLKKV

intron IQKILDGKNKEN"
 912..1045
 /gene="ENA-78"
 /number=1
 exon 1046..1178
 /gene="ENA-78"
 /number=2
 intron 1179..1288
 /gene="ENA-78"
 /number=2
 exon 1289..1372
 /gene="ENA-78"
 /number=3
 intron 1373..1728
 /gene="ENA-78"
 /number=3
 exon 1729..>1747
 /gene="ENA-78"
 /number=4

BASE COUNT 539 a 512 c 496 g 630 t
 ORIGIN

```

1 gaattctcag taagcggact taccaaagta ggtgatctgt aggggagtta acaaaattca
61 gtggtccttt caggccactg acttcaagtg gcaagagaca aggggtctctt gttatcatgt
121 tatcttggtt tccaaagctg gttgaagtcc agagattcat aaagtcattc aagaaaccta
181 gaatgacctg cctgcaagaa gacaggaagg actttcagtt tatagcaatt caaacatgaa
241 taacatttcc tgattaatag taataataat tagaaaggat tgactttcag aaatttttct
301 caaatcaagg ctccgtgttac tttggttcca ctttttctct ctagaaggag aggaggagca
361 tctcccagat gctgcgtgct ccagaaaagc cggcatccct agcccgtctt ggcacaggcc
421 atgagggcgt gctgaatcct gctgaatagc tactcccttc tagctggagc cacagctccc
481 tccaccgcgg aacagggtta caacgtccct ctcggtagag gtgcacgcag ctctcctgg
541 ccaccctccc caccagttcc cattgtctgg cccccctcc ccaacctctt ctttccacac
601 tgcccatga gtccaggga tttcccagc atcccaaagc ttgagtttcc tgtcagtggt
661 gagagatgag tgtagataaa aggagtgcag aaggaacgag gaagccacag tgctccggat
```

```

721 cctccaatct tcgctcctcc aatctccgct cctccacca gttcaggaac ccgcgaccgc
781 tcgcagcgct ctcttgacca ctatgagcct cctgtccagc cgcgcgcccc gtgtccccgg
841 tccttcgagc tccttgtagc cgtgtgtggt gctgctgctg ctgctgacgc agccagggcc
901 catcgccagc ggtgagagcg catggcgcg cggacgcact cgcactcggg cacagaggtg
961 catcccagcc tctgcgggggt cgtgcggttc cagggaaact tcccagcaac ctgccctata
1021 aaggggtgtct ctctttcttc cccagctggt cctgccgctg ctgtgttgag agagctgcgt
1081 tgcgtttgtt tacagaccac gcaaggagt catcccaaaa tgatcagtaa tctgcaagtg
1141 ttcgccatag gcccacagtg ctccaagggt gaagtgggtg aagttctgtg ctgctgtgtc
1201 cgtgtgtagc ttggcaagag agaaatcccg cagcctgggt cttcaacctt ggtatctcat
1261 gagtgtatct tctttttctt tccttcagag cctccctgaa gaacgggaag gaaatttgtc
1321 ttgatccaga agccctttt cttaaagaaag tcattccagaa aattttggac gggacttgtt
1381 cactttgtagc tttgtggtt cttaaactga tctagggaga ccatagactt cacaaggtct
1441 ttattctctg tacgatttaa gtaacacttt tcatgtttag aattaaaagg ttgttgattt
1501 gggaaagtgt ttctggattg tcctgggaaa atataccaat cttacatgta attacttgag
1561 caattacaca cagcttgta ctaagttatg tttttgttt acccattgct tttattgatt
1621 tttgtattct ccttttttac caaacatcat aaacgctgag tttgacaag ggtggagtag
1681 aaaggagtgt gaaaaatggt taaactaata taacatttt ctcaacagtg gaaacaagga
1741 aaactgatta agagaaatga gcacgcattg aaaagtttcc cagtcttcag cagagaagtt
1801 ttctggaggt ctctgaacct agggaagaca agaaggaaag attttgttgt tgtttgttta
1861 tttgtttttc cagtagttag ctttcttct ggattcctca ctttgaagag tgtgaggaaa
1921 acctatgttt gccgcttaag ctttcagctc agctaataaa gtgtttagca tagtaacctt
1981 gctatttgct gttattttat ctgctatgct attgaagttt tggcaattga ctatagtgtg
2041 agccaggaat cactggctgt taatctttca aagtgtcttg aattgtaggt gactattata
2101 tttccaagaa atattcctta agatattaac tgagaaggct gtggatttaa tgtggaaatg
2161 atgtttcata agaattc

```

//

LOCUS HSGCP2 254 bp RNA PRI 04-MAR-1997

DEFINITION H.sapiens mRNA for granulocyte chemotactic protein.

ACCESSION Y08770

NID g1769436

KEYWORDS cell surface receptor; CXC chemokine; GCP-2 gene; granulocyte chemotactic protein.

SOURCE human.

ORGANISM Homo sapiens

Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata; Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 254)

AUTHORS Froyen,G., Proost,P., Ronsse,I., Mitera,T., Haelens,A., Wuyts,A.,

Opdenakker,G., Van Damme,J. and Billiau,A.

TITLE Cloning, bacterial expression and biological characterization of recombinant human granulocyte chemotactic protein-2 and differential expression of granulocyte chemotactic protein-2 and epithelial cell-derived neutrophil activating peptide-78 mRNAs

JOURNAL Eur. J. Biochem. 243 (3), 762-769 (1997)

MEDLINE 97210779

REFERENCE 2 (bases 1 to 254)

AUTHORS Froyen,G.F.V.

TITLE Direct Submission

JOURNAL Submitted (10-OCT-1996) G.F.V. Froyen, Rega Institute, University of Leuven, Minderbroedersstraat 10, B-3000 Leuven, BELGIUM

FEATURES

source Location/Qualifiers

1..254

/organism="Homo sapiens"

/db_xref="taxon:9606"

/haplotype="diploid"

/tissue_type="embryonic"

/rearranged

/cell_type="fibroblast"

/cell_line="E6SM (embryonic strain - skin and muscle)"

gene 1..254

/gene="GCP-2"

exon <1..131

/gene="GCP-2"

/number=2

CDS <1..234

/gene="GCP-2"


```

/codon_start=1
/product="granulocyte chemotactic protein"
/db_xref="PID:e283124"
/db_xref="PID:g1769437"

/translation="GPVSAVLTELRCTCLRVTLRVNPKTIGKLQVFPAGPQCSKVEVV
              ASLKNGKQVCLDPEAPFLKKVIQKILDSGNKKN"
    exon      132..215
              /gene="GCP-2"
              /number=3
    exon      216..254
              /gene="GCP-2"
              /number=4
    3'UTR      235..254
              /gene="GCP-2"
BASE COUNT   66 a    64 c    70 g    54 t
ORIGIN
    1 ggtcctgtct ctgctgtgct cacggagctg cgttgcaactt gtttacgcgt tacgctgaga
   61 gtaaacccca aaacgattgg taaactgcag gtgtccccc caggcccgca gtgctccaag
  121 gtggaagtgg tagcctccct gaagaacggg aagcaagttt gtctggaccc ggaagcccct
  181 tttctaaaga aagtcacca gaaaattttg gacagtggaa acaagaaaaa ctgagtaaca
  241 gtcgacgcgg ccgc

//

LOCUS       D63789      5669 bp    DNA             PRI          27-DEC-1996
DEFINITION  Human DNA for SCM-1beta precursor, complete cds.
ACCESSION   D63789
NID         g1754608
KEYWORDS    SCM-1beta; SCM-1beta precursor.
SOURCE      Homo sapiens placenta DNA, clone:hg44.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
            Hominidae;
            Homo.
REFERENCE   1 (sites)
  AUTHORS   Yoshida,T., Imai,T., Kakizaki,M., Nishimura,M. and Yoshie,O.
  TITLE     Molecular cloning of a novel C or gamma type chemokine, SCM-1
  JOURNAL   FEBS Lett. 360 (2), 155-159 (1995)
  MEDLINE   95180438
REFERENCE   2 (sites)
  AUTHORS   Yoshida,T., Imai,T., Takagi,S., Nishimura,M., Ishikawa,I.,
  Yaoi,T.   and Yoshie,O.
  TITLE     Structure and expression of two highly related genes encoding
            SCM-1/human lymphotactin
  JOURNAL   FEBS Lett. 395 (1), 82-88 (1996)
  MEDLINE   97002294
REFERENCE   3 (bases 1 to 5669)
  AUTHORS   Yoshida,T.
  JOURNAL   Unpublished (1995)
REFERENCE   4 (bases 1 to 5669)
  AUTHORS   Yoshida,T.
  TITLE     Direct Submission
  JOURNAL   Submitted (07-AUG-1995) to the DDBJ/EMBL/GenBank databases.
Tetsuya    Yoshida, Shionogi Institute for Medical Science; 2-5-1,
Mishima,   Settsu, Osaka 566, Japan (E-
mail:teyoshid@fl.lab.shionogi.co.jp,
Tel:06-382-2612, Fax:06-382-2598)
FEATURES    Location/Qualifiers
    source   1..5669
            /organism="Homo sapiens"
            /db_xref="taxon:9606"
            /chromosome="1"
            /clone="hg44"
            /map="1q23"
            /tissue_type="placenta"
    TATA_signal 2154..2158
    exon       2197..2278

```

```

/number=1
prim_transcript 2197..5349
gene            2218..5230
               /gene="SCM-1beta"
CDS             join(2218..2278,4075..4189,5062..5230)
               /gene="SCM-1beta"
               /codon_start=1
               /product="SCM-1beta precursor"
               /db_xref="PID:d1010504"
               /db_xref="PID:g1754609"

/translation="MRLILALLGICSLTAYIVEGVGSEVSHRRTCVSLTTQRLPVSR

IKTYTITEGSLRAVIFITKRLKVCADPQATWVRDVRSMDRKSNTNRNMIQTKPTGT
               QQSTNTAVTLTG"
intron          2279..4074
               /gene="SCM-1beta"
               /number=1
exon            4075..4189
               /gene="SCM-1beta"
               /number=2
mat_peptide     join(4077..4189,5062..5227)
               /gene="SCM-1beta"
intron          4190..5061
               /gene="SCM-1beta"
               /number=2
exon            5062..5349
               /number=3
BASE COUNT      1702 a    1058 c    1248 g    1661 t
ORIGIN
1  ggatccagga ggataacaag ggaatctcct actctcaaag agtctgccat ctagtgggag
61  acgcaggaat gtaattgagt aggagaacac aatgagattc gttgcagaac agccatgaga
121 acagaacaaa gttctaagag agcataaagg ggtggcacia cttaatTTTA tcaaaaaaat
181 tcaggaaaac ttatacagag aggaggagtt tacaagtaac tatgtaggga gctgtcatgg
241 gtattccagt taaaggaaac atgtgaggag cataaaagag gctggcccat tgggttggtc
301 gcacatgtat gtgtttgtta aggtttggga gtgtgtgagt gaatggtgga aggtgagttc
361 gaaaggaaag cagtactaga tcttgagcat tcttatatat cacaatgaaa gatttgaaat
421 acatcctgta ggcattggaa gttagcaaaa gaggttctca gtagggaaat ggcattgatta
481 gattgaggct ttacagtgat taccctggca aagctgcaga gaacagactg agaggaggcc
541 ctggctctggg taaccagtta gtccactgta atttgccata catttgagca gtgtggggag
601 aaaggaggac acatctcaaa ggactaccta gaaggtatac ttagtccagt ttggttgaga
661 atgacatgta ggtggatagc aatgagtcct agatgatccc tatatatcag tatttgaaaa
721 ttatagtgaa gagaacacat tgctccatgc taaggactaa tatgaggaga agcagtttga
781 atagaagatg tgtccagtgt tcaaggagtg attgtgcagt aaggtagaga tcattaaaga
841 gccagtttga agtttagaat gaagctctgg tgaaaaatca aatgcgatta gtgggaagtc
901 tcttagaggt taacctatac tttttatgaa aacataggaa tttattttca tattccctaa
961 tagcaaaagg cctttaacta cacatatatt taataaatac attttataga tacctatgta
1021 aaataaagaa caaccaccac acaacaaact cagtggcaga aaagtccagc tgcaatcagt
1081 atatttaaat tctactgggg gtattgcaaa tcaaatttac attttgggag acttatggc
1141 aatatataat aagagctata aagatgatca tatcattttt ccagtaatc ctactcctgg
1201 ttattaaagg gaagtaattc agtgtatatt aatgaaatcg accttatagt tctgatcttt
1261 ataataagtt ataagaaaat ggtttaactt gtatgtgtat atatttactc gaagtagaaa
1321 tatgaaggct aaaaaaatgg gaagatatTT aaattggtgt taaaacagca tttaaaatta
1381 ccacaattat gagaacacat gtatgccaat gcagattcac tggaaaaata ttgaaaatga
1441 aaactgtcag atggtaagat tataatttta tttctttttt aatttgaaat aaattggtaa
1501 cagcacagct tttcaaaagc ttctataaat gtgtatgtta agttgtaata aagcaaacac
1561 atgcattgta gacatgctta aacagttatt taattgtttc ttgggtacct tgggagatgg
1621 ggtgaagaaa ggggggtgac ttgaatgaag gtggaggaga aaaatgagaa ccaagaaaagc
1681 aaaggatcga gaagctcagt gtggcagcag cctctcttcc cctcctgaga gagtcaaagg
1741 gtggcatcag ggactcatga tccatgggtg tggaaagcctc atgtcacact ggatgtcaca
1801 tgagggtgga tggaaacacag tgaccacccc acctcatttc ctttacagct tccgtggggg
1861 ccatggcagt gaacagcctt caggcatgtc tacggtggaa gatctgaatt caggctgggtg
1921 gcaggagaca acacaaccac gttttctttt atgcatgcat ttggtttaat tgacacatta
1981 accacagaca aaggggtaaa ggccacaagg cgatagggtta gtatgaacag ggaaagggac
2041 attttttttt ttttaagaaaa ataaaagcat cagtattgca aagacttttc atgatcctat
2101 accccactcg aaagcccctc ctcaccacag gaagtgcact gaccattgga ggcataaaag
2161 agatcctcaa agagcccgat cctcactctc cctgcacagc tcagcgggac ctcagccatg
2221 agacttctca tcctggccct ccttggcatc tgctctctca ctgcatacat tgtggaaggt
2281 aagtggagaa gctgtctgtg agataaagaa tagggaggga aggcaggtgg gcacacattt
2341 tgggtttgac tcgggttttg actggactaa actgctgtct ccaggggagc cttaaacttc
2401 ccatgtgcaa gaaaggaatg atgattttga ctgtagaggg cttcgtaaac ttccaaaaca

```

```

2461 gggagaattt gattagtagt tgggctccta cttttccta tgggtaatt tcaggtaaatt
2521 tcccttaacca ctcagggcct gtgcttattt atgtataaac tgaatagaat aagagacatg
2581 atcacctgag attaagatta aataaatatt atggtttatt taataacatc agatttcctt
2641 acaagcagta attttttgat taatgttagc tatggattag aggtgatgat tataaatgca
2701 tttgtagggt ttgcccattt aatatatagt ttgataaatt atcaaaatct tagagagttc
2761 agttacaata tggggatgca ccagaggatg tatgttctgg agcaaatcaa tgttttcaat
2821 acaaaacctg tgtgaaggcg acagtagtgc ttgctgtgga ctggatgtcc cagctctgcc
2881 ttccttcccc ttgataatgc aataaggagc ccccatTTTA ggacgcagga caggcagaaa
2941 gataaccagc ttgatggggg ccacaccatg tgcaatcact accagctgag acttcttgtt
3001 ttccagcaag gtgggtgatga tgttaacccc tgctcaaaga acaggtgatt tcctagtggg
3061 gacaacccct ttgctagcag ctttcttctc agcctggggc aacagtctct gcttcttctc
3121 ttgctttgtc tctggtcagt acttgtggat cagcttaagt ggctgagtag ctgtttgggg
3181 gtctaaggct tgggtgaact gggttaatgg agaaggcatt ttcagctgct tatagaggat
3241 agctctttgc agcttgaacc agatatagcg gggccatttc acaaaagcag ggaggtctct
3301 tttgggctgg atgtcctgtc caatgcctgc ctaagaaaac tcttaggcct tttctcacac
3361 agcgggttca tcactttctt agcctcctgc ttctcacga cggcagggac tgggccacct
3421 tctttccttt ggcttctttt cttttcagca tcttaggcag ctgacagaga gggaaatttg
3481 accatttaaa aaggggaaaca cttttattta ctcagtcaaa agcatgcttc cttcctcac
3541 tgaatgttgc cttgcctaga gtactcttca cgcattactc tgtcatctca cttatggtag
3601 tgtaacatgt tgcactattt gaaatgatct tttctgtttg cctgtctgct gcctggctcc
3661 ctcatgagaa gatatgctct atgaaaacag ggataatgtc tgtcttaata aaacatgtgg
3721 gacacaaacag gcaccattgt ataaatgta gtaatgcgtg cactggggca tttgtagcc
3781 gtcccaaatg tctaagtga aatatacaca gagacgggat aacatcttgt tttttctct
3841 cagcatgaaa ttcttgaaac aattctgttg attgagtttt taaattagtc aaatatttac
3901 taagaatctg tgacgggcaa gagattcggg atgcttatca gtctctctt ccccaaaaaa
3961 gcaaatggcc ttatatctc acaactatc cagagtaatt taacagacga ttgtctctgt
4021 gatctgggta attgctttat ttttaattgt ctgttgtttt ttttctctca tcagggtgtag
4081 ggagtgaagt ctcacatagg aggactgtg tgagcctcac taccagcga ctgccagtta
4141 gcagaatcaa gacctacacc atcacggaag gctccttgag agcagtaatg tgagtctgcc
4201 tcctcagaag ttgggctggg tgggtaccta gaggtataga aatacactct atagaaatgc
4261 tgccatctc aggaaaagta ggtcagcata gaggaacacc tcaacttaac caaaaacctc
4321 tttagttttc cttatcaacc atgtctttct gcagcccaac cgaatagcga ttattgcaga
4381 aattgggctg ccaaagaaag aatagaagtc ctctctatt tgtcttagtg gaagagtctg
4441 ttgataactg tgcacagctc tgagacttgg gtttagagat ggctggctca tgtcagggtt
4501 tccctgcaag cctcactgga gttgggggat cttagggttg agttaggcag agtcccatc
4561 tttatcagtt gccatatctt aagaaaatga gtcaatgcac aacctacatg gtccctttct
4621 tctaccagaa tctcattttt agaagtaata actcttccca atacatattg caagctttgc
4681 tctaaagaat gaaaatgtaa aaatcacctt tttaaaaaaa ataagatgag tattttcaaa
4741 tttgaaaagg aagaggttat ataataatgg aactagatgg cctcaaagt ctttttgta
4801 caacatttgg tgacatggat gagaaaagga gcctgtgaat tatgggtgaac aaaggggctg
4861 gatactactt gcagatattt ctcttttatg ttaaaataga tggcagaaga aggggtgctc
4921 tttatgatct catggctctg aaagactatt tcttgagta atttctgcac aagatctctt
4981 catgtctgcc ctgatcttaa ctctgaccc tgaggctttg agaacgtggc taacttcac
5041 tgtcttttcc ttgctgtaca gttttattac caaacgtggc ctaaaagtct gtgctgatcc
5101 acaagccacg tgggtgagag acgtggtcag gagcatggac aggaaatcca acaccagaaa
5161 taacatgac cagaccaagc caacaggaac ccagcaatcg accaatacag ctgtgacctt
5221 gactggctag tagtctctgg caccctgtcc gtctccagcc agccagctca tttcacttta
5281 caccctcatg gactgagatt atactcacct tttatgaaag cactgcatga ataaaattat
5341 tcttttgtat ttttactttt aaatgtcttc tgtattcact tatatgttct aattaataaa
5401 tttattatta ttaagaatag ttccctagtc tattcattat atttagggaa aggtgagtga
5461 tcattgttgt ttgatttctg acctgtgacc tctctttgat ggtaaccata atggaagaga
5521 ttctggctag tgtctatcag aggtgaaagc tatatcgatc actcttagag tccagcttgt
5581 aatggttctt tacacatcag tcacaagtta cagctgtgac aatggcaaca atttgagatc
5641 tatttcaact tgtctctata atagaattc

```

//

```

LOCUS       D63790             5660 bp      DNA              PRI          27-DEC-1996
DEFINITION   Human DNA for SCM-lalpha precursor, complete cds.
ACCESSION    D63790
NID          g1754610
KEYWORDS     SCM-lalpha precursor; SCM-1 alpha.
SOURCE       Homo sapiens placenta DNA, clone:hg40.
  ORGANISM   Homo sapiens
              Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
              Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
Hominidae;  Homo.
REFERENCE    1 (sites)
AUTHORS      Yoshida,T., Imai,T., Kakizaki,M., Nishimura,M. and Yoshie,O.
TITLE        Molecular cloning of a novel C or gamma type chemokine, SCM-1
JOURNAL      FEBS Lett. 360 (2), 155-159 (1995)

```

MEDLINE 95180438
 REFERENCE 2 (sites)
 AUTHORS Yoshida,T., Imai,T., Takagi,S., Nishimura,M., Ishikawa,I.,
 Yaoi,T.
 TITLE and Yoshie,O.
 Structure and expression of two highly related genes encoding
 SCM-1/human lymphotactin
 JOURNAL FEBS Lett. 395 (1), 82-88 (1996)
 MEDLINE 97002294
 REFERENCE 3 (bases 1 to 5660)
 AUTHORS Yoshida,T.
 JOURNAL Unpublished (1995)
 REFERENCE 4 (bases 1 to 5660)
 AUTHORS Yoshida,T.
 TITLE Direct Submission
 JOURNAL Submitted (07-AUG-1995) to the DDBJ/EMBL/GenBank databases.
 Tetsuya
 Yoshida, Shionogi Institute for Medical Science; 2-5-1,
 Mishima,
 Settsu, Osaka 566, Japan (E-
 mail:teyoshid@fl.lab.shionogi.co.jp,
 Tel:06-382-2612, Fax:06-382-2598)
 FEATURES Location/Qualifiers
 source 1..5660
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /chromosome="1"
 /clone="hg40"
 /map="1q23"
 /tissue_type="placenta"
 TATA_signal 640..644
 exon 683..764
 /number=1
 prim_transcript 683..5340
 CDS join(704..764,4064..4178,5053..5221)
 /codon_start=1
 /product="SCM-1alpha precursor"
 /db_xref="PID:d1010505"
 /db_xref="PID:g1754611"
 /translation="MRLILALLGICSLTAYIVEGVGSEVSDKRTCVSLLTQRLPVSR
 IKTYTITEGSLRAVIFITKRGLKVCADPQATWVRDVRSMDRKSNTNRNMIQTKPTGT
 QQSTNTAVTLTG"
 intron 765..4063
 /number=1
 exon 4064..4178
 /number=2
 mat_peptide join(4066..4178,5053..5218)
 /note="SCM-1alpha mature peptide"
 intron 4179..5052
 /number=2
 exon 5053..5340
 /number=3
 BASE COUNT 1623 a 1139 c 1175 g 1723 t
 ORIGIN
 1 aagcttctat aaatgtgtat gttaagttgt aataaagcaa acacatgcat gtagacatgc
 61 ttaaacagtt atttaattgt ttcttgggta cctggggaga tgggggtgaag aaaggggggt
 121 gacttgaatg aaggtggagg agaaaaatga gaaccaagaa agcaaaggat cgagaagctc
 181 agtgtggcag cagctctctt cccctcctga gagagtcaaa ggggtggcatc agggactcat
 241 gatccatggt tgtggaagcc tcatgtcaca ctggatgtca catgaggtgg gatggaacac
 301 agtgaccacc ccacctatt tcctttacag cttccgtggg gggccatggc agtgaacacc
 361 ttcaggcatg tctacggcgg aatatctgaa ttcaggctgg tggcaggaga caacacaacc
 421 acgttttctt ttatgcatgc atttggttta attgacacat taaccacaga caaaggggta
 481 aaggccacaa ggcgttaggt tagtatgaac agggaaaagg gacttttttt ttttttttta
 541 agaaaaataa aagcatcagt attgcaaaga ctttccatga tcctacaccc acctcgaaag
 601 cccctctca ccacaggaag tgcactgacc actggaggca taaaagaggc cctcaaagag
 661 cccgatcctc actctccttg cacagctcag caggacctca gccatgagac ttctcatcct
 721 ggccctcctt ggcattctgt ctctcactgc atacattgtg gaaggtaagt ggagaagctg
 781 tctgtgagat aaagaacagg gaggcaaggc aggtgggcac acattttggg ttgactcag
 841 gttatgactg gactaatctg ctttccccag gggagcctta aacttcccat gtgcaagaaa

901 ggaatgatga ttttgactgt agagggcttc gtaaaacttc aaaacaggga gaatttgatt
 961 agtatctggg ctctacttt tcctaattgg gtaatttcag gtaaatccct taaccactca
 1021 gggcctgtgc ttatttatgt ataactgaat agtataacag acttgatcac ctgagattaa
 1081 gattaaataa atattatggg ttatttaata acatcagatt tccttacaag cagtaatttt
 1141 ttgattaatg ttagctatgg attagaggtg atgattataa atgcatttgt aggtttggcc
 1201 catttaatat atagtttgat aaattatcaa aatcttagag agttcagtta cgaatgtggg
 1261 atgcaccatt ggatgtatgt tctggagtaa atcaatgttt tcaatacaaa actaagcccc
 1321 aaatgactgg aagttcaaac ctctatgtcc agaaaaatcaa tattaccttc aagtaactgg
 1381 gggactctgt tagtaatgcc atgactatta ctatttatga gaaattttct gtttttgtaa
 1441 gagaacatac aataataact actaccaaat agatcagcac ctatacaca gttcaataaa
 1501 cctgcaagac acatccaggg aagattcaga tataccgagc ccttacctga gcattcagta
 1561 ggtattttctt aaggattgat ttttcctatg actggagggtg aatctgtcga ctattttgtg
 1621 ttctagtttg taggcttatt acttagacta tgatattata acttaataat ggggtcccaa
 1681 ggggttccat gaataaagggt ggctaagctc ggaagtcctt gaaattatgg ataaaacaaa
 1741 aaaatactga tgaacaaaaa gagtttgatt actacattag gccacatgtt gctacctggc
 1801 tggcattttg ctgagacaat gggcatacca tttgagggag actcagatct gagtagggga
 1861 aaggagctct ataagtccca ctggtgctta gcttcttaca taaaaaatg agggaaaacg
 1921 gtctctgctt tgactcaatt ttgcaacctg agtgaagggtg atatttttaa aaataacaca
 1981 gacactcaaa cattgctgac aataaggaaa aggttttgtg gtttcaagca taacaggatt
 2041 ccctgagtct taggagttcca cttcagatac ttcacagaga gaaatattgt ttcttaata
 2101 tgagagaaac agagaaaaaa cccagatttt tcctctttca ttggctacag aaacaattca
 2161 ccactaaaaa taaattggca aaggtagagg atagcaatgt gcagactggc attgagagtg
 2221 aagaaatgat gaagaaaagc acacaatgaa cactctttgt ttagtccctt gctttaaaaa
 2281 atgccttctg atattagcaa cactacagac caatgttggc cattatcagt ggttacttta
 2341 gatgcttttt agctgcctat ttccctggga agcaaagacc agtgtctaca gctaaggaga
 2401 aaatgacac ttagaactt ggattagatt tcaccaacc cttaacagta ttaattctcc
 2461 caagttattt ttctctatgc aatgtttttt tgattctcta cacttaatag ttttaattct
 2521 ttgggccatt actattgggg atgcatattt aagggtgac ttctttttat atatatctta
 2581 ccttttacca tttattaatt ttttgagag tttttattat ttttatgtac agaaaaacta
 2641 acgtgttaca ttttaaccag tttagtggca agttcctctg cctttgctat tccagcttg
 2701 gcattgtgag ccacagattt tggactcggg acattgcaga tctcatcata tccgtcattg
 2761 taatttgctc tgatagcttc caccagctta gccaaagctc ctttgtcttc ctggttaact
 2821 tgtgtgaagg ccacagtggg gcttctctgt gactggatgt cccagcttg ccttcttacc
 2881 ccttgataat gcattaaggg accccccatt ttaggacaca ggacagacg aaagttaacc
 2941 agcttgatgg ggtccacacc atgtgcaata ccagctgagc cttcttcttt tccagcaagg
 3001 tgggtgatagt gttaacccct gctcaaagaa cagggtgattt cctagtgggg acaaccctt
 3061 tgctagcagc ttctttctca gcctgggcca acagtctctg cttcttctct tgtttgtct
 3121 ctggtcagta cttgtgggac agcttaagtg gctgagtagc tgtttggggg tctaaggctt
 3181 ggggtgaactg gttaatggca gaaggcactt tcagctgctt atagaggata gctctttgca
 3241 gctggaacca gatatacgcg ggccatttca caaagcagcg gaggtccctt ttgtcacaca
 3301 tgcctgttcc aatgcctgcc taagaaaaact cttaggcctt ttctcacaca gcggtttcat
 3361 cactttctta gcctcctgct tcctcacgac ggcagggtct ggggccactt tccttcttt
 3421 ggccatcttt cctttcagca tcttaggcag ctgacagaga gagacatttg accatttaaa
 3481 aaggagaaca cctttattta gtctgtcaaa agcatgtctc ctccctcac tgaatgttgc
 3541 cttgcctaga gtactcttca cgcattactc tgtcttctca ctatggtagt gtaacatgtt
 3601 gcactatttg aaatgatctt ctctgtctg ctgctgtctg cctggctctt tcatgagaga
 3661 gatattgctc atgaaaacag gagtaatgtc tgcttagtaa aacatgtggg acacaacagg
 3721 caccattgta taaatgaatg aatgcgtgtc actggggcat ttgctagccg tcccaaatgt
 3781 ctaagtgaat atatacacag agacgggata acatcttgtt attttctctc agcatgaaat
 3841 cctgtaacaa attctgttga ttgagttttt aaattagtca aatatttact aagaatctgt
 3901 gacgggcaag agattcggga tgcttatcag tcctctcttc ccccaaaaag caaatggcct
 3961 taaattctca caacattctc agagtaattt aacagatgat tgttctctgt atctggataa
 4021 ttgctttatt ttttaattgtc tgttgttttt ttttctctac cagggttagg gagtgaagtc
 4081 tcagataaga ggacctgtgt gagcctcact acccagcgac tgccggttag cagaatcaag
 4141 acctacacca tcacggaagg ctcttgaga gcagtaatgt gagtctgcct cctcagaagt
 4201 tgtgctgggt ggggtatctag aagtatagaa atacactctg tagaaatgct gccgtctca
 4261 ggaaaagtag gtcagcatag aggaacacct caacttaacc aaaaacctct ttagttttcc
 4321 ttatcaatca tgtctttctg cagcccaacc gaatagcgat tattgcagaa attgggctgc
 4381 caaagaaaga atagaagtcc tcctctattt agcttagtg gtcagggttt cctgcaagc
 4441 gcacagctct gagacctggg ttttagagatg actggcccat gtcaggcaga gtcccatact
 4501 ctcactggag ttgggggatc tttaggggtg gtcaggcaga gtcccatact tttatcagtt
 4561 ctcactatttc aagaaaatga gtcactgtac aacctacatg gtccctctt ctaccagaat
 4621 ctcatTTTTa gaagttaata actcttctca acatgtaatt gcaagcttta ctctaaaaa
 4681 tgaatattgt aaaatcactt tttattttaa aaataagatg aatattttta aatttgaaaa
 4741 ggaagagggt atgtaataat ggaactagtt ggctcaaaag tctttttgtt acaaatattg
 4801 gtgagattga tgagaaaagg accctgtgaa ttattgtgaa caaaggggct ggaatactat
 4861 tgcagatatt actcctttat gttaaaaatg atggcagaag aagggtactc atttatgatc
 4921 tcatggctct gaaagactat ttcttgcatg aatttctgca caagatctct tcatgtctgc
 4981 cctgatctta actcctgacc ctgaggcttt gagaatgtgg ctaactctgt ctgtcttttc
 5041 cttgcgttac agttttatta ccaaactggg caggaatcc tgtgtgatc cacaagccac
 5101 atgggtgaga gacgtggtca ggagcatgga caggaaatcc aacaccagaa ataacatgat

```

5161 ccagaccaag ccaacaggaa cccagcaatc gaccaataca gctgtgactc tgactggcta
5221 gtagtctctg gcaccctgtc cgtctccagc cagccagctc atttcacttt acacgctcat
5281 ggactgagtt tatactcacc ttttatgaaa gcactgcatg aataaaatta ttcctttgta
5341 tttttacttt taaatgtctt ctgtattcac ttatatgttc taattaataa attatttatt
5401 attaagaata gttccctagt ctattcatta tatttaggga aaggtagtgt atcattgttg
5461 tttgatttct gacctgtac ctctctttga tgtaaacat aatggaagag attctggcta
5521 gtgtctatca gaggtgaaag ctatatcaat ctctcttaga gtccagcttg taatggttct
5581 ttacacatca gtcacaagtt acagctgtga caatggcaac aatttgagat gtatttcaac
5641 ttgtctctat aatagaattc

```

//

```

LOCUS      HSU91835      1635 bp      mRNA      PRI      21-MAR-1997
DEFINITION Human CX3C chemokine precursor, mRNA, alternatively spliced,
            complete cds.
ACCESSION  U91835
NID        g1899258
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 1635)
AUTHORS    Bazan,J.F., Bacon,K.B., Hardiman,G., Wang,W., Soo,K., Rossi,D.,
            Greaves,D.R., Zlotnik,A. and Schall,T.J.
TITLE      A new class of membrane-bound chemokine with a CX3C motif
JOURNAL    Nature 385 (6617), 640-644 (1997)
MEDLINE    97177111
REFERENCE  2 (bases 1 to 1635)
AUTHORS    Bazan,J.F., Bacon,K.B., Hardiman,G., Wang,W., Rossi,D.,
            Greaves,D.R., Zlotnik,A. and Schall,T.J.
TITLE      Direct Submission
JOURNAL    Submitted (03-MAR-1997) Molecular Biology, DNAX Research
Institute,
            901 California Ave., Palo Alto, CA 94304-1104, USA
FEATURES   Location/Qualifiers
            source      1..1635
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
            CDS         80..1273
                        /note="membrane-tethered chemokine module"
                        /codon_start=1
                        /product="CX3C chemokine precursor"
                        /db_xref="PID:g1899259"

/translation="MAPISLSWLLRLATFCHLTVLLAGQHGVTKCNITCSKMTSKIP
VALLIHYQQNQASCGKRAIILETRQHRLFCADPKEQWVKDAMQHLDRQAAALTRNGGT
FEKQIGEVKPRTPPAAGGMDESIVLEPEATGESSSLEPTPSSQEAQRALGTSPELPTG
VTGSSGTRLPPTPKAQDGGPVGTELFRVPPVSTAATWQSSAPHQGPSSLWAEAKTSEA
PSTQDPSTQASTASSPAPEENAPSEGQRVWGQGSPPRPNLSEREEMGPVPAHTDAFQ
DWGPGSMAHVSVPVSSEGTSPREPVASGSWTPKAEPIHATMDPQRLGVLITPVPDA
QAATTRQAVGLLAFLLFCLGVAMFTYQSLQGCPRKMAGEMAEGRLRYIPRSCGSNSY
VLVPV"
            sig_peptide 80..151
            mat_peptide 152..1270
                        /product="CX3C chemokine"
            misc_feature 152..379
                        /note="encodes chemokine module"
            misc_feature 380..1102
                        /note="encodes glycosylation stalk"
            misc_feature 1103..1159
                        /note="encodes transmembrane helix"
            misc_feature 1160..1270
                        /note="encodes intracellular domain"
            3'UTR       1274..1635
                        /note="alternatively spliced; long transcript can be

```

found

in GenBank Accession Number U84487*

BASE COUNT 338 a 544 c 464 g 289 t
 ORIGIN

```

1  ggcacgaggg cactgagctc tgccgcctgg ctctagccgc ctgcctggcc cccgccggga
61  ctcttgccca ccctcagcca tggctccgat atctctgtcg tggctgctcc gcttggccac
121 cttctgccat ctgactgtcc tgctggctgg acagcaccac ggtgtgacga aatgcaacat
181 cacgtgcagc aagatgacat caaagatacc ttagcttttg ctcatccact atcaacagaa
241 ccaggcatca tgcggcaaac gcgcaatcat cttggagacg agacagcaca ggctgttctg
301 tgccgacccg aaggagcaat gggtaagga cgcgatgcag catctggacc gccaggctgc
361 tgccctaact cgaaatggcg gcaccttcga gaagcagatc ggcgaggtga agcccaggac
421 caccctgcc gccgggggaa tggacgagtc tgggtcctg gagcccgaag ccacaggcga
481 aagcagtagc ctggagccga ctcttcttc ccaggaagca cagagggccc tggggacctc
541 cccagagctg ccgacgggcg tgactggttc ctcagggacc aggtccccc cgacgccaaa
601 ggctcaggat ggagggcctg tgggcacgga gcttttcga gtgcctccc tctccactgc
661 cgccacgtgg cagagttctg ctccccacca acctgggccc agcctctggg ctgaggcaca
721 gacctctgag gcccctgcca cccaggacct ctccaccag gcctccactg cgtcctccc
781 agccccagag gagaatgtc cgtctgaagg ccagcgtgtg tggggtcagg gacagagccc
841 cagccagag aactctctg agcgggagga gatgggtccc gtgccagcg acacgatgc
901 cttccaggac tgggggcctg gcagcatggc ccacgtctct gtggtccctg tctcctcaga
961 agggaccccc agcagggagc cagtggcttc aggcagctgg acccctaagg ctgaggaacc
1021 catccatgcc accatggacc cccagaggct gggcgctcct atcactcctg tccctgacgc
1081 ccaggctgcc acccgaggc aggcgggtgg gctgctggcc ttccttggc tctcttctg
1141 cctgggggtg gccatgttca cctaccagag cctccagggc tgccctcga agatggcagg
1201 agagatggcg gagggccttc gctacatccc ccggagctgt ggtagtaatt catatgtcct
1261 ggtgcccgtg tgaactctc tggcctgtgt ctagtgttt gattcagaca gctgcctggg
1321 atccctcctc ctcatacca cccccacca agggcctggc ctgagctggg atgattggag
1381 gggggagggt ggatcctcca ggtgcacaag ctccaagctc ccaggcattc cccaggaggc
1441 cagccttgac cattctccac ctccaggga cagaggggtt ggcctcccaa ctaccccag
1501 ccccaaaact ctctctgtc gctggctggt tagaggttcc ctttgacgcc atcccagccc
1561 caatgaacaa ttatttatta aatgccagc cccttctgaa aaaaaaaaaa aaaaaaaaaa
1621 aaaaaaaaaa aaaaaa

```

//

LOCUS HSU84487 3310 bp mRNA PRI 15-MAR-1997
 DEFINITION Human CX3C chemokine precursor, mRNA, alternatively spliced,
 complete cds.
 ACCESSION U84487
 NID g1888522
 KEYWORDS .
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 3310)
 AUTHORS Bazan,J.F., Bacon,K.B., Hardiman,G., Wang,W., Soo,K., Rossi,D.,
 Greaves,D.R., Zlotnik,A. and Schall,T.J.
 TITLE A new class of membrane-bound chemokine with a CX3C motif
 JOURNAL Nature 385 (6617), 640-644 (1997)
 MEDLINE 97177111
 REFERENCE 2 (bases 1 to 3310)
 AUTHORS Bazan,J.F., Bacon,K.B., Hardiman,G., Wang,W., Rossi,D.,
 Greaves,D.R., Zlotnik,A. and Schall,T.J.
 TITLE Direct Submission
 JOURNAL Submitted (07-JAN-1997) Molecular Biology, DNAX Research
 Institute, 901 California Ave., Palo Alto, CA 94304-1104, USA
 FEATURES
 source Location/Qualifiers
 1..3310
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 CDS 80..1273
 /note="membrane-tethered chemokine module"
 /codon_start=1
 /product="CX3C chemokine precursor"
 /db_xref="PID:g1888523"

/translation="MAPISLSWLLRLATFCHLTVLLAGQHGVTKCNITCSKMTSKIP

VALLIHYQQNQASCGKRAIILETRQHLRFCDPKEQWVKDAMQHLDRQAAALTRNGGT

FEKQIGEVKPRTPPAAGGMDESIVLEPEATGESSSLEPTPSSQEAQRALGTSPELPTG

VTGSSGTRLPPTPKAQDGGFVGTELFRVPPVSTAATWQSSAPHQPGPSLWAEAKTSEA

PSTQDPSTQASTASSPAPEENAPSEGRVWVGQGSFPRPENSLEEREEMGPVPAHTDAFQ

DWGPGSMAHVSVPVSSEGTSPREPVASGSWTPKAEPIHATMDPQRLGVLITPVPDA

QAATRRQAVGLLAFLLFCLGVAMFTYQSLQGCPRKMAGEMAEGRLYIPRSCGSNSY

VLVPV"
 sig_peptide 80..151
 mat_peptide 152..1270
 /product="CX3C chemokine"
 misc_feature 152..379
 /note="encodes chemokine module"
 misc_feature 380..1102
 /note="encodes glycosylation stalk"
 misc_feature 1103..1159
 /note="encodes transmembrane helix"
 misc_feature 1160..1270
 /note="encodes intracellular domain"
 3'UTR 1274..3310
 /note="alternatively spliced; short transcript

deposited

as GenBank Accession Number U91835"

BASE COUNT 659 a 1051 c 916 g 682 t 2 others
 ORIGIN

```

1 ggcacgaggg cactgagctc tgccgcctgg ctctagccgc ctgcctggcc cccgccggga
61 ctcttgccca ccctcagcca tggctccgat atctctgtcg tggctgctcc gcttggccac
121 cttctgccat ctgactgtcc tgctggctgg acagcaccac ggtgtgacga aatgcaacat
181 cagctgcagc aagatgacat caaagatacc tgtagctttg ctcatccact atcaacagaa
241 ccaggcatca tgcggcaaac gcgcaatcat cttggagacg agacagcaca ggctgttctg
301 tgccgacccg aaggagcaat gggtaagga cgcgatgcag catctggacc gccaggctgc
361 tgccctaact cgaaatggcg gcaccttcca gaagcagatc ggcgaggtga agcccaggac
421 caccctgcc gccgggggaa tggacgagtc tgtggtcctg gagcccgaag ccacaggcga
481 aagcagtagc ctggagccga ctcttctctc ccaggaagca cagagggccc tggggacctc
541 cccagagctg ccgacggcg tgactggctc ctacgggacc aggtctcccc cgacgcaaaa
601 ggctcaggat ggagggcctg tgggcacgga gcttttccga gtgctcccc tctccactgc
661 gccacgtgg cagagttctg ctccccacca acctggggccc agcctctggg ctgaggcaaa
721 gacctctgag gccccgtcca cecaggaccc ctccaccag gcctccactg cgtcctcccc
781 agccccagag gagaatgtct cgtctgaagg ccagcgtgtg tggggtcagg gacagagccc
841 caggccagag aactctctgg agcgggagga gatgggtccc gtgccagcgc acacggatgc
901 cttccaggac tgggggctcg gcagcatggc ccacgtctct gtggtccctg tctcctcaga
961 agggaccccc agcagggagc cagtggcttc aggcagctgg acccctaagg ctgaggaacc
1021 catccatgcc accatggacc cccagaggct gggcgtcctt atcactcctg tccctgacgc
1081 ccaggctgcc acccgaggc aggcggtggg gctgctggcc ttccttggg tctcctctg
1141 cctgggggtg gccatgttca cctaccagag cctccagggc tgccctcgaa agatggcagg
1201 agagatggcg gagggccttc gctacatccc ccgagctgtt ggtagtaatt catatgtcct
1261 ggtgccctg tgaactcctc tggcctgtgt ctagtgtgtt gattcagaca gctgcctggg
1321 atccctcatc ctcatacca cccccacca agggcctggc ctgagctggg atgattggag
1381 gggggagggt ggatcctcca ggtgcacaag ctccaagctc ccaggcatc cccaggaggc
1441 cagccttgac cattctccac ctccaggga cagaggggtt ggcctcccaa ctacccccag
1501 ccccaaaaact ctctctgtct gctggctggg tagaggttcc ctttgacgcc atcccagccc
1561 caatgaacaa ttatttatta aatgccagc cccttctgac ccagtgtgcc ctgtgagtac
1621 tacagtcctc ccattctaca catgagcatc aggccaggcc ctctgcccac tccctgcaac
1681 ctgatttgtt ctcttggctc tgctgcagtt gccagtcacc ccggccacct gcggtgctat
1741 ctccccagc cccatcctct gtacagagcc cagcccccac ctggtgacat gtcttttctt
1801 gcatgaggct agtgtgtgtt ttcttgggca ctgcttccag tgaggctctg cccttgggta
1861 ggsatttgtg gaaggggaga taagggtatc tggtagcttt cctcttggg ctacactgtg
1921 ctgagctgta aggtgggtt ctgactctag ttccaccatc aagccacca cactactcca
1981 tctgtgaaag gaaagaggga ggtaaggaa acctgtcccc ctgacaacac tcattgacct
2041 gaggcccttc tctccagccc ctggatgcag cctcacagtc cttaccagca gagcacctta
2101 gacagtccct gccaatggac taacttctct ttggaccctg aggccagag ggcctgcarg
2161 ggagttagtt gatagcacag accctgcctt gtgggcccc aaatggaaat gggcagagca
2221 gagaccatcc ctgaaggccc cgcccaggct tagtactgta gacagcccgg gctctgcttc
2281 ccatcaccgg ctaagaggga gggagggtct cagacacatg tccaagaag ccaggaaagg
2341 ctccaggagc agccacattc ctgatgcttc ttcagagact cctgagggca gccaggccac
2401 aagacccttg tggteccacc ccacacagc cagattcttt cctgaggctg ggtctccctc
2461 ccacctctct cactccttga aaacactgtt ctctgccctc caagaccttc tcttccacct
2521 ttgtccccac cgcagacagg accaggggat ttccatgatg ttttccatga gtcccctgtt
2581 tgtttctgaa agggacgcta cccgggaagg gggctgggac atgggaaagg ggaagtgtga

```



```

2641 ggcataaagt caggggttcc cttttttggc tgctgaaggc tcgagcatgc ctggatgggg
2701 ctgcaccggc tggcctggcc cctcagggtc cctgggtggc gctcacctct cccttggatt
2761 gtccccgacc cttgccgtct acctgagggg cctcttatgg gctgggttct acccaggtgc
2821 taggaacact ccttcacaga tgggtgcttg gaggaaggaa acccagctct ggtccataga
2881 gagcaaaacg ctgtgctgcc ctgcccaccc tggcctctgc actcccctgc tgggtgtggc
2941 gcagcatatt caggaagctc agggccctgg ctgaggtggg gtcactctgg cagctcagag
3001 aggggtgggag tgggtccaat gcactttgtt ctggctcttc caggctggga gaggcttca
3061 ggggtgggac accctgtgat ggggccctgc ctctttgtg aggaagccgc tggggccagt
3121 tgggtccctt tccatggact ttgttagttt ctccaagcag gacatggaca aggatgatct
3181 aggaagactt tggaaagagt aggaagactt tggaaagact ttccaaccc tcatcaccaa
3241 cgtctgtgcc attttgtatt ttactaataa aatttaaaag tcttgtgaaa aaaaaaaaaa
3301 aaaaaaaaaa

```

//

```

LOCUS      HSU91746      1430 bp      mRNA      PRI      12-MAR-1998
DEFINITION Homo sapiens IL-10-inducible chemokine (HCC-4) mRNA, complete
            cds.
ACCESSION  U91746
NID        g2581780
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 1430)
AUTHORS    Hedrick,J.A., Helms,A., Gorman,D. and Zlotnik,A.
TITLE      Identification of a novel human CC chemokine upregulated by IL-
10
JOURNAL    Blood (1998) In press
REFERENCE  2 (bases 1 to 1430)
AUTHORS    Hedrick,J.A., Helms,A., Gorman,D. and Zlotnik,A.
TITLE      Direct Submission
JOURNAL    Submitted (02-MAR-1997) Immunology, DNAX Research Institute,
901
            California Ave, Palo Alto, CA 94304, USA
FEATURES   Location/Qualifiers
            source      1..1430
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /chromosome="17"
            gene        1..1430
                        /gene="HCC-4"
            CDS          1..363
                        /gene="HCC-4"
                        /note="CC or beta chemokine family member"
                        /codon_start=1
                        /product="IL-10-inducible chemokine"
                        /db_xref="PID:g2581781"

```

```

/translation="MKVSEAALSLVLILIIITSASRSQPKVPEWVNTPTCCLKYIEK
VLPRRLVVGYRKALNCHLPAIIFVTKRNRVCTNPNDWVQEIYKDPNLPLLPTRNLS
TVKIIITAKNGQPQLLSQ"
BASE COUNT      401 a      351 c      293 g      385 t
ORIGIN
1 atgaaggtct ccgaggtctc cctgtctctc cttgtctctc tccttatcat tacttgggct
61 tctcgagccc agccaaaagt tcctgagtggt gtgaacaccc catccacctg ctgcttgaag
121 tattatgaga aagtgttgcc aaggagacta gtggtgggat acagaaaggc cctcaactgt
181 cacctgccag caatcatctt cgtcaccaag aggaaccgag aagtctgcac caacccaat
241 gacgactggg tccaagagta catcaaggat cccaacctac ctttctgtgc taccaggaac
301 ttgtccacgg ttaaaattat tacagcaaag aatggtcaac ccagctcct caactccag
361 tgatgaccag gctttagtgg aagcccttgt ttacagaaga gaggggtaaa cctatgaaaa
421 caggggaagc cttattaggc tgaactagc cagtcacatt gagagaagca gaacaatgat
481 caaaataaag gagaagtatt tgaatatatt tctcaatctt aggaggaaat accaaagtta
541 agggacgtgg gcagagggtac gctcttttat ttttatattt atatttttat tttttgaga
601 taggtcttac tctgtcacc aggtctggag gcagtggtgt gatcttggct cacttgatct
661 tggctcactg taacctccac ctcccaggct caagtgatec tcccaccaca gcctcccgag
721 tagctgggac tacaggcttg cggcaccaca cctggctaat ttttgtattt ttggtagaga
781 cgggattcta ccatgttgcc caggctgggc tcaaactcgt gtgcccagc aatccacctg
841 cctcagcctt ccaaaagtgc tgggattaca ggcgtgagcc accacatccg gccagtgac
901 tcttaataca cagaaaaata tatttcacat ccttctctg ctctcttca attcctcact

```

```
961 tcacaccagt acacaagcca ttctaaatac ttagccagtt tccagccttc cagatgatct
1021 ttgccctctg ggtcttgacc cattaagagc cccatagaac tcttgathtt tcctgtccat
1081 ctttatggat ttttctggat ctatatcttc ttcaattatt ctttcatttt ataatgcaac
1141 tttttcatag gaagtcgga tgggaatatt cacattaatc atttttgcag agactttgct
1201 agatcctctc atattttgtc ttctcaggg tggcaggggt acagagagtg cctgattgga
1261 aaaaaaaaaa aaagagagag agagagaaga agaagaagaa gagacacaaa tctctacctc
1321 ccatgttaag ctttgcagga cagggaaaga aagggtatga gacacggcta ggggtaaact
1381 cttagtccaa aaccaagca tgcaataaat aaaactccct tatttgacaa
```

//

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/26291

A. CLASSIFICATION OF SUBJECT MATTER

IPC(b) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/84, 85.1, 184.1, 186.1, 188.1, 278.1; 514/2, 8, 12, 44; 530/300, 324

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5,141, 867 A (IVANOFF et al.) 25 August 1992, see entire document.	22-32, 45-55
A	ENG et al. The Stimulatory Effects of Interleukin (IL)-12 On Hematopoiesis Are Antagonized by IL-12-induced Interferon γ In Vivo. J. Exp. Med. May 1995, Vol.181, pages 1893-1898, see entire document.	1-21, 33-44
A	ORANGE et al. Mechanism of Interleukin 12-mediated Toxicities during Experimental Viral Infections: Role of Tumor Necrosis Factor and Glucocorticoids. J. Exp. Med. March 1995, Vol.181, pages 901-914, see entire document.	1-21, 33-44

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

25 MARCH 1999

Date of mailing of the international search report

15 APR 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

PREMA MERTZ

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/26291

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WU et al. Receptor-mediated in Vitro Gene Transformation by a Soluble DNA Carrier System. The Journal of Biological Chemistry. 05 April 1987, Vol.252, No. 10, pages 4429-4432, see entire document.	22-32, 45-55

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/26291**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐

The additional search fees were accompanied by the applicant's protest.

☐

No protest accompanied the payment of additional search fees.

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

C07K 14/47, 14/52; C12N 15/12, 15/19, 15/63; A61K 38/16, 38/19, 48/00

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

424/84, 85.1, 184.1, 186.1, 188.1, 278.1; 514/2, 8, 12, 44; 530/300, 324

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, CAN ONLINE, MEDLINE, CAPLUS

search terms: chemokine, vaccination, immunogenic, antigen, HIV, efficacy, macrophage-derived chemokine, stromal cell-derived factor, monocyte chemotactic protein, composition, administration

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1.

Group I, claims 1-21, 33-44, drawn to a method to enhance the efficacy of a vaccine in a subject comprising administering an antigen and one or more chemokines and a composition thereto.

Group II, claims 22-32, 45-55, drawn to a method to enhance the efficacy of a vaccine in a subject comprising administering nucleic acid sequences encoding one or more antigens and nucleic acid sequences encoding one or more chemokines.

The inventions listed as Groups I-II do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The inventions listed as Groups I-II do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Pursuant to 37 C.F.R. § 1.475 (d), the ISA/US considers that where multiple products and processes are claimed, the main invention shall consist of the first invention of the category first mentioned in the claims and the first recited invention of each of the other categories related thereto. Accordingly, the main invention (Group I) comprises the first-recited product and method, a method to enhance the efficacy of a vaccine in a subject comprising administering an antigen and one or more chemokines and a composition thereto. Further pursuant to 37

C.F.R. § 1.475 (d), the ISA/US considers that any feature which the subsequently recited products and methods share with the main invention does not constitute a special technical feature within the meaning of PCT Rule 13.2 and that each of such products and methods accordingly defines a separate invention.